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Patients receiving medical treatments such as blood transfusion, haemodialysis or 
nutritional support may be exposed to high amounts of plasticisers. The most commonly 
used plasticiser in flexible polyvinyl chloride (PVC) products, frequently found in 
medical devices such as blood bags and tubes, is di(2-ethylhexyl) phthalate (DEHP) [1-
3]. PVC medical devices contain up to 40% of DEHP by weight [4-6]. Since DEHP is 
not chemically bound to the PVC it can easily migrate into the blood and blood products, 
such as red blood cells, whole blood, platelets and plasma [5-8]. 
Due to the toxic effects of DEHP the concentrations of its metabolites in urine have been 
determined to evaluate the exposure of DEHP to children and the general population [9-
18]. In humans DEHP is rapidly converted into its primary monoester, mono(2-
ethylhexyl)phthalate (MEHP), through phase-I biotransformation. Following a multistep 
oxidative pathway it is further metabolised mainly to mono(2-ethyl-5-
hydroxyhexyl)phthalate (5OH-MEHP), mono(2-ethyl-5-oxohexyl)phthalate 
(5oxo-MEHP), mono(2-ethyl-5-carboxypentyl)phthalate and mono[2-
(carboxymethyl)hexyl]phthalate [19]. The metabolites are mainly eliminated as 
conjugates following phase-II glucuronidation with the highest urinary levels of 
5OH-MEHP followed by 5oxo-MEHP and MEHP [20-22]. 
Since increased urinary amounts of DEHP metabolites can result from blood transfusion, 
monitoring of concentration levels can be utilised as a marker for blood doping. Taking 
into consideration that for anti-doping testing mainly urinary sampling is conducted and 
existing methods are based on blood analysis and cover only homologous blood 
transfusion, the detection of blood transfusion is limited [23-28]. Accordingly, it would 
be a great leap forward to detect both homologous and autologous blood transfusions 
from urine samples. Monitoring urinary concentrations of DEHP metabolites in order to 
test for blood transfusion in athletes was proposed by Monfort et al. [29]. Analysing 
urine samples for DEHP metabolites from patients subjected to clinical care or to blood 
transfusions and from an elite athlete population it was noticed that urine samples 
collected up to two days after blood transfusion contained significantly higher amounts 
of DEHP metabolites compared to a control group. This indicates that DEHP metabolites 
are good candidates to be used in sports drug testing as alert markers for the potential 








2cx-MMHP mono[2-(carboxymethyl)hexyl] phthalate 
5cx-MEPP  mono(2-ethyl-5-carboxypentyl) phthalate 
5OH-MEHP mono(2-ethyl-5-hydroxyhexyl) phthalate 
5OH-MEHP-gluc glucuronidated mono(2-ethyl-5-hydroxyhexyl) phthalate 
5oxo-MEHP mono(2-ethyl-5-oxohexyl) phthalate 
5oxo-MEHP-gluc glucuronidated mono(2-ethyl-5-oxohexyl) phthalate 
ACD acid-citrate-dextrose 
AICAR 5-amino-4-imidazolecarboxyamide ribonucleoside 
ASE alkyl sulphonic acid phenyl ester 
ATBC acetyl tri-n-butyl citrate 
ATP adenosine triphosphate 
BTHC butyril trihexyl citrate,  
CE collision energy 
CID collision-induced dissociation 
CPD citrate-phosphate-dextrose 
cps counts per second 
CV coefficient of variation 
DEHA di(2-ethylhexyl) adipate 
DEHP di(2-ethylhexyl) phthalate 
DEHT di(2-ethylhexyl) terephthalate 
DIDP diisodecyl phthalate 
DINCH 1,2-cyclohexanedicarboxylic acid diisononyl ester 
DINP diisononyl phthalate 
DP declustering potential 
EAS-61 experimental additive solution-61 
ECD electron capture detector 
ECMO extracorporeal membrane oxygenation 
EI electron ionisation 
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ESI electrospray ionisation 
EU European Union 
EVA ethylene vinyl acetate 
FID flame ionisation detector 
GC gas chromatography 
Hb haemoglobin 
HPLC high performance liquid chromatography 
IC in-competition 
ICC intraclass correlation coefficient 
ISTD internal standard 
IV intravenous 
LC-MS/MS liquid chromatography/tandem mass spectrometry 
LIT linear ion trap 
LOD limit of detection 
LOQ limit of quantification 
MEHP mono(2-ethylhexyl) phthalate 
MRM multiple reaction monitoring 
MS mass spectrometer / mass spectrometry 
MS/MS tandem mass spectrometry 
NHANES National Health and Nutrition Examination Survey 
OOC out-of-competition 
PCI positive chemical ionisation 
PE polyethylene 
PEL permissible exposure limit 




PVE plasma volume expander 
QC quality control 
QQQ triple quadrupole mass analyser 
QTOF-MS quadrupole time-of-flight mass spectrometry 
QTrap hybrid triple quadrupole/linear ion trap 
Abbreviations 
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RBC red blood cell 
RT retention time 
S/N signal to noise ratio 
SAGM saline-adenine-glucose-mannitol 
SPE solid phase extraction 
TEHTM tri-(2-ethylhexyl) trimellitate 
TOF time-of-flight mass analyser 
TPE thermoplastic elastomers 
TPN total parenteral nutrition 
TWA time weighted average 
UHPLC ultra-high performance liquid chromatography 
WADA World Anti-Doping Agency 
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4. LITERATURE OVERVIEW 
4.1. DI(2-ETHYLHEXYL) PHTHALATE 
Phthalate ester plasticisers are used to impart flexibility, softness and extensibility to 
inherently rigid thermoplastic and thermoset resins [30]. The most commonly used 
phthalate ester plasticiser is di(2-ethylhexyl) phthalate (DEHP, Figure 4.1), which is 
mainly added to polyvinyl chloride (PVC), but also compatible with ethyl cellulose, 
cellulose nitrate and polystyrene [31]. More than 95% of the total amount of DEHP 
produced is used as a plasticiser in polymer products, while the rest is utilised for non-
polymer applications. The content of DEHP in flexible polymer materials usually varies 
between 10 and 40% by weight. DEHP plasticised PVC is used in various products e.g. 
in building materials, in consumer products as well as in medical devices. 
 
Figure 4.1: Chemical structure of di(2-ethylhexyl) phthalate (DEHP). 
 
According to Annex I of Directive 67/548/EEC, DEHP is classified as a substance toxic 
to reproduction (Repr. Cat. 2; R60-61; May impair fertility; May cause harm to the 
unborn child) [32,33]. Since it is known that DEHP can be leached out from the polymer 
products the toxic effects of DEHP and its metabolites were studied to evaluate the 
human exposure and the possible sources of the plasticiser [1-4,7,34-37]. The main 
source was found to be food products, which can be contaminated through the 
manufacturing process or from the packaging material. Therefore, there are certain 
restrictions on the use of DEHP in food contact materials. It is not permitted for use in 
single-use applications, such as cap seals or gaskets. However, it can be safely and 
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legally used in non-fatty food contact materials for repeated use and as a technical 
support agent in concentrations up to 0,1 % in the final product, provided the migration 
of the plasticiser does not exceed the Substance Migration Limit (SML) of 1.5 mg/kg 
food [38,39]. Other possible sources are consumer products or indoor air and house dust 
contaminated from building materials. The EU Directive 2005/84/EC took effect in 
January 2007 and set the limit of DEHP in toys and childcare products at 0.1% by mass 
[40,41]. Other countries (US, Canada, Argentina, Brazil) have also set the same limit of 
DEHP in toys and children's products. DEHP is also prohibited in cosmetics in the 
European Union (EU) due to its classification as a reproductive toxicant [42,43]. 
Literature Overview 
 10 
4.1.1. Production and uses of di(2-ethylhexyl) phthalate 
The market for DEHP has been decreasing over the last ten years. In 1997, the total 
Western European production of DEHP was 595,000 t/y and in the early 1990s DEHP 
represented about 51% of the total phthalate plasticiser market in the EU. Of the 341,000 
tonnes produced in 2007, 187,000 tonnes were produced in Western Europe 
corresponding to 31% of the 1997 level [35]. The use of diisononyl phthalate (DINP) and 
diisodecyl phthalate (DIDP) have increased during the same period, indicating that 
DEHP has been replaced by DINP and DIDP in several applications. No data has been 
available for estimating the global production of DEHP. The content of DEHP is not 
known, but a rough estimate can be obtained assuming a phthalate content of the 
polymer of 30% and that DEHP accounts for 18% of the phthalates (EU manufacturing 
average). DEHP may be traded in end-product preparations such as sealants, adhesives 
and paint, but no information is available for estimating the DEHP content of these 
product groups [36]. 
The fate of the DEHP sent into circulation in the EU in 2007 is illustrated in Figure 4.2, 
where release from the use of end-products and disposal represent the total life-time 
emission of the articles produced in 2007 instead of total DEHP emission from end-
products in the EU in 2007 [36]. The latter would depend on the total amount of DEHP 
accumulated in society and would probably be higher, as the amount of DEHP sent into 
circulation has been decreasing in recent years. 
 
 




The manufactured DEHP is further processed in different formulation and processing 
steps, through which a wide range of end-products are produced as illustrated in the 
overview flow chart in Figure 4.3 [36]. 
 
 





The main end-product uses of DEHP are as follows [35-37]: 
Polymer applications: 
 Flooring; 
- PVC flooring (with PVC surface); 
- Carpets with PVC back-coating; 
- Cork with PVC top-coating or back-coating; 
 Wall covering; 
 Roofing; 
 Film/sheet and coated products: 
- Curtains, blinds, table linen, etc.; 
- Packaging; 
- Tape and self-adhesive foils; 
- Office supplies (ring binders, files, slip cases, etc.); 
- Toys (swimming pools, rubber beach toy, beach balls, etc.); 
- Medical bag/sheet devices; 
- Bottom sheets for hospitals; 
 Wires and cables; 
 Hoses and profiles; 
- Garden hoses and tubes; 
- Hoses and tubes in industry; 
- Profiles of windows and electrical products; 
- Medical tubing; 
 Coated fabric; 




- Water beds; 
 Moulded product; 
- Footwear; 
- Adult toys (DEHP is not permitted in toys for children); 




 Lacquers and paints; 
 Printing inks (see comment below); 
 Sealants (glass insulation, construction); 
 Ceramics. 
 
The estimated amount of DEHP in end-products marketed in the EU based on EU 
manufacture, import, export data is summarised in Table 4.1. 
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In the European Union, DEHP is not permitted for use in toys and childcare articles 
[40,41] or in cosmetics [42,43]. Additionally, there are certain restrictions on the use of 
DEHP in food contact materials [38,39]. 
 
Table 4.1: The estimated DEHP tonnage in end-products marketed in the EU based on EU 
manufacture, import and export data in 2007 (n.d.: no data) [36]. 
End-product use area Tonnage (t/year) % of total use 
EU Manufacture Import Export End- 
product use 
Indoor uses      
Polymer applications      
Flooring 33,000 2,000 4,800 30,200 10.6 
Wall covering 11,000 700 1,600 10,100 3.5 
Film/sheet and coated products  
made by calendering 
44,000 13,600 16,400 41,200 14.5 
Wires and cables 52,000 6,200 5,600 52,600 18.5 
Hoses and profiles 31,000 1,600 3,000 29,600 10.4 
Coated fabric and  
other products from plastisol 
31,000 2,200 1,400 31,800 11.2 
Moulded products 3,000 2,700 700 5,000 1.8 
Other polymer applications 12,300 10,900 3,100 20,100 7.1 
Non-polymer applications      
Adhesives and sealant 4,000 n.d. n.d. 4,000 1.4 
Lacquers and paints 500 n.d. n.d. 500 0.2 
Printing ink 1,000 n.d. n.d. 1,000 0.4 
Other non-polymeric applications 20 n.d. n.d. 20 0.0 
Outdoor uses      
Polymer applications      
Calendered roofing material 600 n.d. n.d. 600 0.2 
Coil coated roofing material 3,000 n.d. n.d. 3,000 1.1 
Wire and cables – air 2,400 n.d. n.d. 2,400 0.8 
Wire and cables – soil 9,700 n.d. n.d. 9,700 3.4 
Coated fabric 12,800 n.d. n.d. 12,800 4.5 
Car undercoating 4,000 n.d. n.d. 4,000 1.4 
Hoses and profiles 3,700 n.d. n.d. 3,700 1.3 
Shoe soles 19,400 n.d. n.d. 19,400 6.8 
Non-polymer applications      
Lacquers and paints 400 n.d. n.d. 400 0.1 
Adhesives and sealant 3,300 n.d. n.d. 3,300 1.2 




The use in medical devices is estimated at 0.5% of the total DEHP production, of which 
the major use (more than 95%) is soft medical grade PVC in containers, flexible tubing 
and medical gloves [2]. The typical concentration of DEHP in plasticised PVC is 
approximately 30% (w/w). 
The estimated releases from all activities are summarised in Table 4.2 [36]. The main 
releases are to soil and waste water. The use of end-products gives rise to the largest 
releases to the environment with washing of flooring, releases from underground cables 
and abrasive releases and pieces lost in the environment as the largest single sources. The 
releases from landfill may in fact be six times higher than indicated if total releases until 
the DEHP is ultimately degraded is considered, but no data on the long term fate of 
DEHP in landfills have been made available. 
 
Table 4.2: Tonnage handled and releases of DEHP from manufacturing, formulation, processing, 
end-products use and disposal in the EU in 2007 [36]. 




Air Soil Waste water 
EU manufacture of DEHP 341,000 1 4 220 
Transportation of substance  
from manufacturing a 
345,479 0 0 29 
Formulation 61,000 30 1 97 
Processing 283,000 174 41 125 
End-product uses, indoor 223,000 380 0 1,240 
End-product uses, outdoor,  
non-abrasive 
33,000 30 3,980 500 
End-product uses, outdoor,  
abrasive leakages 
33,000 5 3,500 1,200 
Disposal and recycling operations 275,133 9 48 10 
Total releases (round)  600 7,600 3,400 
a The tonnage handled is the sum of EU production and import. 
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4.1.2. Occurrence of di(2-ethylhexyl) phthalate 
4.1.2.1. Di(2-ethylhexyl) phthalate in the environment 
Release of DEHP to the environment occurs during the production, transport, storage, 
formulation and processing of PVC. Since DEHP is not chemically bound to the polymer 
in flexible PVC the plasticiser will become released from the finished article during its 
use and after its final disposal. 
DEHP enters the environment mainly via direct releases to air and waste water, from 
sewage sludge and from solid waste. In air, DEHP may occur both in the vapour phase 
and as solid particles. The nature of these particles can be either aggregated pure DEHP 
or polymer particles containing DEHP. Particles formed by weathering of polymer 
products probably represent an important route of DEHP distribution. It is estimated that 
around 800 industrial sites in the EU use DEHP or preparations containing DEHP [35]. 
Releases from these sources are expected to cause higher local exposure. 
 
Table 4.3: Contribution to the total emissions of DEHP from different life-cycle stages [35]. 
Source Emission contribution Uncertainty in estimate Emission type 
Production ~2.5% low Point sources 
Industrial uses ~2.5% medium Point sources 
End-product uses ~32% medium Wide dispersive (and point sources) 
Waste handling a ~63% high Wide dispersive (and point sources) 
a Car shredding, incineration, landfills and waste remaining in the environment 
 
The release of DEHP from industrial point source is low compared to the releases during 
end-product uses (Table 4.3). The primary recipients during production, formulation and 
processing are air and wastewater; while surface water and soil are exposed from outdoor 
use. Emission from car shredding, municipal landfills and incineration stations seem to 
be low and the main recipients are soil (car shredding), water (municipal landfills) and 
air (incineration). The low dissipation rate of DEHP in the municipal landfill 
environment will probably cause accumulation. The emissions from landfills may 
therefore increase in the future. Dominating sources are shoe soles, outdoor use of coil 
and fabric coatings and indoor floors. The primary recipients are expected to be soil 
followed by the aquatic compartment (mainly sediment) and to a lesser extent air. DEHP 
in waste formed from buried cables and demolished building material is assumed to 
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cause emission to ground water in urban areas. However, the uncertainty of these 
estimations is, high due to limited data. The overall distribution of DEHP is 2% to air, 
21% to water and 77% to urban/industrial soil [35]. 
4.1.2.1.1. Environmental fate of di(2-ethylhexyl) phthalate 
Photodegradation of DEHP (reaction with OH radicals) is important in the atmosphere 
(t½ = 1 day) but is assumed to be of little importance in water and soil [35]. DEHP does 
not hydrolyse in water. The biodegradation of DEHP varies in available studies. Based 
on the results of standard biodegradation tests, DEHP is readily biodegradable. 
Experimental data indicates a biodegradation half-life for DEHP in surface water of 50 
days and 300 days in aerobic sediment. Anaerobic conditions and low temperature 
further reduce the degradation rate. The primary biodegradation product of DEHP is 
mono(2-ethylhexyl) phthalate (MEHP). 
DEHP is expected to be strongly adsorbed to organic matter and expected to be found in 
the solid organic phase in the environment. It will be strongly adsorbed to sludge in 
sewage treatment plants. DEHP has a low evaporation rate from its pure state and a 
moderate evaporation rate from a pure water solution (‘semi-volatile’). 
DEHP is found to bioaccumulate in aquatic organisms. This indicates that uptake via the 
food chain might be an important exposure route. 
4.1.2.1. Di(2-ethylhexyl) phthalate in food 
Food is generally regarded as a major source of phthalate exposure in the general 
population. Contamination of food can occur during processing, handling, transportation, 
packaging and storage. There is a considerable difference in the degree of phthalate 
contamination of foods depending on packaging and processing practices and the lipid 
content [44]. The most important food sources of exposure are beverages, excluding 
water, dairy products, fats and oils, grains, milk and meat (Table 4.4) [45]. 
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Table 4.4: Food concentrations of DEHP [3,45]. 
Food Median concentration, μg/kg (Range) 
Beverages 0.043 (0.006–1.7) 
Cereal 0.05 (0.02–1.7) 
Dairy (excluding milk) 0.96 (0.059–16.8) 
Eggs 0.12 (<0.01–0.6) 
Fats and oils 2.4 (0.7–11.9) 
Fish 0.001 (0.00005-not given, 90th percentile 0.02) 
Fruits 0.02 (<0.02–0.11) 
Grains 0.14 (<0.1–1.5) 
Meat, not processed 0.05 (<0.01–0.8) 
Milk 0.035 (<0.005–1.4) 
Nuts and beans 0.045 (<0.08–0.8) 
Poultry 0.9 (0.05–2.6) 
Processed meat 0.45 (<0.1–4.32) 
Vegetables 0.048 (0.0098–2.2) 
Infant formula, powdered 0.12 (<0.012–0.98) 
Infant formula, liquid 0.006 (<0.005–0.15) 
Breast milk 0.062 (0.01–0.6) 
Baby food 0.12 (0.01–0.6) 
Other food 0.05 (<0.01–25) 
4.1.2.2. Di(2-ethylhexyl) phthalate in medical devices 
PVC is ubiquitous in the health care environment. Due to of its properties, processability 
and relatively low cost, PVC is used in a wide range of products in hospitals. Some of 
them impact directly on patient care, whilst others contribute to the overall environment 
of the patient, including floor and wall coverings and clinical equipment. 
The flexibility and barrier properties of plasticised PVC have resulted in extensive uses 
as tubes, sheets, containers and coverings. One of the oldest medical use of plasticised 
PVC is the blood bag. It remains the material of choice for the storage of blood and 
blood products, including red cell preparations and platelet rich plasma. It is also used in 
intravenous tubing for blood collection and infusion and in bags and tubes for the 
delivery of liquid food products. A wide variety of components are used to assist patients 
in respiration, including oxygen masks and tubes, endotracheal and tracheostomy tubes, 
nasal cannulas, humidifier equipment and resuscitator and ventilator components. Some 
major medical procedures aimed at short, medium or long-term functional assistance to 
organs involve PVC tubes and components. This includes extracorporeal membrane 
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oxygenation and haemodialysis. It is also used in umbilical vessel catheters, wound 
drainage tubes and osteotomy shunts. Examination gloves are used very extensively in 
clinical and laboratory procedures and they employ a wide variety of materials, including 
plasticised PVC [7]. 
Wahl et al. tested different phthalates in medical plastic articles and DEHP was found 
mainly in soft pliable PVC plastics used for invasive applications, such as dialysis 
tubing, infusion and blood storage bags and tubing (Table 4.5) [46]. 
 
Table 4.5: Phthalates identified in medical plastic articles
a
 [46]. 
Plastic article DEP DIBP DBP BEP DEHP 
Eppendorf pipette tips x  (x)   
Eppendorf cup (x)  (x)   
Urine container 100 ml (x)  (x)   
Urine container 500 ml (x)  (x)   
Urine container 2500 ml (x)  (x)   
Urine bag 1500 ml (x)  (x)  x 
Syringe 60 ml (x)  (x)  (x) 
Insulin syringe (x)  (x)   
Heparin syringe (x)  (x)  x 
Microfilter 40 μl x  x (x) x 
Serum monovette (x)  (x)   
Butterfly x   x x 
Luerlock obturator (x)  (x)  x 
Infusion tubing (x) x x x xx 
Infusion bag (x)  x (x) xx 
Blood storage bag     xx 
Blood infusion tubing (x)  (x) x xx 
Intestinal tubing x  x  x 
Dialysis tubing (x)  (x)  xx 
a (x) < 1%, x < 20% and xx > 85% of total volatiles. 
DEP: diethyl phthalate, DIBP: diisobutyl phthalate, DBP: dibutyl phthalate, 
BEP: butyl 2-ethylhexyl phthalate, DEHP: di(2-ethylhexyl) phthalate. 
 
Quantitative information of the amount of plasticised PVC used for medical devices is 
not available. Medical applications account for 0.5% of the total PVC volume used in 
Western Europe [47].  
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4.1.2.3. Di(2-ethylhexyl) phthalate in blood and blood products 
4.1.2.3.1. Accumulation of DEHP during storage of blood 
It is well established that DEHP could leach out from PVC bags and accumulate in the 
stored blood and blood products [48-59]. While plasticisers have very low solubility in 
water (0.01 mg/100 mL at 25°C), DEHP is accumulated in whole blood (stored in PVC 
bag) at a rate of 0.25 mg/100 mL blood/day during storage at 4°C, to a level of 
5-7 mg/100 mL of blood at the end of 21 days [51,52,58]. 
The extraction of DEHP into blood products is biphasic [60]. The rate is maximal during 
the first few hours when the blood is handled at a higher temperature and is moved over 
new surfaces in handling. After this, when the blood is stored at refrigerated 
temperatures and the surfaces area of the plastic is held constant, the rate of extraction 
becomes much lower. 
Essentially, all DEHP in blood is protein bound with about three-quarters being bound to 
lipoprotein [61]. Fractionation of the blood indicated that the plasticiser was located 
almost exclusively in the plasma fraction and was specifically associated with the 
lipoprotein fraction of plasma [51]. Proteins such as albumin, fibrinogen, plasminogen 
and immunoglobulin G have very low affinities for DEHP in comparison with plasma 
[62]. Several early reports indicated that the amount of DEHP that leaches from 
transfusion packs correlated with triglyceride concentrations in the plasma [63-65]. 
DEHP added to the plasma tended to migrate to the areas of low and very low density 
lipoproteins, thus supporting the suggestion that DEHP may be solubilised and 
transported in blood in a manner similar to the triglycerides. DEHP is also found in 
platelet concentrates stored in PVC bags (approximately 11% in the platelet pellet and 
89% in the supernatant) [54]. 
Rock et al. demonstrated that there is a constant hydrolysis of DEHP to MEHP in stored 
whole blood [56]. The accumulation of DEHP and MEHP continued throughout the 
storage of whole blood, platelet-rich plasma, platelet concentrates and platelet-poor 
plasma. The levels of DEHP were much higher than those of MEHP and the highest 
concentrations were detected in platelet-poor plasma. The authors concluded that the 
accumulation of MEHP was due to the hydrolysis of DEHP by plasma proteins rather 
than by leaching from the blood bags. Similar conclusions were reached by Peck et al. 
[57]. In addition, they observed that the storage temperature affects not only the extent of 
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leaching but activity of the enzyme, however, DEHP continues to be hydrolysed to 
MEHP even in the frozen state [66]. 
The distribution of MEHP in the plasma protein fractions was different from that of 
DEHP. MEHP is bound principally to non-lipoprotein constituents in the serum and this 
binding distribution is unaffected by lipid concentration [65]. The supernatant contained 
more MEHP and measurable amounts of MEHP were found in the albumin fraction [62].  
Miripol et al. reported that irrespective of whether whole blood or packed cells were 
stored in acid-citrate-dextrose (ACD)-adenine or citrate-phosphate-dextrose 
(CPD)-adenine solution in PVC bags, there was a continuing and increasing level of 
DEHP observed [67]. However, in packed cells the levels of DEHP were lower by a 
factor of about three. Given that plasma proteins and not erythrocytes provide the major 
binding sites for DEHP. Similar data were obtained by Peck et al. [57]. They also found 
that the accumulation of DEHP may be related to the increase in ratio of the plastic 
surface area to the volume of plasma in red blood cell (RBC) concentrates. Gulliksson et 
al. studied the effect of decreased plasma residue and replacement solutions on the 
extraction of materials from plastic storage bags into RBC concentrates [68]. 
Significantly less accumulation of DEHP per unit was observed in RBC components 
resuspended in saline-adenine-glucose-mannitol (SAGM) medium compared to CPD-
adenine solution. It was observed that the final level of DEHP appeared to be related to 
the amount of residual plasma, rather than to the volume of SAGM added. 
Although, earlier reports had not found significant amounts of DEHP taken up by RBCs, 
Rock et al. reported that labelled DEHP was incorporated into RBC concentrates stored 
at 4°C [69]. There was an immediate binding of 28% of the available 14C-DEHP into the 
RBCs on day 0, with approximately equal amounts being incorporated into the cytosol 
and membrane fractions. The total amount and relative distribution of the 14C-DEHP did 
not change significantly over 7 days. Since earlier studies examined RBCs stored as 
whole blood, not RBC concentrates and DEHP which is taken up by the lipid fraction of 
plasma, much of the DEHP in the former experiments may have preferentially bound to 
the plasma lipoproteins. In the case of RBC concentrates, limited plasma is available, 
thus favouring association of the DEHP with RBCs. This difference has important 
implications since in the majority of blood banks RBC concentrates are stored rather than 
whole blood. 
Rock et al. also found that DEHP leaches also into platelet concentrates and that 6-10% 
of the labelled DEHP added might bind to the platelets [70]. They also suggested that 
Literature Overview 
 21 
DEHP might be involved in the loss of the platelet function during storage and affect the 
viability of stored platelets. DEHP bound to the platelets was found to be 90% in the 
membrane and 10% in the cytosol. The binding was reversible – DEHP was lost on 
resuspension of the platelets into new plasma [71]. 
4.1.2.3.2. Effect of plasticisers on erythrocytes 
It was subsequently shown that the DEHP improves RBC storage by reducing 
haemolysis and membrane loss by microvesiculation [72,73]. Other plastics, such as 
polyolefins (PO), which are used in platelet storage bags because of their high gas 
permeability, were associated with greater RBC haemolysis and microvesiculation when 
used in conjunction with standard storage solutions. However, the addition of DEHP or 
similar plasticisers to the RBCs stored in PO bags resulted in a better survival rate of the 
erythrocytes [69,74,75]. Similar results were found using glass storage tubes supporting 
the idea that DEHP has a beneficial influence on the RBCs. This excludes the possibility 
that PO bags might adversely affect them [69]. Without the protection afforded by the 
plasticiser, RBC storage would be limited to 3 weeks by using conventional storage 
solutions [76,77]. 
Hess et al. developed an additive storage solution, Experimental Additive Solution-61 
(EAS-61), in which RBCs can be stored for 9 weeks in PVC bags [78]. EAS-61 works, 
in part, by suppressing RBC microvesiculation and haemolysis. The increased volume of 
additive solution also seemed to be important for raising adenosine triphosphate (ATP) 
levels in RBC concentrates, improving RBC morphology and reducing haemolysis [79]. 
To evaluate whether EAS-61 might suppress RBC haemolysis during storage in a 
different plastic and to learn more about cellular mechanisms important for blood 
storage, Hill et al. conducted a study comparing RBCs stored in PVC and PO containers 
in 100 and 200 ml volumes of EAS-61 [80]. Although haemolysis of RBCs stored in 
EAS-61 was below conventional limits for at least 6 weeks, RBCs stored in PO bags had 
four times more haemolysis and lower RBC ATP concentrations than those stored in 
PVC. When DEHP was added to RBC stored in the PO bags, the degree of shape change, 
microvesiculation and haemolysis were reduced. Exposure of warm blood to PO bags 
caused a rapid initial shape change which persisted but progressed at a slower rate after 
the RBCs were transferred to PVC bags. This result suggests that DEHP can suppress 
further shape change and haemolysis, even after the processes have been initiated. 
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Several studies investigated the possible preservation role of butyril trihexyl citrate 
(BTHC) in RBC concentrates stored in BTHC-plasticised PVC bags [81-83]. 
Furthermore, it was found to be suitable for the storage of platelets [84,85]. Chemically, 
BTHC is esterified citric acid. The central hydroxyl group is esterified with butyrate, 
while the three carboxyl groups are esterified with hexanol. During metabolism it is 
hydrolysed to hexanol, butyric acid and citric acid. Straight-chain alcohols (such as 
hexanol) were found to expand RBCs ghost membrane areas sufficiently to inhibit 
haemolysis [86-88]. It was also reported that hexanol (144.6 µg/mL) found to suppress 
haemolysis and vesiculation of RBCs during storage, which supports that the hexanol is a 
key component of BTHC [89]. 
 
 





4.1.3. Pharmacokinetics of di(2-ethylhexyl) phthalate 
The metabolism and excretion of DEHP was extensively studied in rats whereas only a 
limited number of studies are available on humans. 
After oral uptake, DEHP is enzymatically hydrolysed into its primary monoester, 
mono(2-ethylhexyl) phthalate (MEHP), partially in the mouth by salivary esterase [90], 
then mainly in the gastrointestinal tract through phase-I biotransformation [91,92]. 
Therefore, the majority of DEHP is rapidly adsorbed as MEHP in the gut [2]. DEHP 
hydrolysing lipases can be found in many tissues (especially in the pancreas, intestinal 
mucosa, liver) and in blood plasma [92,93]. Following a multistep oxidative pathway 
MEHP is further metabolised in the liver [94]. The hydroxylation of the alkyl chain at 
various positions results in the formation of primary (ω-oxidation) and secondary 
alcohols (ω-1 and ω-2 oxidation) which can be further oxidised to ketones and carboxylic 
acids. The carboxylated alkyl chain can undergo α- or β-oxidation yielding shorter 
carboxylated alkyl chains [91,95-97]. 
Most of the orally administered DEHP is systemically absorbed in humans and excreted 
in urine in the form of the five major metabolites (mono(2-ethyl-5-hydroxyhexyl) 
phthalate (5OH-MEHP), mono(2-ethyl-5-carboxypentyl) phthalate (5cx-MEPP), 
mono(2-ethyl-5-oxohexyl) phthalate (5oxo-MEHP), mono(2-ethylhexyl) phthalate 
(MEHP) and mono[2-(carboxymethyl)hexyl] phthalate (2cx-MMHP) as illustrated in 
Figure 4.7. The major metabolite in urine detectable up to 12 h after oral administration 
of D4-DEHP was 5OH-MEHP, followed by 5oxo-MEHP and MEHP; after 12 h it was 
5cx-MEPP and after 24 h it was 2cx-MMHP (Figure 4.5) [22,98]. Excretion in urine 
follows a multiphase elimination pattern. After an absorption and distribution phase of 4 
to 8 h the half-lives of excretion in the first elimination phase (until 14-16 h after 
administration) were approximately 2 h for MEHP with slightly higher half-lives for 
5OH-MEHP and 5oxo-MEHP. The elimination half-lives of 5cx-MEPP and 2cx-MMHP 
were between 15 and 24 h. In the second phase, beginning 14 to 18 h post dose, 
half-lives were 5 h for MEHP and 10 h for 5OH-MEHP and 5oxo-MEHP. In the time 
window 36 to 44 h, no decrease in the excreted concentrations of 5OH-MEHP and 
5oxo-MEHP was observed. 
In the first elimination phase (8 to 14 h post dose), the mean excretion ratios of MEHP to 
5oxo-MEHP and MEHP to 5OH-MEHP were 1 to 1.8 and 1 to 3.1, respectively. In the 
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second elimination phase (up to 24 h post dose) mean excretion ratios of MEHP to 
5oxo-MEHP to 5OH-MEHP changed to 1 to 5.0 to 9.3, respectively. The excretion ratio 
of 5OH-MEHP to 5oxo-MEHP remained constant throughout at 1.7. The respective 
half-lives of the metabolites in serum were estimated to be less than 2 h except for 
2cx-MMHP, for which the half-life was at least 5 h. In contrast to urine the major DEHP 
metabolite in serum was MEHP. 
After 24 h, 67.0% (range: 65.8-70.5%) of the DEHP dose was excreted in urine, 
comprising 5OH-MEHP (23.3%), 5cx-MEPP (18.5%), 5oxo-MEHP (15.0%), MEHP 
(5.9%) and 2cx-MMHP (4.2%) [98]. An additional 3.8% of the DEHP dose was excreted 
on the second day, comprising 2cx-MMHP (1.6%), 5cx-MEPP (1.2%), 5OH-MEHP 
(0.6%) and 5oxo-MEHP (0.4%). In total, about 75% of the administered DEHP dose was 
excreted in urine within two days. No dose dependency in metabolism and excretion was 
observed. 5OH-MEHP and 5oxo-MEHP in urine reflect short-term and 5cx-MEPP and 
2cx-MMHP long-term exposure. 
First-morning urine samples collected from children showed decreasing ratios of the 
oxidative metabolites 5OH-MEHP, 5oxo-MEHP relative to the monoester (MEHP) with 




Figure 4.5: Time course of the excretion of the DEHP metabolites in urine (mg/L) after a high dose 




After intravenous exposure to DEHP a sharp increase in urinary DEHP metabolite 
concentrations were observed [100-102]. Maximum concentrations of 5OH-MEHP, 
5oxo-MEHP, 5cx-MEPP and MEHP were observed 4 h after the procedure. 2cx-MMHP 
was excreted at highest concentrations after 8 h (Figure 4.6). As an indication of longer 
elimination half-lives, the major metabolites excreted in urine 24 h after the exposure 
were 5cx-MEPP and 2cx-MMHP [103]. The elimination characteristics and relative 
distribution of the DEHP metabolites in urine were found to be similar to that after oral 
administration, which indicates that the toxicokinetic behaviour of DEHP in humans 
appears to be qualitatively unaffected by the route of administration [2,103]. 
 
 
Figure 4.6: Time course of excretion of the DEHP metabolites in urine (μg/l) after intravenous 
exposure to DEHP [103]. 
 
Athletes are thought to have blood transfusions only a short time before competition, 
therefore the measurement of DEHP metabolites provides a sufficient detection window 
to test for blood doping. The most suitable metabolites are the oxidative secondary 
metabolites, such as 5OH-MEHP and 5oxo-MEHP. Although the elimination rate of 
5cx-MEPP is higher than the elimination rate of 5oxo-MEHP, its elimination is slower, 




In humans, at least 65% of metabolites are eliminated as conjugates following phase-II 
glucuronidation [91,97,20]. While the carboxylic acid metabolites were found to be 
excreted only partially in their glucuronidated form, the alcohol and ketone metabolites 
are excreted mainly as glucuronic acid conjugates [2,104]. 
The data regarding metabolism and bioavailability following inhalation and dermal 
exposure are limited. It can be assumed that only a fraction of the amount inhaled will be 
available to the lungs while the majority will probably be swallowed and become orally 
bioavailable. The dermal absorption appears to be poor in human [2,35]. 
 
 
Figure 4.7: DEHP metabolism in humans [3,15,91,97]. 
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4.1.4. Di(2-ethylhexyl) phthalate exposure 
4.1.4.1. Di(2-ethylhexyl) phthalate exposure of the general population 
Humans are exposed to DEHP via oral, dermal and inhalation routes of exposure. 
General population intake estimates for DEHP have been developed using probabilistic 
analysis [45]. The average level of exposure to DEHP from all sources in the general 
population has been estimated to be in the range of 3 to 30 μg/kg body weight/day [7]. 
Dietary intake has been identified as an important route of exposure [45,105]. More than 
90% of estimated daily DEHP intake in people over the age of 6 months is from food. 
Estimated DEHP intakes by age group and from different sources of exposure are shown 
in Table 4.6 and Table 4.7. It was noted that exposure estimates, back-calculated based 
on measurements of urinary metabolites, gave lower estimates of daily intake compared 
to probabilistic analysis. They suggested that the current study may have overestimated 
food exposure to DEHP due to the use of outdated food measurements or due to failure 
to account for cooking-associated loss of DEHP in food. Nevertheless, important 
differences exist among populations and individuals associated with various dietary 
habits and lifestyles; therefore, in certain cases daily intakes can reach the order of a few 
mg/kg [7,45]. 
 
Table 4.6: Estimated DEHP intake by age group [45]. 
Age group Median DEHP intake (μg/kg/day) 
Adult (20-70 years) 8.2 
Teen (12-19 years) 10 
Child (5-11 years) 18.9 
Toddler (7 months-4 years) 25.8 




DEHP has also been shown to be a constituent of dust in households. Ingested dust 
represents the most important non-food source of exposure, accounting for 4.3% of total 
exposure to DEHP. Inhalation of indoor air represents approximately 1% of exposure. 
Fromme et al. found 775.5 mg/kg DEHP in dust collected from 30 apartments in 
Germany [105]. Bornehag et al. investigated 346 dust samples from children’s bedrooms 
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in Denmark and the geometric mean of DEHP concentration was 789 mg/kg of dust 
[106]. 
 








(7 months-4 years) 
Infant 
(0-6 months) 
     Formula-fed Breast-fed 
Outdoor air  0.0 0.0 0.0 0.0 0.1 0.0 
Indoor air  1.0 0.9 1.0 0.9 1.5 1.1 
Drinking water  0.1 0.1 0.1 0.1 0.7 0.0 
Ingested soil  0.0 0.0 0.0 0.0 0.0 0.0 
Ingested dust  4.3 4.2 5.0 6.6 54.1 39.3 
Beverages a  11.2 5.2 3.3 2.2 0.0 0.0 
Cereals  2.4 2.0 3.5 5.5 0.0 0.0 
Dairy products b  13.2 11.7 12.2 12.9 0.0 0.0 
Eggs  1.1 0.7 0.8 1.3 0.0 0.0 
Fats and oils  16.9 19.1 16.5 11.1 0.0 0.0 
Fish  1.6 0.8 0.7 0.4 0.0 0.0 
Fruit products  0.9 0.8 1.1 1.4 0.0 0.0 
Grains  13.4 16.6 18.1 11.1 0.0 0.0 
Meats  5.5 5.2 3.7 3.3 0.0 0.0 
Milk  3.1 6.7 8.6 12.6 0.0 0.0 
Nuts and beans  1.0 1.0 0.9 0.8 0.0 0.0 
Other foods  10.3 11.2 11.3 18.9 0.0 0.0 
Poultry  3.9 3.5 3.5 3.6 0.0 0.0 
Processed meats  3.4 3.4 3.4 2.5 0.0 0.0 
Vegetable products  6.6 6.1 6.1 4.9 0.0 0.0 
Formula/breast milk  – – – – 43.7 59.6 
a Excluding water. 
b Excluding milk. 
 
The EU Scientific Committee on Food (SCF) has recommended a tolerable daily intake 
(TDI) for DEHP of 50 μg/kg/day [107]. Likewise, for the exposure of children to DEHP 
from PVC toys a TDI of 50 μg/kg/day was estimated by the EU Scientific Committee on 
Toxicity, Ecotoxicity and the Environment [108]. The Reference Dose (RfD) for DEHP 
recommended by the US Environmental Protection Agency (EPA) is 20 μg/kg/day [109]. 
DEHP and its metabolites can be measured in the blood and urine to confirm recent 
exposures. For monitoring purposes urine samples are preferred since they can be 
collected by using noninvasive techniques. Being the major urinary metabolites, 
5oxo-MEHP and 5OH-MEHP may be sensitive predictors of DEHP exposure due to 
their relatively high concentration in urine and their lack of susceptibility to 
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contaminants in the sample collection process or during the analytical procedure 
[14,3,15,21]. 
Calculations of population exposure based on urinary metabolites are generally within 
the range of 3 to 30 μg/kg/day, but estimates made from the upper 95th percentile of 
measured ranges in some studies exceed this range by up to a factor of 2 [14,15]. 
Contrarily, alternative estimates have been calculated using different methods as much as 
5-fold lower [110]. 
DEHP exposure levels have been shown to have high geographical variability. Estimates 
based on the urinary MEHP measurements obtained by Blount et al. [11] suggest that the 
average total daily ambient exposure of individuals in the United States to DEHP is 
likely to be <3.6 μg/kg/day [111,112]. Another regional exposure calculated by EUSES 
(The European Union System for the Evaluation of Substances) based on measured 
urinary excretion of DEHP metabolites in a German adult population [15] was estimated 
at 17 μg/kg/day (95th percentile) [35]. The chosen exposure estimates can be compared 
with measured DEHP concentrations in food from Denmark and Japan, indicating intake 
levels up to 16 μg/kg/day and 59.9 μg/kg/day, respectively [35]. Guo et al. compare 
urinary DEHP metabolite levels in humans from seven Asian countries during 2006-
2007 indicating widespread exposure to phthalates [113]. Urine samples from Kuwait 
contained the highest concentrations of the metabolites of DEHP followed by samples 
from India, China, Japan, Vietnam Korea and Malaysia. The estimated exposure doses to 
DEHP in Kuwait exceeded the 20 μg/kg/day RfD value recommended by the EPA. 
The National Health and Nutrition Examination Survey (NHANES) of the Centers for 
Disease Control and Prevention 2001–2002 measured monoester metabolites of various 
phthalate esters (including MEHP, 5OH-MEHP and 5oxo-MEHP) in 2782 urine samples 
from adults and children of the US population [114]. The NHANES database was 
updated regularly for the following periods: 2003–2004 (n = 2605), 2005-2006 
(n = 2548) and 2007-2008 (n = 2604). The phthalate levels in these different periods 
were found to be similar (Table 4.8). Mean concentrations vary by age with younger age 
groups having higher urinary concentrations of the metabolites than older children and 
adults. In addition, a number of investigators have evaluated the concentrations of 
urinary DEHP metabolites in small populations (without known elevated exposure) for a 
variety of purposes and these results are summarized in Table 4.8. 
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Table 4.8: Urinary concentrations of DEHP metabolite in different populations without known elevated exposure. 
Population Gender Origin Year n Sample type 
Urinary DEHP metabolite concentration (ng/mL) 
References References MEHP 5oxo-MEHP 5OH-MEHP 
Mean Max Mean Max Mean Max 
Adult  






46 first morning   16.5 143.9         










2002  85 first morning  15.7 177 57.2 544 79.6 818 




14 women,  
5 men 
Germany   19 first morning  9.0* 43.1 19.6* 55.1 32.1* 103 
Koch et al., Int. J. Hyg. Environ. Health 
207:15-22 (2004) 
[99] 
Adult 11 men MA, U.S.   369   5.7 110** - - - - 
Hauser et al., Environ. Health Perspect. 
112:1734-1740 (2004) 
[116] 
Adult   U.S. 2001 127 spot na 20.4** 14.8 243** 19.3 220** 
Kato et al., Environ. Health Perspect. 
112 (3):327-330 (2004) 
[13] 
Adult 
(25 - 51 years) 
men Germany   5 spot 15.5 44.5 38.2 100.8 52.3 125.8 
Koch et al., Int. J. Hyg. Environ.-Health 
208:489–498  (2005) [102] 
Adult men MA, U.S. 
1999-
2003 
295   5.9 131**         
Duty et al., Hum. Reprod. 20 (3):604-
610 (2005) 
[117] 
Adult   U.S.   43   <0.9* 11.84 5.68* 116.38 7.99* 134.90 





  Germany   19 spot 14.0 49.9 41.3 72.5 52.1 96.1 
Preuss et al., J. Chromatogr. B 816 (1-
2):269-280 (2005) 
[16] 
Student   







634 24 h  7.6* 129 16.7* 251 21* 275 
Wittassek et al., Int. J. Hyg. Environ.-
Health 210:319–333 (2007) [18] 
Adult 
(14 - 60 years) 
27 women  
Munich,  
Germany  
2005 399 spot 5.6 206.5 17.3 439.9 22.0 674.3 
Fromme et al., Int. J. Hyg. Environ. 
Health 210 (1):21-33 (2007) 
[12] 
Adult 




2005 399 spot 5.4 55.4 15.6 215.4 23.0 309.3 
Fromme et al., Int. J. Hyg. Environ. 
Health 210 (1):21-33 (2007) 
[12] 
Adult 28 women NY, U.S.   246 spot 4.8* 46.8** 18.2* 107.6** 20.2* 149.6** 
Adibi et al., Environ. Health Perspect. 
116:467–473 (2008) [119] 
Adult 
(23 - 39 years) 
women Sweden 2001 38   13 57 19 83 25 126 
Högberg et al., Environ. Health 




Population Gender Origin Year n Sample type 
Urinary DEHP metabolite concentration (ng/mL) 
References References MEHP 5oxo-MEHP 5OH-MEHP 
Mean Max Mean Max Mean Max 
Adult  
(>20 years) 
  U.S. 
2001-
2002 
1647 first morning 4.20 39.5** 12.0 116** 18.1 175** NHANES 2001-2002 [114] 
Adult  
(>20 years) 
  U.S. 
2003-
2004 
1534 first morning 2.23 29.5** 12.9 139** 19.5 225** NHANES 2003-2004 [114] 
Adult  
(>20 years) 
  U.S. 
2005-
2006 
1490 first morning 2.94 41.5** 14.7 182** 23.4 306** NHANES 2005-2006 [114] 
Adult  
(>20 years) 
  U.S. 
2007-
2008 






349 spot 4.35* 175.43 9.02* 224.65 12.66* 325.73 
Herr et al., Int. J. Hyg. Environ. Health 
212 (6):648-653 (2009) 
[121] 
Adult  




 2006 60 spot 9.18 59.12 34.4 264.89 46.56 423.87 




(21 - 26 years) 




  30   11.7* 47.7 34.7* 105.3 27.7* 90.9 
Monfort et al. Transfusion 50 (1):145-
149 (2010) 
[29] 
Athletes       127 spot 7.1 19.7*** 18.4 49.8*** 18.4 51.7*** 




(30 - 50 years) 
men Seoul, Korea   25 spot 2.14 83.50 2.56 72.4 3.45 154.00 








45 first morning 3.6 30.8 13.9 164.3 20.9 268.2 
Peck et al., J. Expo. Anal. Environ. 
Epidemiol. 20:90-100 (2010) 
[124] 
All women  China 2010 99 spot 5.9 56.9 12.3 111 20.4 299 
Guo et al., Environ. Int. 37 (5):893-898 
(2011) 
[125] 
All men China 2010 84 spot 11.3 207 22.0 564 36.2 1120 




(21 - 31 years) 




  30 24 h 16.0* 26.4*** 38.2* 111.7*** 51.4* 112.7*** 
Monfort et al., J. Chromatogr. B 
908:113-121 (2012) 
[126] 
Athletes       464 spot 5.5* 15.3*** 13.6* 39.8*** 27.3* 76.0*** 
Monfort et al., J. Chromatogr. B 
908:113-121 (2012) 
[126] 
*Median value; ** 95th percentile value; *** 90th percentile value. 
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4.1.4.2. Occupational exposure to di(2-ethylhexyl) phthalate 
Workers in industries manufacturing or using DEHP plasticisers might be frequently 
exposed to above average levels of this compound [1]. Those living near industrial 
facilities or hazardous waste sites, with higher than average levels of DEHP in water, 
might also be exposed to higher than average concentration of DEHP. 
Maximum occupational exposures to DEHP, mainly by inhalation, are generally set at 
0.7 mg/kg/day when the workplace air concentrations meet the Occupational Safety and 
Health Administration's Permissible Exposure Limit (PEL) expressed as a Time 
Weighted Average (TWA) standard for 8 h, usually 5 mg/m3 [7,127]. Workplace air 
levels ranging from 0.02 to 4.1 mg/m3 were reported at facilities using or manufacturing 
DEHP [128]. Exposures of phthalate and PVC production workers to DEHP are 
estimated to be typically less than 143 and 286 μg/kg/day, respectively [3]. Between 
2003 and 2005, Hines et al. estimated DEHP exposure of 156 workers from eight 
industries handling DEHP. The combined estimates based on the urinary concentrations 
of three DEHP metabolites ranged from 0.6 to 850 μg/kg/day [129]. The external and 
internal exposure of DEHP in occupationally exposed population is summarised in Table 
4.9. 
 
Table 4.9: The external and internal exposure of DEHP in occupationally exposed adults [35]. 
Population Inhalation Dermal Total 
multiple routes 
 External Internal External Internal Internal 
 (mg/m3) (μg/kg/day) (mg/day) (μg/kg/day) (μg/kg/day) 
Production of DEHP 5 530 650 460 990 
Industrial use of DEHP 10 1060 420 300 1360 




4.1.4.3. Di(2-ethylhexyl) phthalate exposure from medical devices 
DEHP is currently the primary plasticiser used in PVC-containing medical devices such 
as containers for blood or liquid nutrients, tubing and catheters [2]. Thus, patients 
undergoing medical treatment may be exposed to DEHP released from PVC medical 
devices. The exposure to DEHP varies depending on the medical procedure as it is a 
function of the lipophilicity of the fluid that comes into contact with the medical device, 
the relative surface area of the PVC material, the temperature, the flow rate and the 
contact time [130-136]. Substances such as blood [6], plasma [6,134,137], red blood cell 
[6,134,138] or platelet concentrates [6,134], intravenous lipid emulsion [134-
136,139,140] or total parenteral nutrition solution [140,133] and formulation aids used to 
solubilise IV medications [130,131,134,141-143] can extract DEHP from PVC tubing 
and containers. In contrast, nonlipid-containing fluids, such as crystalloid IV solutions, 
saline priming solutions for extracorporeal membrane oxygenation (ECMO) and 
hemodialysis and peritoneal dialysis solutions extract relatively small amounts of DEHP 
from the PVC constituents of the devices [7]. 
The exposure can be long- or short-term. Long-term exposures in adults are 
haemodialysis, continuous ambulatory peritoneal dialysis (CAPD), transfusions of blood 
and blood products to patients with leukemia, aplastic anaemia, sickle cell anaemia, 
clotting disorders, administration of TPN and enteral nutrition of critically ill patients. 
Short-term DEHP exposures include blood transfusions, e.g. in trauma patients, patients 
undergoing surgical procedures or ECMO procedures, and intravenous infusion of drugs 
[2]. Estimated upper-bound doses of DEHP received by patients undergoing various 
medical procedures are summarised in Table 4.10 [3]. 
Transfusion of blood and its components is one of the major source of exposure to DEHP 
in infants and adults. DEHP leaches from the PVC blood bag during storage and from the 
tubing used during infusion. MEHP is formed through the hydrolysis of DEHP by 
plasma lipases in blood during storage [92,57]. The conversion was shown to increase 
with increasing storage time and temperature, while storage at low temperatures reduced 
the rate of hydrolysis [56]. Blood transfusion of trauma patients was found to be the 
short-term procedure that gives the highest acute DEHP exposure in adults up to 
8.5 mg/kg/day. MEHP exposure due to exchange transfusion has been estimated to be in 
the range of 5 to 680 μg/kg/day [144,145]. 
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Exposure to DEHP can also occur through voluntary medical treatments such as blood 
donation. Buchta et al. determined serum DEHP concentrations in donors after apheresis 
procedure [100]. The median amount of DEHP exposed during a single plateletpheresis 
procedure was estimated to be 6.5 mg/kg, with a broad inter-individual variation ranking 
from 1.8 to 20.3 mg/kg. Koch et al. estimated DEHP exposure of plasma donors, 
discontinuous-flow platelet donors and continuous-flow platelet donors by determining 
three DEHP metabolites in urine (5OH-MEHP, 5oxo-MEHP and MEHP). The highest 
exposure was observed for continuous-flow plateletpheresis with daily DEHP intakes of 
28.2-38.1 μg/kg/day. For discontinuous-flow platelet donors values were lower 
(14-24 μg/kg/day), while the internal burden after plasma donation (3.1-9.6 μg/kg/day) 
was not elevated in comparison to controls (3.0-11.6 μg/kg/day). This may be due to the 
fact that the lipid-rich plasma may contain most of the DEHP which is removed from the 




Table 4.10: Estimated upper-bound dose of DEHP received by adult and neonatal patients 
undergoing various medical procedures [3]. 
Medical procedure Estimated DEHP dose (mg/kg/day) 
 Adult (70 kg) Neonate (4 kg) 
Crystalloid intravenous (IV) solution infusion  0.005 0.03 
Infusion of pharmaceuticals with solubilisation vehicles   
Administered according to manufacturer instructions  0.04 0.03 
Mixed and stored at room temperature for 24 hours  0.15  
TPN administration   
Without added lipid  0.03 0.03 
With added lipid  0.13 2.5 
Administered via ethyl vinyl acetate bag and PVC tubing  0.06  
Blood transfusion   
Trauma patient  8.5  
Transfusion/extracorporeal membrane oxygenation (ECMO) 
 in adult patients 
3.0  
Exchange transfusion in neonates   22.6 
Replacement transfusions in neonates in NICU   0.3 
Replacement transfusions to treat anaemia in chemotherapy and  
sickle cells disease patients  
0.09  
Replacement transfusions in patients undergoing  
coronary artery bypass grafting  
0.28  
Treatment of cryodisorders with cryoprecipitate  0.03  
Cardiopulmonary bypass   
Coronary artery bypass grafting  1  
Orthotopic heart transplant 0.3  
Artificial heart transplant  2.4  
ECMO   14 
Apheresis  0.03  
Haemodialysis  0.36  
Peritoneal dialysis  < 0.01  
Enteral nutrition  0.14 0.14 
Aggregate exposures of NICU infants undergoing IV administration  





4.1.5. Alternatives to di(2-ethylhexyl) phthalate-plasticised poly(vinyl 
chloride) 
After DEHP was classified as toxic to reproduction (Repr. Cat. 2), it has been replaced 
by alternative substances for many applications, which is reflected in the decline in the 
total consumption of the substance. In addition, for some applications the plasticised 
PVC has been replaced with other materials. The main alternatives to DEHP are 
diisononyl phthalate (DINP) and diisodecyl phthalate (DIDP). Since 2000 DINP and 
DIDP have been exclusively used in PVC flooring, wall covering and in carpets with 
PVC back-coating. DEHP was mainly replaced by DINP and DIDP in synthetic (PVC) 
leather for upholstery, in toys and childcare products and in soft PVC for medical 
applications. Non-phthalate alternatives are used in PVC for applications where there has 
been a concern regarding human exposure to the substance (e.g. toys, medical devices 
and food packaging). Alternatives marketed specifically for these product groups include 
adipates, citrates, carboxylates, alkylsulphonic acid ester and castor oil derivatives. The 
alternatives are in general more expensive than DEHP with DINP being the least 
expensive alternative at an incremental cost of about 10%. Applications for which the 
selected alternatives are specifically mentioned by certain suppliers are shown in Table 
4.11, but the substances may be used for other applications as well [36]. 
 
Table 4.11: Applications specifically mentioned by suppliers of selected alternatives of DEHP [36]. 
 DINPa DEHTa BTHCa DINCHa ASEa 
Polymer applications      
Flooring and wall covering x x    
Film/sheet and coated products x x  x x 
Medical products   x x  
Wire and cable x     
Coated fabric and footwear  x  x x 
Toys  x   x 
Automotive x     
Non-polymer applications      
Adhesives    x x 
Printing inks    x x 
Sealants (glass insulation, construction) x    x 
a DINP: diisononyl phthalate, DEHT: di(2-ethylhexyl) terephthalate, BTHC: butyril trihexyl citrate, 
DINCH: 1,2-cyclohexanedicarboxylic acid diisononyl ester, ASE: alkyl sulphonic acid phenyl ester. 
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4.1.5.1. Alternatives to di(2-ethylhexyl) phthalate-plasticised poly(vinyl chloride) in 
medical devices 
There have been several attempts trying to eliminate or reduce the use of DEHP in 
medical devices. As it has been discussed above DEHP is beneficial for maintaining the 
viability and long-term storage of RBCs. Other components in blood, such as platelets, 
have a higher metabolic rate therefore suitable containers must have higher permeability 
to oxygen and carbon dioxide. This is achieved by using other plasticisers, such as 
trimellitates and citrates [146]. In medical tubing and parenteral infusion bags DEHP has 
been almost completely substituted. However, for RBCs only a limited number of 
DEHP-free products are available [147,148]. 
The most important factors influencing the viability of RBCs are the content of ATP, 
2,3-diphosphoglycerate, haemoglobin (Hb), the integrity of RBC membrane lipids and 
proteins and the flexibility of the RBC membrane in the microcirculation. Metabolic 
changes and oxidative damage depend strongly on the storage medium, its pH and the 
temperature. The requirements necessary for a blood bag material are resistance to heat 
and chemicals, especially during the sterilisation, and permeability of gases to assure that 
the pH and the oxygen level are kept constant [147]. 
Other plasticisers have been considered to substitute DEHP in PVC medical devices, 
such as acetyl tri-n-butyl citrate (ATBC), 1,2-cyclohexanedicarboxylic acid diisononyl 
ester (DINCH), di(2-ethylhexyl) adipate (DEHA), butyril trihexyl citrate (BTHC) [89] 
and tri-(2-ethylhexyl) trimellitate (TEHTM, also known as TOTM) [73]. Possible 
alternatives for blood bags are ATBC, TEHTM and BTHC, the latter being the most 
satisfactory plasticiser [146]. It was found to be effective for the storage of blood, red 
cell concentrates and platelet rich plasma [81-85,89]. ATBC might be used in medical 
tubing, DINCH for tubing and nutrient solution bags and TEHTM in infusion equipment 
[148,149]. Since the leaching rates of these plasticisers are usually lower than that of 
DEHP they seem to be promising alternatives, however, insufficient information is 
available to assess the use and safety of these compounds in medical devices. 
Another alternative to phthalate plasticisers is using polymeric plasticisers [2]. In order 
to minimise migration their molecular weight must be medium-high. In addition, 
polymeric plasticisers generally make processing of the plastic more difficult [150]. 
Another possibility is to replace PVC in blood bags with other polymers. Several 
polymer materials and their blends have been suggested, including ethylene vinyl acetate 
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(EVA), polyethylene (PE), polypropylene (PP), polyurethane (PU), thermoplastic 
elastomers (TPE) and fluoropolymers (e.g. polytetrafluoroethylene, PTFE) [2,151]. At 
the moment PVC is the most economical material for medical applications and unless 
other alternatives match in price, PVC will continue as the market leader in medical 
applications [146]. 
Recently, the addition of polyethylene oxide (PEO) to plasticised PVC bags has been 
suggested either as an additive or copolymer [152,153]. Furthermore, PEO was used as 
an inner coating of PVC bags in order to reduce the migration of DEHP into lipophilic 
solutions [154]. 
The main difficulty for the substitution of DEHP-plasticised PVC in blood bags is caused 
by the improved survival rate of erythrocytes facilitated by DEHP (see Section 
4.1.2.3.2). These alternative materials and the elimination of DEHP can lead to shorter 
RBC storage time and further health risks for patients receiving blood transfusions. In 
order to improve RBC survival different additive solutions have been proposed which 
seem to be promising in combination with some of the alternative materials 
[80,155,156]. 
The safety evaluation of medical devices and their composing materials including 
material characteristics, leaching and toxicology is described in the EN ISO 10993 series 
on Biological Evaluation of Medical Devices (ISO, Geneva, Switzerland; CEN, Brussels, 
Belgium). 
For some compounds sufficient toxicological data is available to indicate a lower hazard 
compared to DEHP. However, a risk assessment of these alternative materials could not 
yet be performed due to a lack of human exposure data. For others, information on the 
toxicological profile is inadequate to identify the hazard. This limits the proper 
evaluation of the potential to replace DEHP-plasticised PVC in medical devices. The risk 
and benefit should be carefully evaluated for each individual medical device and each 
medical procedure in which the alternative needs to be used [2]. 
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4.2. BLOOD TRANSFUSION IN SPORTS DRUG TESTING 
The World Anti-Doping Agency (WADA) defines blood doping as “the misuse of 
certain techniques and/or substances to increase one’s red blood cell mass, which allows 
the body to transport more O2 to muscles and therefore increase stamina and 
performance” [157]. The most widely known prohibited methods are the stimulation of 
erythropoiesis, the use of synthetic oxygen carriers and the transfusion of blood. 
Blood transfusion is the process of transferring blood or a blood-based product into the 
circulatory system of a person [158]. Homologous blood transfusion is the transfusion of 
blood from another person compatible for ABO and Rhesus D blood groups, whereas 
autologous blood transfusion is the reinfusion of the individual’s own stored blood [158]. 
Using blood transfusion in order to improve physical performance first appeared in the 
1970s among elite endurance athletes [159,160]. It became less popular at the end of the 
1980s due to the introduction of recombinant erythropoietin and the prohibition of blood 
transfusion methods by the International Olympic Committee for the 1988 Olympic 
Games [158]. The implementation of a direct test to detect exogenous erythropoietin in 
urine in 2001 [161] compelled cheating athletes to start using blood transfusion 
procedures again [162,163]. 
In order to further improve detection of abnormal blood profiles, WADA is leading the 
development of a strategy against doping in sport called the Athlete Biological Passport 
[164-166] which follows the athlete's biological variables over time. The objective of this 
strategy is to detect abnormal variations of determined biological parameters (e.g. 
haematocrit, haemoglobin, red blood cell count, percentage of reticulocytes and 
reticulocyte count) in order to better target testing and/or sanction those found with 
abnormal variations [157]. WADA’s Athlete Biological Passport Operating Guidelines 




4.2.1. Methods for the investigation of blood transfusion 
Detection of homologous blood transfusion was implemented by Nelson et al. using 
blood group antibodies to identify minor RBC populations in blood samples by 
fluorescence-based flow cytometry even 2-3 weeks after infusion [26,168]. The method 
was later validated by Giraud et al. analysing 140 blood samples containing different 
percentages (0-5%) of a minor RBCs population and most samples containing 1.5% 
minor RBC population were unambiguously detected, yielding 78% sensitivity [24]. An 
improved method was published by Voss et al. which allowed clear identification of 
mixed red blood cell populations in homologous blood transfusion samples containing 
0.3-2.0% of donor blood [25]. 
However, as the direct detection of autologous blood transfusion is still not possible, 
indirect methods are in development evaluating blood parameters such as haematocrit 
value, haemoglobin concentration, percentage of reticulocytes and corresponding 
parameters (ratios or total number of cell types). With the combination of haemoglobin, 
bilirubin, iron and erythropoietin measurements in serum 50% of autologous blood 
transfusion was detectable during the first week after transfusion [169]. Examining 
haematological response to blood withdrawal and reinfusion, Damsgaard et el. found that 
individual variations in [Hb] exceeding 15% between samples obtained shortly before 
competition may be indicative of autologous blood manipulation [170]. However, these 
variables are mainly based on concentrations and therefore highly affected by 
fluctuations in plasma volume; consequently they may not adequately reflect the absolute 
changes of Hb mass induced by blood transfusions [28,27]. Thus, a more sensitive 
parameter is the determination of loss in total Hb mass through blood donation using CO 
rebreathing [171,172]. It is still unproven if Hb mass measurements are suitable to detect 
the absolute changes induced by blood transfusions. Furthermore, the individual 
variability of Hb mass and the impact of other biological factors need to be investigated 
[27,173]. The total Hb mass showed moderate variation (approximately 2%) in subjects 
undertaking regular exercise [174] and was not influenced by short periods of training 
[175,176]. In contrast, total Hb mass was found to be increased in elite athletes following 
exercise in combination with altitude exposure [177-179]. Prommer et al. reported the 
high stability of total Hb mass over a period of 1 year (variation <6%), suggesting that it 
should be included in the Athlete Biological Passport and analysed by probabilistic 
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inference techniques that define subject-based reference ranges [180]. Compared to the 
currently used indirect parameters, the ratio between the mass of Hb in the mature 
erythrocyte population and in the reticulocyte fraction (RBCHb/RetHb) is the best 
indicator of autologous blood doping [181,182]. 
Besides the difficulties related to the practical applicability of CO rebreathing method for 
detecting nonphysiologic increases in Hb mass, its integration into the Biological 
Passport may be problematic due to the lack of clear standardisation and harmonisation 
in the determination of Hb mass [183,184]. In addition, blood samples for doping control 
are available in some selected situations only and therefore they cannot be considered as 
a general screening approach. 
In the recent years, research focused on the development of further indirect markers of 
autologous blood transfusion, such as a marker of degradation during storage 
(2,3-bisphosphoglycerate levels), markers of alteration of the red cell membrane 
structure, gene expression levels and transcriptional markers, proteomic and 
metabolomic approaches and markers of neocytolosis [158]. These markers may be 
included in the Biological Passport in the future. 
Current research on direct testing of autologous blood transfusion is based on the 
detection of exogenous substances in the athletes blood or urine samples spread during 
the withdrawal, the storage or the reinfusion of the blood, such as plasticisers leaked 
from the blood bags and residues of solvents used for cryogenic storage of the blood 
[158]. Monfort et al. compared the urinary concentrations of DEHP metabolites in 
patients subjected to clinical care and to blood transfusion. It was noticed that urine 
samples collected up to two days after blood transfusion contained significantly higher 
amounts of DEHP metabolites compared to control samples, indicating that DEHP 
metabolites could be used in sports drug testing as alert markers for the potential misuse 
of blood transfusion [29]. 
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4.3. METHODS USED FOR THE DETERMINATION OF URINARY 
DI(2-ETHYLHEXYL) PHTHALATE METABOLITES 
Due to the increased use of plasticised PVC products in the last few decades and the 
toxic properties of phthalate plasticisers the need for testing phthalate esters and their 
metabolites in environmental, biological and food samples gained remarkable 
importance. 
Monitoring the concentration of DEHP in biological samples might underestimate 
exposure since it is quickly and extensively metabolised in vivo. Therefore, for 
biomonitoring purposes mainly MEHP and the secondary metabolites 5oxo-MEHP and 
5OH-MEHP have been tested in various matrices, such as urine, blood, plasma, serum, 
saliva, sweat and milk. 
Since DEHP and its metabolites are present in environmental and biological samples at 
low level different techniques have been used for their extraction and concentration from 
the matrices. For DEHP measurement mainly gas chromatographic (GC) methods were 
used in combination with electron capture (ECD), flame ionisation (FID) or mass 
spectrometric (MS) detection. In some cases high performance liquid chromatographic 
(HPLC) methods were applied using UV spectrometric detection and found to be useful 
for the analysis of isomeric mixtures and metabolites of phthalates without derivatisation. 
Recently, several LC-MS and LC-MS/MS methods have been developed mainly 
applying electrospray ionisation in positive ionisation mode for DEHP and negative 
mode for the monoesters, 5oxo-MEHP and 5OH-MEHP. 
4.3.1. Sample extraction and clean-up 
Due to its highly apolar characteristic DEHP is mainly extracted using apolar organic 
solvents, such as dichloromethane, cyclohexane, hexane, isooctane or by non-polar solid 
phase extraction (SPE). The extraction is usually carried out by shaking the samples; 
however, there are examples for Soxhlet extraction, accelerated solvent extraction and 
ultrasonic or microwave assisted extraction procedures in solid matrices. 
Since DEHP metabolites are less apolar and excreted in urine as glucuronide conjugates, 
the samples are usually hydrolysed using β-glucuronidase prior to extraction. In some 
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cases liquid-liquid extraction was applied using ethyl acetate as the solvent [29,185,126]. 
A more common procedure is the SPE technique using C8 [16,186,187], C18 
[188,118,189] on other mixed-mode solid phase materials [190-193]. In order to avoid 
contamination from the laboratory environment automated SPE [191,194] and online-
SPE, so-called column-switching techniques [16,186-188,118,195,196], have been 
developed as well. 
Though the sample extract can be purified by gel permeation chromatography [197] or 
by SPE using sorbents, such as aluminium oxide [198], silica [199] or Florisil [200], it is 
most commonly analysed without any additional clean-up. 
4.3.2. Measurement techniques 
DEHP was primarily measured using gas chromatography coupled to mass spectrometry. 
In some cases flame ionisation or electron capture detection in combination with gas 
chromatography was applied. However, FID is not specific for phthalates and ECD 
detectors respond more sensitively towards halogenated compounds. 
Using electron ionisation (EI) for GC-MS, the major fragment at m/z 149 corresponds to 
the protonated phthalic acid anhydride ion which is generally used for quantification. 
Besides the most abundant ion at m/z 149, the spectrum is rather poor and the molecular 
ion (m/z 390) is not detectable. Additional ions at m/z 279 and 167 confirm the identity 
of the peak (Figure 4.8) [201]. 
 
 




Positive chemical ionisation (PCI), applying methane or ammonia as reagent gas, 
provides a mass spectra containing more abundant peaks for high-mass ions allowing 
better identification and distinction of the different phthalates [202,203]. 
The free fatty acid group on the monoester metabolites can cause adsorption of the 
molecule on the column during gas chromatographic analysis. Therefore, derivatisation 
is necessary to allow quantitative analysis of trace level monoester by GC. This can be 
achieved by esterification [95] or oximation [204] and silylation of the acid group. 
However, derivatisation can lead to further hydrolysis with the formation of phthalic acid 
dimethyl ester or to the hydrolysis of the parent molecule causing false positive results 
for the monoesters [201]. 
Alternatively, phthalate monoesters were analysed in urine samples without 
derivatisation using HPLC coupled to UV detection. Separation of the DEHP metabolites 
were reported by using CN [205], C18 [29,126,187-189,193], phenyl [118,190-192,194] 
and phenyl-hexyl [16,186] columns showing reasonable separations. 
Recently, several LC-MS or LC-MS/MS methods have been developed for the analysis 
of DEHP and its metabolites in biological samples. The ionisation of the compounds 
were achieved by either using electrospray ionisation (ESI) in negative [16,186-
188,118,191,194] and positive mode [29,126] or atmospheric pressure chemical 
ionisation in negative mode [185,190,192]. 
The product ion spectra of MEHP produced by collision-induced dissociation (CID) was 
described by Blount et al. [190] and phthalate specific negative ions were found at 
m/z 77, 105, 121, and 147, corresponding to putative benzyl, benzaldehyde, benzoate and 
phthalic anhydride fragment anions (Figure 4.9). Later Koch et al. published ESI 
negative Q1 mass spectra of the secondary metabolites 5OH-MEHP and 5oxo-MEHP 
with the predicted structures of the fragment ions (Figure 4.10) [186]. 
 





Figure 4.10: ESI negative Q1 mass spectra of MEHP, 5OH-MEHP, 5oxo-MEHP and 
D4-5OH-MEHP with the predicted structures of the fragments published by Koch et al. [186]. 
4.3.3. Quality assurance and blank values 
Due to their widespread use and physicochemical properties many phthalates are 
ubiquitous; therefore, their direct measurement is difficult. The samples can be 
contaminated during sample collection, transportation, storage and the analytical testing 
procedure. Consequently, caution should be taken to keep background concentrations at 
low levels, blank values should be controlled and a correction has to be made. 
In bioanalytical applications mostly phthalate metabolites are analysed which are usually 
not subject to contamination [206]. In particular, the secondary metabolites of DEHP 
were found to be more sensitive biomarkers of exposure to DEHP than MEHP [207]. 
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4.4. SCREENING METHODS IN SPORTS DRUGS TESTING 
In sports drug testing the number of samples and doping agents constantly increases; 
thus, multi-target approaches, combining high-throughput, simplified sample preparation 
and a reliable detection for various classes of compounds are required. On the basis of 
modern and powerful analytical instruments, consisting of liquid chromatographs 
coupled to sensitive mass spectrometers, e.g. triple-quadrupole, time-of-flight (TOF) or 
Fourier transform (OrbiTrap) instruments, numerous new multi-target assays have been 
developed providing reliable detection of prohibited substances. Currently, different 
screening procedures are utilised for the analysis of diuretics [208-215], beta2-agonists 
[213,214,216], stimulants [211,213,214,217], narcotics [214,213,218-220] and plasma 
volume expanders (PVE) [221-223]. With the ongoing progress in the field of liquid 
chromatography and triple quadrupole mass spectrometry, new generation instruments 
have become accessible with the possibility of enhanced scan speed and scan-to-scan 
polarity switching. These achievements allow the development of new multi-target 
approaches by combining classical “stand-alone” screening procedures to detect several 
different categories of prohibited substances with versatile chemical structures. In 
contrast to TOF based approaches fast polarity switching allows the detection of acidic 
and basic compounds within a single run. Moreover, the high sensitivity of such 
instruments enables the identification of many prohibited substances without pre-
concentration steps, resulting in very simple and fast “dilute-and-shoot” methods. In 
sports drug testing two assays have demonstrated its applicability for the combined 
detection of diuretics, stimulants and narcotics using direct injection of urine specimens 
based on ultra-high performance liquid chromatography/tandem mass spectroscopy 
(UHPLC-MS/MS) and ultra-high performance liquid chromatography/quadrupole time-
of-flight mass spectrometry (UHPLC-QTOF-MS) [224,225]. 
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4.5. STATISTICAL METHODS 
4.5.1. Huber’s statistics 
Most estimates of central tendency (e.g. arithmetic mean) and dispersion (e.g. standard 
deviation) depend on an implicit assumption that the data comprises a random sample 
from a normal distribution. Analytical data often contains a higher than expected 
proportion of results far from the arithmetic mean, as well as outliers. In such cases 
statistical models which assume normal distribution of the data points are inappropriate 
to describe the dataset. As Figure 4.11 illustrated the mean has a high bias and the 
standard deviation is too large. In addition the actual values of the outliers have a great 
influence on the estimate values. 
 
 
Figure 4.11: Illustration of the statistics using the model based on a normal distribution on data 
containing outliers [226]. 
 
A more reasonable interpretation of the dataset is to exclude the outliers from the 
calculations resulting in a plausible normal model for most of the data points (Figure 
4.12). Although it provides us with no warning about the possible outliers, this model is 




Figure 4.12: Illustration of the statistics using the model based on a normal distribution on data 
excluding outliers [227]. 
 
A typical solution to handle suspect values is the identification of the outliers at 
particular confidence levels by employing tests such as Dixon’s or Grubbs’. These 
procedures are not necessarily straightforward, since the test may be misleading if two or 
more outliers are present and it raises the question of when it is justifiable to exclude 
outliers [227]. 
Robust statistical models provide alternative solutions as describing the dataset without 
excluding any outliers. Huber’s method, for example transforms the original data by a 
process called Winsorisation, in which an outlying value is ‘moved’ so that its residual is 
reduced (i.e. the difference between the single value and the sample mean) [228]. 
Starting with initial estimates    as the median or arithmetic mean and    as the standard 
deviation, if a value    falls above         , it will be changed to  ̃          . 
Similarly, if a value    falls below         , it will be changed to  ̃          . All 
the other data remains unchanged ( ̃    ). From the new data, improved estimates of 
the mean        ( ̃ ) and standard deviation               ( ̃ ) are calculated. 
The factor 1.134 is derived from the normal distribution, given a value 1.5 for the 
multiplier most often used in the Winsorisation process. This procedure is then iterated 
using the improved estimates for the Winsorisation at each cycle. The process converges 
to an acceptable degree of accuracy and the resulting values are the robust estimates    
and    [227]. 
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4.5.2. Intraclass correlation 
Intraclass correlation was introduced by Fisher et al. as descriptive statistic that can be 
used to describe how strongly values of the same group coincide with each other [229]. 
The coefficient ( ) can be described as the proportion of the total variance which is 
attributed to variation between groups (   ):             , 
where     is the within-group variability. 
The intraclass correlation coefficient (ICC) approaches 0 in the case of low within-group 
homogeneity and it approaches 1 when the between-group variation is large compared to 
the within-group variation. 
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5. AIM OF THE THESIS 
The overall aim of this thesis was to investigate the possibility of the detection of blood 
transfusion by testing athletes’ urine samples for DEHP metabolites. 
The main objectives were:  
 To develop a straightforward and rapid assay for the identification and 
quantification of the three major DEHP metabolites (MEHP, 5oxo-MEHP and 
5OH-MEHP) in urine samples. 
 To determine the levels of the phthalate metabolites in control samples, in 
athletes’ samples and in post-transfusion samples. 
 To estimate an upper reference limit for the urinary concentrations of the 
metabolites in subjects without extraordinary DEHP exposure. 
 To investigate the possible intra-individual variability of the metabolites over 
time. 
 To integrate the DEHP metabolites into an existing screening procedure and 
apply the method for routine doping control samples. 
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6. MATERIALS AND METHODS 
6.1. DETERMINATION OF URINARY DI(2-ETHYLHEXYL) PHTHALATE 
METABOLITES 
6.1.1. Materials 
6.1.1.1. Chemicals and reagents 
MEHP, 5oxo-MEHP, 5OH-MEHP, 13C4-MEHP and 
13C4-5oxo-MEHP were obtained 
from Cambridge Isotope Laboratories Inc. (Andover, MA, USA) and they were of 
analytical purity (Table 6.1). β-Glucuronidase (from E. coli K12, 140 U/mL at 37.0°C) 
was acquired from Roche Diagnostics GmbH (Mannheim, Germany). Acetic acid and 
ammonium acetate were purchased from Sigma (Steinheim, Germany). All reagents were 
of analytical grade. Acetonitrile (LC-MS grade) was supplied by VWR International 
GmbH (Darmstadt, Germany). Standard solutions and other aqueous solutions were 
prepared using deionised water (Sartorius AG, Goettingen, Germany). 
 
Table 6.1: Reference materials 
Analyte Name Abbreviation Formula CAS No. Molecular Weight 
mono(2-ethylhexyl) 
phthalate 
MEHP C16H22O4 4376-20-9 278.3435 
mono(2-ethyl-5-oxohexyl)  
phthalate 
5oxo-MEHP C16H20O5 40321-98-0 292.3270 
mono(2-ethyl-5-hydroxyhexyl)  
phthalate 
5OH-MEHP C16H22O5 40321-99-1 294.3429 
13C4-mono(2-ethylhexyl)  
phthalate 
13C4-MEHP *C4C12H22O4 n.a. 282.3141 
13C4-mono(2-ethyl-5-oxohexyl)  
phthalate 
13C4-5oxo-MEHP *C4C12H20O5 n.a. 296.2976 
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6.1.1.2. Reference solutions 
A stock standard solution was prepared of each individual compound with a 
concentration of 100 µg/mL in acetonitrile and stored at +4°C. The working solutions of 
the compounds were prepared at the concentration level of 1 µg/mL in 
acetonitrile:water (1:1, v:v). 
6.1.2. LC-MS/MS method development 
6.1.2.1. Chromatographic parameters 
For the chromatographic separation an Agilent 1100 HPLC system was used which 
consisted of a vacuum degasser, an autosampler and a binary pump. Reversed phase 
liquid chromatography was performed on a Phenomenex Gemini C6-phenyl 
column (100 x 2 mm; 3 µm) connected to a Phenomenex Gemini C6-phenyl 
pre-column (2 x 4 mm). The mobile phase consisted of 5 mM ammonium acetate buffer 
containing 0.1% acetic acid (pH = 3.5, mobile phase A) and acetonitrile (mobile phase 
B). The flow rate was set to 0.25 mL/min. The gradient program started at 0% B, then 
increased to 100% B in 8 min and then was held at 100% B for 2 min. The analysis run 
time was 10 min with a 4.5 min post-run equilibration time resulting in a 14.5 min 
injection-to-injection duration. The injection volume was 10 µL. 
6.1.2.2. Mass spectrometric parameters 
Mass spectrometric detection was carried out using a hybrid triple quadrupole/linear ion 
trap mass spectrometer (AB SCIEX 5500 QTrap; Darmstadt, Germany) using negative 
electrospray ionisation in multiple reaction monitoring (MRM) mode. The ion source 
was operated at 400°C and the applied ionspray voltage was set to -4500 V. Nitrogen 
was used as curtain, nebuliser, and auxiliary gas delivered from a nitrogen generator 
(CMC Instruments, Eschborn, Germany). Collision energy and declustering potential 
were optimised for each analyte via direct injection of pure reference compounds using a 
1 mL syringe at a flow rate of 10 µL/min (Table 6.3). Enhanced product ion spectra were 
acquired using linear ion trap (LIT) mode. Detailed method parameters are listed in 
Table 6.2. To evaluate the acquired data Analyst 1.5 software was used. 
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Table 6.2: LC-MS/MS method parameters. 
Chromatographic Parameters 
HPLC system Agilent 1100 Series LC System   
HPLC column Phenomenex Gemini C6-phenyl (100 x 2.0 mm; 3 µm) column 
 Phenomenex Gemini C6-phenyl (4 x 2.0 mm) pre-column 
Mobile Phase A: 5 mM ammonium acetate, 0.1% acetic acid (pH = 3.5) B: acetonitrile 
Gradient 0 min 100% A 0% B 
 8 min 0% A 100% B 
 10 min 0% A 100% B 
 re-equilibration 4.5 min at 100% A   
Flow rate 0.25 mL/min   
Injection Volume 10 µL   
Mass spectrometric parameters 
Mass spectrometer AB SCIEX 5500 QTrap  
Ionisation ESI in negative ionisation mode  
Scan Mode MRM  
Interface Temperature 400°C  
Nebulizer Gas N2, 40 psi 
Auxiliary Gas N2, 20 psi 
Curtain Gas N2, 20 psi 
Ionspray Voltage -4500 V 
Entrance Potential -10 V 
Collision Gas N2, 3.5 x 10
-3 Pa 
Collision Cell Exit Potential -10 V 
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(min) (m/z) (m/z) (eV) (V) 
Mono(2-
ethylhexyl) phthalate 
MEHP 10.96 277 134 -22 -70 
    127 -24 -70 
    77 -36 -70 
Mono(2-ethyl-5-
oxohexyl) phthalate 
5oxo-MEHP 9.41 291 143 -20 -70 
    121 -26 -70 
    77 -46 -70 
Mono(2-ethyl-5-
hydroxyhexyl) phthalate 
5OH-MEHP 9.25 293 121 -28 -70 
    77 -46 -70 




13C4-MEHP 10.95 281 137 -22 -70 
    79 -38 -70 






9.40 295 143 -20 -70 
    124 -26 -70 
    79 -46 -70 
a Retention time was calculated as the mean value of six replicates. 
b The analysis was performed in negative ionisation mode. 
c The values in bold font indicate the quantifier ions. 
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6.1.3. Sample preparation 
A 1 mL aliquot of the urine sample was fortified with 100 ng of the internal standards 
(13C4-MEHP and 
13C4-5oxo-MEHP), then 25 µL of β-glucuronidase (140 U/mL at 
37.0°C) was added. The enzymatic hydrolysis was carried out at room temperature 
within 10 min. The hydrolyzed samples were prepared by appropriate dilution (1:5, v:v) 
with a mixture of acetonitrile:water (1:1, v:v) and an aliquot of 10 µL was injected into 
the instrument. 
6.1.4. Quantification of target compounds 
To enable quantification of the target compounds the peak area ratios of the quantifier 
ion transitions of the analytes and the respective internal standards (MEHP to 
13C4-MEHP, 5oxo-MEHP and 5OH-MEHP to 
13C4-5oxo-MEHP) were used. Calibration 
graphs were obtained by analysing spiked blank urine samples at concentration levels of 
1, 10, 50, 100, 150, 200 and 250 ng/mL. Samples with concentrations above the highest 
calibration point were diluted with water to fit the calibration range. 
Due to the lack of phthalate-free urine matrices the quantitative results were corrected to 
the physiological amount of the respective analytes in the used blank matrix and adjusted 
to a standard urine density of 1.020 g/mL according to WADA guidelines [230]. 
For quantification purposes the most suitable ion transitions were m/z 277/134 for 
MEHP, m/z 291/143 for 5oxo-MEHP and m/z 293/121 for 5OH-MEHP. The chosen 
qualifier transitions were m/z 277/127 and m/z 277/77 for MEHP, m/z 291/121 and m/z 
291/77 for 5oxo-MEHP, and m/z 293/77 and m/z 293/145 for 5OH-MEHP. 
Compound identification was performed based on the relative retention time and the 
relative ratios of three ion transitions for each analyte. 
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6.1.5. Assay validation 
For validation the following parameters were determined; specificity, linearity, ion 
suppression, accuracy, intra- and inter-day precision, limit of detection (LOD) and limit 
of quantification (LOQ). The validation was performed according to the guidelines of the 
International Conference on Harmonisation and WADA [231,232]. All calibration 
samples were prepared as described above, using 1 mL of blank urine spiked with 
respective amounts of reference standards and subsequent dilution with 
acetonitrile:water (1:1, v:v) to a volume of 5 mL. 
6.1.5.1. Specificity 
Evaluation of the specificity was carried out by analyzing six different spiked and blank 
urine samples collected from healthy volunteers to test for interfering signals in the 
selected MRM chromatograms at the expected retention times of the analytes. 
6.1.5.2. Linearity 
Calibration curves (n = 6) for the metabolites were generated using aliquots of a blank 
urine sample spiked at concentrations of 1, 10, 50, 100, 150, 200, 250 ng/mL. The ratio 
of peak areas for the analytes and the corresponding internal standards (ISTDs) were 
used to calculate the correlation coefficient, intercept and slope. 
6.1.5.3. Ion suppression / enhancement 
The extent of ion suppression or enhancement was investigated by analysing six different 
blank urine samples via post-column continuous infusion of a mixture of the reference 
compounds (100 ng/mL, 20 µL/min) [233]. 
6.1.5.4. Accuracy and precision 
The accuracy and precision were determined using six replicates of spiked urine samples 
at the concentration levels of 10, 100 and 250 ng/mL (QClow, QCmedium, QChigh). To test 
for accuracy the concentrations of the respective aliquots were calculated utilising an 
external calibration curve. To establish the inter-day precision the same samples were 
prepared and analysed on three consecutive days (n = 6+6+6). The precision of the 
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method was determined by calculation of the coefficient of variation (CV) of the area 
ratio of the quantifier ion transition of the analytes and the respective internal standards. 
6.1.5.5. Stability 
In earlier studies the decomposition of DEHP metabolites was noticed in urine above 
4°C [234]. To ensure accurate analytical results the stability of the DEHP metabolites in 
the prepared samples was tested. Therefore, three different quality control (QC) samples 
were prepared at the concentration level of 100 ng/mL stored for up to 4 months at -20, 
4°C and room temperature, respectively. 
6.1.5.6. Limit of detection and limit of quantification 
LOD and LOQ were defined as the lowest concentrations of the analyte in a sample that 
gave signal-to-noise ratios of 3:1 and 10:1 for the quantifier ion transition with a 
precision of less than 20% and an accuracy of 80 to 120%. Six blank urine samples were 
analysed to establish the noise intensity. Three parallel artificial urine samples spiked at a 
concentration of 0.5 ng/mL for LOD and 1 ng/mL for LOQ were prepared and analysed. 
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6.1.5.7. Uncertainty of the method 
The uncertainty of the measurement (  ) was calculated according to WADA 
guidelines [235]. It is based on the data obtained through the validation of the method.   ( )  √ (  )   ( ) , 
where    is the intermediate precision,   is the average recovery bias and  ( ) 
was calculated using the equation:  ( )  √( )  (  √ )  (    ) , 
where    is the standard deviation of the average bias of   replicate analysis 
(   ) and      is a random error contribution (      ). 
For determination of the expanded uncertainty (    ) a coverage factor     can be 
applied if    has a 95% confidence level.           (   ). 
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6.1.6. Density and creatinine measurement 
The density of the urine samples was measured using an Anton Paar DMA 38 density 
meter (Graz, Austria). 
Creatinine measurements were carried out using a Creatinine Assay Kit (Cayman 
Chemical Company, Ann Arbor, MI, USA). The assay relies on the Jaffe’ reaction [236]. 
The dynamic range of the kit is 0-15 mg/dL of creatinine. Since creatinine levels in 
human urine typically range from 25 to 400 mg/dL urine samples were diluted 1:20 with 
HPLC-grade water. The sample creatinine concentration was determined using a 
creatinine standard curve (0, 2, 4, 6, 8, 10, 12, and 15 mg/dL). 
6.1.7. Study subjects 
6.1.7.1. Reference populations 
6.1.7.1.1.  Control samples 
In order to determine the physiological levels of DEHP metabolites, urine samples were 
collected from 100 healthy volunteers (68 male, 31 female, 1 unknown) from the 
German Sport University Cologne (control samples). The participants were between 20 
and 59 years of age and regularly exercised. 
6.1.7.1.2. Athletes’ samples 
In addition, 468 official doping control urine samples were analysed (374 male, 90 
female, 4 unknown), received between January 2010 and June 2010 from national and 
international federations, taken in-competition (n = 217, IC) and out-of-competition 
(n = 251, OOC) covering different sporting disciplines. 
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6.1.7.2. Post-transfusion samples 
6.1.7.2.1. Excretion urine samples 
Urine samples of patients receiving autologous blood transfusion were collected between 
0 to 24 hours after transfusion (n = 10, 2 samples from each volunteer after blood 
transfusion, 2 female and 3 male, age 44-79, Surface-Zentrum für Orthopädie, Neuss, 
Germany) and blank samples of each volunteer were taken before transfusion to estimate 
the individual reference values. Written consent was received from each volunteer. 
6.1.7.2.2. Post-transfusion samples with 14 and 28 days storage of transfused blood 
Urine samples were collected from 25 healthy volunteers, who partake in moderate 
training, and receive autologous RBC transfusions. 
Blood collection, preparation, storage of RBCs and the autologous RBC transfusion were 
performed by a specialised laboratory according to usual clinical practice, using blood 
bags (Macopharma, Tourcoing, France) and leukoreduction filtration systems (Fenwal 
Inc., Lake Zurich, IL, USA) with the approval of the Ethics Committee of the 
Ruhr-University Bochum (Reg. No. 3200-08). 
The subjects were separated into two groups in terms of transfusion. The first group 
consisted of 12 subjects (5 female, 7 male, aged 15-40 n = 161) who received the RBC 
transfusions (500 ml) 14 days after the phlebotomy, and the 13 subjects of the second 
group (5 female, 8 male, aged 21-28, n = 220) were reinfused after 28 days of RBC 
storage (500 ml). Urine samples were collected several days before blood transfusion 
(including the day of blood collection), on the day of the reinfusion and up to 21 days 
after transfusion (Figure 6.1). Samples from the first group were collected on days 3, 4 
(blood collection), 5, 11, 17, 18 (blood transfusion), 19, 20, 21, 23, 25, 28, 32, 39 and 
from the second group on days 0, 3, 4 (blood collection), 5, 11, 18, 25, 31, 32 (blood 
transfusion), 33, 34, 35, 37, 39, 42, 46 and 53. On the day of the blood collection and the 
reinfusion samples were obtained from 1 to 3 hours after procedure. 
An independent blind analysis was carried out on this set of samples using a different 
analytical procedure by the Bioanalysis Research Group, IMIM-Hospital del Mar 
(Barcelona, Spain). The correlation between the results obtained by the two laboratories 
was published by Monfort et al. [237]. In this study only our results are shown. 
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Figure 6.1: Sample collection protocol from 25 healthy volunteers, who partake in moderate 
training, and receive autologous RBC transfusions: Group 1 (a), Group 2 (b). Green arrows indicate 
the days of phlebotomy and red arrows indicate the days of transfusion. 
 
6.1.7.3. Longitudinal study 
In order to determine the intra-individual variability of urinary concentrations of DEHP 
metabolites, urine samples were collected from seven healthy volunteers (3 female, 4 
male; age: 27-37 years) during one week (29-45 samples per volunteer, n = 253). The 
samples were collected from a different starting date and during a different period of time 
(153 h-193 h) from each volunteer. The study was not a specially designed experiment. 
The volunteers did not follow any restrictions and did not answer questionnaires. 
 
All samples were stored in polyethylene bottles at -20°C until analysis. 
Informed consent was obtained from all medicated patients and volunteers. 
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6.1.8. Statistical evaluation 
6.1.8.1. Reference populations  
The values of all investigated compounds exhibited heavily skewed distributions. 
Log-transformation yielded nearly symmetric distributions which, however, still 
contained numerous high values. Therefore, calculation of mean and standard deviation 
to describe the population was inappropriate. Instead, Huber's method [227] was applied 
to the log-transformed values for descriptive statistics as well as for the calculation of 
reference limits. Huber's M-estimator yields robust estimates for the central tendency 
(µH) and for the dispersion (σH) of an empirical distribution. The distribution should be 
symmetrical but may contain a limited number of outliers. Ideally, µH will reflect the 
mean or median of the uncontaminated distribution. Similarly, σH approximates the 
standard deviation under ideal conditions. Therefore, these parameters were used in 
analogous fashion to mean and standard deviation in order to estimate the probability of 
given values falling outside a certain interval. 
On a logarithmic scale, the σH of all compounds except MEHP was multiplied with the 
0.999 quantile of the Gaussian distribution (3.09). This value was then added to the 
respective values of µH to obtain upper 99.9% reference limits. These resulting values 
were transformed back to concentrations. The data below LOQ were substituted with the 
value of the LOQ divided by two (LOQ/2). Statistical analysis was performed using the 
latest version of the software “R” [238] where the functions for Huber's statistics can be 
found in library “MASS” [239] and STATISTICA software version 7.0 (StatSoft Inc., 
Tulsa, OK, USA). 
6.1.8.2. Longitudinal study 
Within-subject variability was assessed using intra-class correlation. Intra-class 
correlation coefficients (ICCs) were calculated for each metabolite using random effects 
models, which were applied for the log-transformed data. As markers for reliability, ICCs 
range from 0 to 1, with values near 1 indicating high reliability. 
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6.2. INTEGRATION OF DI(2-ETHYLHEXYL) PHTHALATE METABOLITES 
INTO AN EXISTING SCREENING PROCEDURE FOR SPORTS DRUG 
TESTING 
6.2.1. Materials 
6.2.1.1. Chemicals and reagents 
Internal standard mefruside was acquired from Bayer AG (Leverkusen, Germany). 
Glacial acetic acid and ammonium acetate were purchased from Sigma (Steinheim, 
Germany). All references and reagents were of analytical grade. Acetonitrile (LC-MS 
grade) was supplied by VWR International GmbH (Darmstadt, Germany). Standard 
solutions and other aqueous solutions were prepared using deionised water (Sartorius 
Stedim Biotech GmbH., Göttingen, Germany). 
6.2.1.2. Reference solutions 
A stock standard solution of the internal standard was prepared at a concentration of 
1 mg/mL in methanol and stored at -20°C. The reference working solution of the 
compound was prepared at a concentration level of 10 µg/mL in methanol. 
6.2.1.3. Quality Control samples 
For the phthalate glucuronides, quantified post-transfusion samples were analysed as 
QCs. 
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6.2.2. Sample preparation 
An aliquot of 90 µL of urine sample was fortified with 50 ng of the internal standard 
mefruside (corresponding to 10 µL of a 5 µg/mL solution of the ISTD in methanol) the 
samples were then mixed, and an aliquot of 5 µL was injected into the instrument. 
6.2.3. LC-MS/MS analysis 
Chromatographic separation of target analytes was achieved on an Agilent 1100 Series 
HPLC system equipped with a Nucleodur C18 Pyramid analytical column (50 x 2 mm, 
3 µm particle size; Macherey-Nagel, Düren, Germany) connected to a Phenomenex 
Gemini C6-phenyl (2 x 4 mm) pre-column. The mobile phase consisted of 5 mM 
ammonium acetate buffer containing 0.1% glacial acetic acid (pH = 3.5, mobile phase A) 
and acetonitrile (mobile phase B). A linear gradient at a flow rate of 0.35 mL/min was 
employed starting at 0% B, increasing to 90% B within 4.5 min and then re-equilibrating 
(0.5 mL/min) at 0% B for 6.25 min. The overall runtime was 10.75 min injection-to-
injection. The injection volume used was 5 µL. 
Tandem mass spectrometry was carried out using a hybrid triple quadrupole / linear ion 
trap mass spectrometer (AB Sciex 5500 QTrap; Darmstadt, Germany) controlled by 
Analyst Software 1.5 (AB Sciex). Fast polarity switching (50 msec) electrospray 
ionisation was used with the following conditions: ionspray voltage +5500 V (positive) 
and -4500 V (negative), ion source temperature 450°C, nitrogen was used as curtain, 
nebuliser, and auxiliary gas. The analytes and the ISTD (mefruside) were detected 
utilising multiple reaction monitoring (MRM) of diagnostic ion transitions at dwell times 
of 10 msec. For optimisation of the orifice potential and the collision energy solutions of 
pure reference compounds for each analyte were directly injected using a 1 mL syringe at 
a flow rate of 10 µL/min. Nitrogen was used as the collision gas (3.5 x 10-3 Pa) delivered 
from a nitrogen generator (CMC Instruments, Eschborn, Germany). Detailed method 
parameters are listed in Table 6.4. Target ion transition of MRM experiments are listed in 
Table 6.5. 
Materials and Methods 
 65 
 
Table 6.4: LC-MS/MS screening method parameters. 
Chromatographic Parameters 
HPLC system Agilent 1100 Series LC System   
HPLC column Macherey-Nagel Nucleodur C18 Pyramid analytical column (2 x 50 mm, 3 µm) 
 Phenomenex Gemini C6-phenyl (4 x 2.0 mm) pre-column 
Mobile Phase A: 5 mM ammonium acetate, 0.1% acetic acid (pH = 3.5) B: acetonitrile 
Gradient 0 min 100% A 0% B 
 4.5 min 10% A 90% B 
 10 min 0% A 100% B 
 6.25 min post-run equilibration time (using 0.5 mL/min flow rate) 
Flow rate 0.35 mL/min   
Injection Volume 5 µL   
Mass spectrometric parameters 
Mass spectrometer AB SCIEX 5500 QTrap 
Ionisation ESI in polarity switching mode (50 msec) 
Scan Mode MRM 
Interface Temperature 450°C 
Nebulizer Gas N2, 60 psi 
Auxiliary Gas N2, 30 psi 
Curtain Gas N2, 30 psi 
Ionspray Voltage +5500 V, -4500 V 
Entrance Potential +/-10 V 
Collision Gas N2, 3.5 x 10
-3 Pa 
Collision Cell Exit Potential -10 V (for DEHP metabolites) 
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mefruside (ISTD) 5.43 1.00 - 381 78 -80 -100 
5OH-MEHP-gluc 5.15 0.95 - 469 293 -20 -70 
5oxo-MEHP-gluc 5.18 0.95 - 467 291 -20 -70 
a RT: retention time 
b RRT: relative retention time 
c – negative ionisation mode 
6.2.4. Validation of the method 
For validation the following parameters were determined; specificity, ion suppression, 
intra- and inter-day precision, limit of detection (LOD) and robustness. Additionally, to 
test for linearity and accuracy correlation between the conjugated metabolites and the 
unconjugated analogues were investigated. The validation for identification of target 
analytes was performed according to the guidelines of the International Conference on 
Harmonisation and WADA [240,241]. All calibration samples were prepared and 
analysed as described above. 
6.2.4.1. Specificity 
Evaluation of specificity was carried out by analysing six different spiked and six 
different blank urine samples collected from healthy volunteers (5 female, 1 male) to test 
for interfering signals in the selected MRM chromatograms at expected retention times 
of the analytes. 
6.2.4.2. Ion suppression / enhancement 
The extent of ion suppression or enhancement was investigated by analysing six different 
blank urine samples via post-column continuous infusion of a mixture of the reference 
compounds (1 µg/mL, 20 µL/min) [233]. 
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6.2.4.3. Accuracy and linearity 
To ensure the ability of the method for semi-quantitative purposes the correlation of 
5OH-MEHP and 5oxo-MEHP concentrations and the relative intensities of the 
corresponding 5OH-MEHP-gluc and 5oxo-MEHP-gluc were determined. 
6.2.4.4. Precision 
Intra-day precision was determined at three concentration levels for each compound 
(QClow, QCmedium, QChigh) using six replicates of spiked urine samples. The 
corresponding inter-assay precision was calculated from samples prepared and analysed 
on three different days. The precision of the method was determined by calculation of the 
coefficient of variation (CV) of the area ratio of the ion transition of the analytes and the 
internal standard. 
6.2.4.5. Limit of detection 
LOD was estimated via the signal to noise ratio (S/N) of the respective ion traces using 
ten blank samples and ten fortified samples at concentration levels of 50 ng/mL. 
6.2.4.6. Robustness 
Robustness was tested by comparison of the relative retention times of the analytes in the 
QC samples over a month. 
6.2.5. Post-transfusion samples 
Post-transfusion samples provided by Surface-Zentrum für Orthopädie (Neuss, 
Germany) were analysed for 5oxo-MEHP-gluc and 5OH-MEHP-gluc. Urine samples 
were collected from 5 volunteers between 0 to 24 h after blood transfusion (2 female, 
3 male, age 44-79). Informed consent was obtained from all medicated patients and 
volunteers. 
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6.2.6. Routine samples 
Approximately 13,000 samples were tested for the glucuronide conjugates of DEHP 
metabolites using the screening procedure (Section 6.2.2 and 6.2.3) within a year. 
Samples showing higher relative intensities (5oxo-MEHP-gluc and 5OH-MEHP-gluc 
related to the internal standard) than the relative intensities corresponding to the 99.9% 
reference limits were tested using the original method (Section 6.1.2 and 6.1.3) in order 
to confirm the results and determine the accurate concentrations of the DEHP 
metabolites. 
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7. RESULTS AND DISCUSSION 
7.1. DETERMINATION OF URINARY DI(2-ETHYLHEXYL) PHTHALATE 
METABOLITES 
7.1.1. Chromatographic and mass spectrometric parameters 
Good chromatographic separation was achieved using a Phenomenex Gemini 
phenyl-hexyl column. Phenyl-hexyl columns have the structure of a phenyl column in 
which the hexyl group acts as a spacer. It shows high selectivity for aromatic compounds 
due to the π – π interactions which can lead to increased retention of polar aromatic 
compounds compared to an alkyl-bonded phase [242]. 
After optimization, electrospray ionisation of all DEHP metabolites produced negatively 
charged molecular ions [M-H]ˉ in suitable abundance. Product ion mass spectra 
generated after collision-induced dissociation (CID) of deprotonated molecules yielded 
phthalate-specific fragment ions for all DEHP monoesters using appropriate collision 
energies (Figure 7.1). All metabolites produced common ions at m/z 77 and 121 
corresponding to benzyl and benzoate fragments. The most abundant fragments were 
observed at m/z 127, 134 and 147 for MEHP corresponding to the anions of 
2-ethylhexanol, methylbenzoate and phthalic anhydride, respectively, as demonstrated in 
earlier studies [186,190]. The stable isotope-labelled internal standard of MEHP 
dissociated similarly showing ions at m/z 79, 124, 127, 137 and 151 consistent with the 
presence of two, three or four 13C-atoms. Furthermore, a characteristic ion was found at 
m/z 143 and m/z 145 in the case of 5oxo-MEHP and 5OH-MEHP corresponding to 
deprotonated analogues of 5-(hydroxymethyl)heptane-2-one and 2-ethylhexane-1,5-diol. 
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The relative retention time and the relative ratios of three ion transitions of each 
compound were used to confirm the identity of the analyte (Table 7.1). The average 
retention times of the target compounds under the chosen conditions were 10.99 min for 
MEHP, 9.41 min for 5oxo-MEHP and 9.25 min for 5OH-MEHP (Table 7.1, Figure 7.2).  
 
 
Figure 7.2: Extracted ion chromatograms of human urine samples: (a) blank urine sample; (b) 
quality control (QC) sample (urine sample fortified with 100 ng/mL of phthalate monoesters). Only 
quantifier ion transitions of analytes are shown. 
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7.1.2. Sample preparation aspects  
Phthalate metabolites are excreted into urine mainly as glucuronides. Within the present 
study, the effect of incubation time on enzymatic hydrolysis was tested by determining 
deconjugated phthalate metabolites released after 2, 10, 20, 30 and 60 minutes of 
incubation at room temperature and also at 50°C for 30 minutes. Enzymatic hydrolysis of 
the analytes was found to be complete after 10 minutes at room temperature for all 
analytes (Figure 7.3). No improvement was observed in the case of incubation at 50°C 
from 30 minutes onwards. Further dilution yielded the final solution that was injected 
into the LC-MS/MS system resulting in a very simple and rapid sample preparation. 
 































Figure 7.3: Optimization of enzyme deconjugation time of phthalate monoester glucuronides in 
urine at room temperature. 
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7.1.3. Validation results 
In order to test for assay suitability, the following parameters were determined; 
specificity, linearity, ion suppression, accuracy, intra- and inter-day precision, LOD and 
LOQ. 
7.1.3.1. Specificity 
In terms of specificity, no significant interfering signals of the blank samples were 
detected at the expected retention times of the analytes. As expected, low basal levels of 
the analytes were always detectable with stable relative ion ratios identical to the 
reference compound. 
7.1.3.2. Linearity 
The assay demonstrated a linear correlation between analyte concentration and response 
within the given concentration range (1-250 ng/mL) with the correlation coefficients (R2) 
above 0.99. The slope and the intercept of the calibration curves were 0.004 and 0.009 
for MEHP, 0.008 and 0.001 for 5oxo-MEHP, 0.014 and -0.015 for 5OH-MEHP, 
respectively. 
7.1.3.3. Ion suppression / enhancement 
With regard to ion suppression or enhancement there was no significant decrease or 
increase of the electrospray response at the expected retention times of the analytes while 
the urinary matrix was injected. 
7.1.3.4. Accuracy and precision 
For accuracy, the relative recoveries were determined at three concentration levels (10, 
100, 250 ng/mL) by means of comparison of theoretical and calculated concentrations 
ranging from 84% to 106% as shown in Table 7.1. The intra- and inter-day precisions 
were determined at three concentration levels with coefficients of variation less than 10% 
for low (10 ng/mL), medium (100 ng/mL), and high (250 ng/mL) concentration levels. 
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7.1.3.5. LOD and LOQ 
At the required signal-to-noise ratio of 3, the LODs were estimated at 0.2-0.3 ng/mL and 
the corresponding LOQs at 1 ng/mL for MEHP, 5oxo-MEHP and 5OH-MEHP (Table 
7.1) with CVs below 6.2% and accuracies ranging from 92.1 to 106.6%. The analytes 
were identified at the concentration level of the LOD using two and at the LOQ using 
three ion transitions. This assay demonstrated good sensitivity, although samples were 
diluted (1:5) and injected directly without any preconcentration steps. 
7.1.3.6. Stability 
Within this study the stability of the DEHP metabolites in the prepared samples (QCs) 
was tested. No significant decrease of the phthalate concentrations was observed in the 
quality control samples stored at -20, 4°C and room temperature for up to 4 months 
ensuring accurate quantification. Although in earlier studies the decomposition of DEHP 
metabolites was observed in urine samples stored above 4°C [234], quality control 
samples in this study were found to be stable, this was probably influenced by sample 
dilution (acetonitrile/water). 
7.1.3.7. Uncertainty of the measurement 
The uncertainty of the measurement is 12.88% for MEHP, 11.15% for 5oxo-MEHP and 
19.84% for 5OH-MEHP which represents the expanded uncertainties at 95% confidence 
level using a coverage factor of k = 2. 
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Table 7.1: Summary of assay validation results. 
 Accuracy  Precision  LOD LOQ 
 QClow  QCmedium  QChigh  QClow  QCmedium  QChigh  
Retention 
Time 
 MRM ratioc 
 
(S/N>3) (S/N>10) 
 Relative Recovery (%)a CV (%)  CV (%)  CV (%)  Meana CVa  Meana CVa  Conc. Conc. 
       intra-daya inter-dayb  intra-daya inter-dayb  intra-daya inter-dayb  (min) (%)  (%) (%)  (ng/mL) (ng/mL) 
MEHP 94.8  99.4  97.7  6.10 2.89  3.61 2.63  3.33 2.70  10.99 0.32  34.35 0.88  0.2 1.0 
5oxo-
MEHP 





84.9  91.8  89.0  1.69 4.26  3.99 2.38  2.92 3.66  9.25 0.28  16.13 0.35 
 
0.2 1.0 
a Intra-day precision was calculated as the mean value of six replicates (n=6). 
b Inter-day precision was calculated as the mean value of six replicates measured on three different days (n=18). 
C MRM ratio: Ratio of the peak area detected at the quantifier and the qualifier ion transitions. The quantifier and qualifier ion transitions are m/z 277/134 and 277/127 for MEHP, 291/143 and 291/121 for 5oxo-MEHP, 
293/121 and 293/77 for 5OH-MEHP, respectively. 
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7.1.4. Correlation of the results corrected to creatinine and specific gravity 
In this study, creatinine was assayed in samples collected from healthy volunteers of the 
control group (n = 100) and of the longitudinal study (n = 253). In addition, the density 
was measured in all of the samples. Pearson correlation showed high correlation between 
the density and creatinine values (Figure 7.4). 
 





















Control group:        y = -79.0594 + 78.8985*x; r = 0.7558, p = 0.0000
Longitudinal study: y = -68.7546 + 68.7516*x; r = 0.7606, p = 0.0000
 
Figure 7.4: Correlation of density and creatinine values in urine samples from healthy volunteers: 
control group (blue circles), longitudinal study (red triangles). 
 
However, Lorber et al. found that creatinine may not be suitable for the correction of 
DEHP metabolite concentration due to the short elimination time of the metabolites. 
Creatinine correction predicted higher concentrations when the ratio of the analytes 
suggested that the DEHP exposure was close in time and it began to underpredict the 
intake after approximately 8 hours [243]. Therefore, correction to specific gravity was 
used for statistical evaluation and routine purpose. 
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7.1.5. Reference populations 
7.1.5.1. Control samples 
In order to determine physiological levels of DEHP metabolites, urine samples from 100 
healthy volunteers were analysed. The primary metabolite MEHP was quantifiable in 
100% of the control samples (n = 100), the secondary metabolites 5OH-MEHP and 
5oxo-MEHP could be quantified in 93% and 91% of the control specimens, with 
concentrations of MEHP, 5oxo-MEHP and 5OH-MEHP ranging from 2.1 ng/mL to 
50.4 ng/mL, from < LOQ to 36.2 ng/mL and from < LOQ to 65.5 ng/mL in the control 
samples (Table 7.2, Figure 7.5), respectively.  
 
Table 7.2: Results of statistical evaluation of phthalate monoester levels in the control urine samples 








 (ng/mL) (ng/mL) (ng/mL) (ng/mL) % 
5oxo-MEHP 6.2 < LOQ 36.2 54.4 93 
5OH-MEHP 12.5 < LOQ 65.5 94.8 91 
MEHP 9.3 2.1 50.4 74.6 100 
a Estimators for the central tendency (µH) and upper reference limit (99.9%) of the control group (ng/mL). Estimates based on Huber's 
robust statistical method (see 6.1.8.1 for the precise meaning of µH). 
 
The log-transformed data of MEHP demonstrated a bimodal distribution compared to 
secondary metabolites that yielded approximate gaussianity. Additionally, the maximum 
concentration for MEHP in the investigated control group was higher than the minimum 
concentration determined in samples after blood transfusion (Table 7.4). Thus, 
5oxo-MEHP and 5OH-MEHP represented more appropriate markers to indicate blood 
transfusion. 
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7.1.5.2. Athletes’ samples 
For the determination of the concentration levels of secondary DEHP metabolites in elite 
athletes, 468 official doping control samples covering different kind of sport and origin 
were investigated. It is stressed that the athletes’ samples cannot fulfil the criteria of a 
controlled study, since medical treatment cannot be excluded. 
MEHP, 5OH-MEHP and 5oxo-MEHP were quantifiable in 58%, 95% and 80% of the 
samples, respectively. The highest concentration in the doping control samples was 
found for 5OH-MEHP, followed by 5oxo-MEHP and MEHP (Table 7.3). Figure 7.5 
shows the histogram and the density plot for log-normal distribution of urinary 
5oxo-MEHP and 5OH-MEHP monoester levels quantified in 468 athlete specimens. The 
99.9% upper reference limits of the athletes’ group were determined as 157.3 ng/mL for 
5oxo-MEHP and 193.0 ng/mL for 5OH-MEHP. Within the investigated athletes’ group 
there were 4 outliers (0.85%) identified, yielding concentrations in the range found after 
blood transfusion (Figure 7.6). Since information regarding the medical treatment of 
these athletes was not available, increased levels of secondary DEHP metabolites may 
indicate an unusual increased environmental exposure or blood transfusion. Three out of 
four outliers were taken out-of competition at the same time, originating from one 
cycling team. As recommended by Monfort et al. the basal levels of DEHP metabolites 
may be implemented to athletes’ Biological Passport [164-167] to suspect the misuse of 
blood transfusions [29]. 
 
Table 7.3: Results of statistical evaluation of phthalate monoester levels in athletes’ urine samples 








 (ng/mL) (ng/mL) (ng/mL) (ng/mL) % 
5oxo-MEHP 6.1 < LOQ 590.7 157.3 80 
5OH-MEHP 18.9 < LOQ 1125.0 193.0 95 
MEHP 2.1 < LOQ 203.3 96.1 58 
a Estimators for the central tendency (µH) and upper reference limit (99.9%) of the athletes group (ng/mL). Estimates based on 
Huber's robust statistical method (see 6.1.8.1 for the precise meaning of µH). 
 












1 1 1 1




















































     58.8
     28.2
    7.3
  2.8   1.3   0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2



















     16.0
  4.1
  0.9    0.4 0.2 0.2 0.2 0.2 0.2 0.2 0.2

















Figure 7.5: Histograms and density plots for log-normal distributions of urinary DEHP monoester 
values in 100 urine samples of the control group: 5OH-MEHP (a), 5oxo-MEHP (b); and in 468 urine 
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7.1.6. Post-transfusion samples 
7.1.6.1. Excretion study 
Urine samples of the excretion study showed elevated DEHP metabolite concentrations 
up to 24 hours after blood transfusion. In comparison to the control group (Table 7.2) 
significantly higher concentrations of the secondary DEHP metabolites were observed in 
urine samples collected after blood transfusion (Table 7.4). The maximum concentrations 
of 5oxo-MEHP and 5OH-MEHP in the control samples were 18- and 13-times lower 
than the minimum concentrations determined after transfusion. 
 
Table 7.4: Concentrations of phthalate monoesters in the urine samples of transfused patients. 
Patient Time after transfusion Concentration (ng/mL) 
(hours)a 5oxo-MEHP 5OH-MEHP MEHP 
1 
12 634.4 908.2 239.7 
24 484.5 540.8 204.3 
Blank 24.7 41.6 15.2 
2 
6 740.9 876.1 351.8 
12 250.4 279.6 116.6 
Blank 24.7 41.6 15.2 
3 
6 1098.0 2122.0 46.2 
12 980.2 2333.3 29.8 
Blank 0.5 25.3 10.7 
4 
6 1374.4 1720.8 139.8 
12 390.0 532.0 39.6 
Blank 31.2 67.8 4.5 
5 
5 4995.0 8605.0 471.3 
14 940.4 1692.4 98.0 
Blank 9.8 68.0 15.8 
a Blank samples were taken before blood transfusion. 
 
The 99.9% upper reference limits of the control group were determined as 54.4 ng/mL 
for 5oxo-MEHP and 94.8 ng/mL for 5OH-MEHP which are 12- and 9-times lower than 
the lowest value measured after blood transfusion. The chromatogram of a control 
sample and a post-transfusion sample are shown in Figure 7.7. 





Figure 7.6: Concentrations of urinary DEHP metabolites 5OH-MEHP (a) and 5oxo-MEHP (b) in 
athletes’ samples, in the control group and in transfused patients (TF). Horizontal bars indicate the 




 percentiles, whiskers indicate the minimum and maximum 
data values excluding the outliers and circles illustrate the outside values. The 99.9% reference limits 
are calculated from the log-transformed concentrations. 
(a) 
(b) 
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The 99.9% upper reference limits of the athletes’ group were determined as 157.3 ng/mL 
for 5oxo-MEHP and 193.0 ng/mL for 5OH-MEHP which are 4- and 5-times lower than 
the lowest concentration received after blood transfusion. Within the investigated 
athletes’ group there were 4 outliers (0.85%) identified, yielding concentrations in the 
range found after blood transfusion (Figure 7.6). 
 
 
Figure 7.7: Extracted ion chromatograms of human urine samples: (a) control sample containing 
13 ng/mL of 5oxo-MEHP, 32.8 ng/mL of 5OH-MEHP and 5.1 ng/mL of MEHP and (b) undiluted 
sample of transfused patient containing 1374.4 ng/mL of 5oxo-MEHP, 1720.8 ng/mL of 5OH-MEHP 
and 139.8 ng/mL of MEHP. Only quantifier ion transitions of analytes are shown. 
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7.1.6.2. Urinary concentrations of the metabolites related to the storage time of the 
transfused blood 
Samples collected at the Ruhr-University Bochum were divided into three groups: 
control samples (collected from Group 1 and Group 2 excluding the day of blood 
transfusion), samples collected on the day of transfusion from Group 1 (TF-1, blood 
stored for 14 days before transfusion) and from Group 2 (TF-2, blood stored for 
28 days). 
5oxo-MEHP, 5OH-MEHP and MEHP were quantified in 80%, 89% and 57% of the 
specimens of the control group, with concentrations ranging from < LOQ to 
175.0 ng/mL, from < LOQ to 496.5 ng/mL and from < LOQ to 9.5 ng/mL, respectively. 
The 99.9% upper reference limits of the control group were determined as 198.5 ng/mL 
for 5oxo-MEHP and 341.6 ng/mL for 5OH-MEHP (Table 7.5). The urinary levels of the 
metabolites significantly increased on the day of transfusion compared to the day before 
with maximum concentrations of 8440 ng/mL and 11200 ng/mL for 5oxo-MEHP and 
5OH-MEHP respectively (Table 7.6 , Figure 7.8). 
 
Table 7.5: Results of statistical evaluation of phthalate monoester levels in the control samples 








 (ng/mL) (ng/mL) (ng/mL) (ng/mL) % 
5oxo-MEHP 5.9 < LOQ 175.0 198.5 80 
5OH-MEHP 12.1 < LOQ 496.5 341.6 89 
MEHP 2.5 < LOQ 9.5 60.8 57 
a Estimators for the central tendency (µH) and upper reference limit (99.9%) of the hospitalized patients (ng/mL). Estimates based on 
Huber's robust statistical method (see 6.1.8.1 for the precise meaning of µH). 
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Figure 7.8: Concentrations of urinary DEHP metabolites 5OH-MEHP (a,c) and 5oxo-MEHP (b,d) in 
samples collected from subjects receiving blood transfusions at the Ruhr-University Bochum. Group 
1: transfusion of blood stored for 14 days (a,b), Group 2: transfusion of blood stored for 28 days 
(c,d). Vertical red lines indicate the day of phlebotomy (4
th
 day) and the day of blood transfusion 
(18
th
 day (a,b) and 32
nd
 day (c,d)). 
 
Median (µH) values of the control group were in agreement with the other reference 
populations (Section 7.1.5). However, the 99.9% reference limits were higher than the 
ones calculated from the athletes’ populations. A possible reason for the higher values is 
that the concentration of the phthalate metabolites can be elevated up to 24 hours after 
transfusion [103] and the values from the day after transfusion were included in the 
control group. The concentrations on the day after transfusion in some cases were 
slightly but not significantly higher than the median values of the control group. Some 
samples from TF-2 showed higher levels of the metabolites than samples from TF-1 
(Figure 7.9) which is in agreement with data showing increasing DEHP concentration 
over time in blood stored in PVC bags [6]. 
(a) (b) 
(c) (d) 
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Table 7.6: Concentrations of phthalate monoesters in urine samples collected on the day of 
reinfusion at the Ruhr-University Bochum (n = 25). 
Subjects Concentration (ng/mL) 
5oxo-MEHP 5OH-MEHP MEHP 
Group TF-1    
1 354.7 506.0 80.0 
2 656.0 976.0 295.6 
3 76.6 131.3 42.0 
4 753.3 1306.7 458.7 
5 554.7 693.3 211.3 
6 288.8 548.0 44.4 
7 210.0 282.0 112.6 
8 362.9 617.1 228.9 
9 245.0 356.7 78.0 
10 766.0 1270.0 324.0 
11 366.9 590.0 318.5 
12 399.3 648.7 174.0 
Average 419.5 660.5 197.3 
Min 76.6 131.3 42.0 
Max 766.0 1306.7 458.7 
Group TF-2 
1 886.0 1320.0 396.0 
2 2105.0 3325.0 1550.0 
3 559.1 796.4 750.0 
4 3080.0 4433.3 2050.0 
5 894.4 1122.2 498.9 
6 126.8 213.3 100.0 
7 8440.0 11200.0 5860.0 
8 580.0 1110.0 193.5 
9 436.3 687.5 393.8 
10 200.0 288.3 118.0 
11 195.7 392.2 149.6 
12 170.0 293.0 185.0 
13 1400.0 1914.3 654.3 
Average 1467.2 2084.3 992.2 
Min 126.8 213.3 100.0 
Max 8440.0 11200.0 5860.0 
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Figure 7.9: Concentrations of urinary DEHP metabolites 5OH-MEHP (a) and 5oxo-MEHP (b) in samples 
collected from subjects receiving blood transfusions at the Ruhr-University Bochum; in the control samples 
(Control), after transfusion of blood stored for 14 days (TF-1), after transfusion of blood stored for 28 days 
(TF-2). Horizontal bars indicate the medians, boxes enclose the 25th and 75th percentiles, whiskers indicate the 
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Independent analysis was performed on this set of samples by the Bioanalysis Research 
Group, IMIM-Hospital del Mar (Barcelona, Spain) using a different analytical method. 
The results obtained by the two laboratories were compared by Monfort et al. showing 
high correlation between the two sets of data [237]. 
The 99.9% reference limits calculated from the control samples of this study were found 
to be 198.5 ng/mL and 341.6 ng/mL for 5oxo-MEHP and 5OH-MEHP, respectively 
(Table 7.5). The values are comparable with the reference limits established by 
Monfort et al. at 158.5 ng/mL for 5oxo-MEHP and 338.8 ng/mL for 5OH-MEHP [126]. 
The lower reference limit calculated for 5oxo-MEHP by Monfort et al. is possibly due to 
the use of a different analytical procedure or different statistical calculation. The higher 
value for 5OH-MEHP compared to the reference limit originating from the athletes’ 
population (Table 7.3) is probably due to the different origin of the samples. 
Urinary concentrations of DEHP metabolites obtained from transfused patients were in 
agreement with the results of other publications testing urine samples of plasma and 
platelet donors shortly after apheresis [103,102] and hospitalized patients receiving 
autologous blood transfusion [29]. 
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7.1.7. Longitudinal study 
To indicate homologous or autologous blood transfusion in sports drug testing, 
quantification of increased urinary concentrations of DEHP metabolites presents a 
promising approach; however, the possible intra-individual variation of the metabolite 
concentrations over time has not been well characterized. 
Intra-individual variability of urinary DEHP metabolites was tested among seven 
volunteers without special occupational exposure to DEHP during one week (n = 253) in 
order to investigate the possibility of increased urinary concentrations of the metabolites 
caused by e.g. residential, dietary or environmental exposure. 
Within this study the primary metabolite MEHP was quantified in 57% of the samples, 
the secondary metabolites 5oxo-MEHP and 5OH-MEHP could be quantified in 87% and 
96% of the specimens, with maximum concentrations for MEHP, 5oxo-MEHP and 
5OH-MEHP of 56.0 ng/mL, 77.7 ng/mL and 154.3 ng/mL, respectively (Table 7.7). The 
calculated median values for each volunteer ranged from 2.5 to 10.1 ng/mL for 
5oxo-MEHP, from 10.8 to 22.9 ng/mL for 5OH-MEHP and from 1.0 to 3.8 ng/mL for 
MEHP. 
 
Table 7.7: Results of statistical evaluation of phthalate monoester levels in the samples collected for 








 (ng/mL) (ng/mL) (ng/mL) (ng/mL) % 
5oxo-MEHP 6.0 < LOQ 77.7 86.2 87 
5OH-MEHP 14.6 < LOQ 154.3 103.6 96 
MEHP 1.9 < LOQ 56.0 48.3 57 
a Estimators for the central tendency (µH) and upper reference limit (99.9%) of the longitudinal study group (ng/mL). Estimates based 
on Huber's robust statistical method (see 6.1.8.1 for the precise meaning of µH). 
 
The urinary concentrations of MEHP, 5oxo-MEHP and 5OH-MEHP corrected to specific 
gravity are plotted for each subject in Figure 7.10. 
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In accordance with earlier studies, moderate ICCs for the DEHP metabolites were 
observed, with calculated values of 0.43, 0.19 and 0.22 for MEHP, 5oxo-MEHP and 
5OH-MEHP for the concentrations corrected to specific gravity. The values indicate high 
within-subject variability and low reliability of the measurement over time. As illustrated 
in Figure 7.10, some of the studied subjects demonstrated only weak variability 
(volunteers 1-5) while others showed considerable variance (volunteers 6 and 7). 
However, no correlation between the elevated values of volunteers 6 and 7 could be 
identified (Figure 7.10 (b)). 
Generally, the median values within this study were in agreement with earlier results 
[29,244,245,123,119], although slightly higher median concentrations were observed in 
some cases [12,15,246,124]. Regarding the maximum concentrations, the values were 
consistent with the maximum concentrations found in the reference populations (Section 
7.1.5.1 and 7.1.5.2). However, some studies reported significantly higher maximum 
concentrations. In 2007, Fromme et al. demonstrated a substantial within-subject 
variability of urinary DEHP metabolites by investigating 50 healthy volunteers (Munich, 
Germany) on 8 consecutive days, with maximum concentrations for 5oxo- and 
5OH-MEHP ranging from 439.9 to 674.3 ng/mL for women and from 215.4 to 
309.3 ng/mL for men [12]. Inter-individual variability of urinary DEHP metabolites was 
also studied by Preau et al. analysing samples collected from 8 volunteers (Atlanta, 
USA) over one week. While some of the subjects demonstrated moderate intra-individual 
variability others showed substantial variance with maximum concentration for 
5OH-MEHP of 706.3 µg/g creatinine [246]. Analysis of samples from 25 men working in 
dental laboratories (Seoul, Korea), with possible occupational exposure to DEHP, 
showed a significant difference in the concentrations of urinary DEHP metabolites before 
and after work with maximum post-shift concentrations for 5oxo- and 5OH-MEHP of 
97.9 and 276.0 ng/mL [123]. Contrarily, when analysing first morning urine samples the 
level of DEHP metabolites was observed to be more reproducible over time [124,115]. 
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As described above, samples of transfused patients and reference populations were 
investigated, and the determined 99.9% upper reference limits of an athletes’ population 
(n = 468) provided values of 157.3 ng/mL for 5oxo-MEHP and 193.0 ng/mL for 
5OH-MEHP (Section 7.1.5.2). In this work, the determined concentrations of each 
subject did not exceed this upper reference limits. Although urinary concentrations of the 
metabolites showed considerable intra-individual variation, no increased values have 
been observed comparable to the concentrations measured in urine specimens collected 
after blood transfusion (Section 7.1.6). The results confirm our findings that 
determination of the urinary concentration of DEHP metabolites has a high potential to 
indicate homologous or autologous blood transfusion, and may provide supporting 
evidence to prove blood doping. Additionally, longitudinal studies would present 
valuable data that can be utilised for interpretation of abnormally high DEHP metabolite 
concentrations in athletes. 
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7.1.8. Comparison of reference populations 
Control samples were classified into 4 groups: samples collected from healthy volunteers 
at the German Sport University Cologne (Control-1), samples collected from healthy 
volunteers for the longitudinal study (Control-2), samples collected from subjects 
receiving blood transfusions at the Ruhr-University Bochum (Control-3) and the official 
doping-control urine samples (Athletes). 
All control populations tested in this study gave consistent results (Figure 7.11). Higher 
values were found only in the athletes’ samples which were considered as outliers 
(Section 7.1.5.2). Compared to the athletes’ population (Table 7.3) the slightly increased 
concentration of MEHP in the control samples (Control-1, Table 7.2) is probably caused 
by contamination of urine specimens since MEHP is also present ubiquitously in the 
environment (e.g. light induced conversion of DEHP) [10,22,190]. The basal 
concentration of the metabolites in the reference populations were on the lower side of 
the usual range reported earlier [12,15,245,246,122] probably due to the more 
homogenous nature of these populations. The mean values were in accordance with most 
of the studies [12,13,18,29,118,237,244,245,123,119,246,124,115,126], only slightly 
higher values were found in some cases [15,16,99,122,125]. Other studies showed 
considerably higher maximum urinary concentrations of DEHP metabolites 
[12,15,246,122,125] probably due to higher occupational or environmental exposure or 
the different origin of the samples. 
It is noteworthy that in most studies of DEHP exposure first morning urine samples were 
collected which are known to have slightly higher phthalate levels than spot urine 
samples collected throughout the day [246,247]. 
No correlation was observed between the concentrations of the metabolites and the 
gender or the age of the subjects. In the case of the athletes’ population no significant 
difference in the urinary DEHP metabolite levels was found for samples collected in-
competition and out-of competition or regarding the sport type. 
Since in different countries there is a trend in substituting DEHP according to its toxicity. 
This may result in lower general exposure in humans, and thus, decreasing urinary 
concentrations over time [18]. 
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Figure 7.11: Concentrations of urinary DEHP metabolites 5OH-MEHP (a) and 5oxo-MEHP (b) in athletes’ 
samples and in different control groups. 100 samples collected from healthy volunteers (Control-1), samples 
collected from healthy volunteers for the longitudinal study (Control-2), and control samples collected from 
subjects receiving blood transfusions at the Ruhr-University Bochum (Control-3). Horizontal bars indicate the 
medians, boxes enclose the 25th and 75th percentiles, whiskers indicate the minimum and maximum data values 
excluding the outliers and circles illustrate the outside values. 
(a) 
(b) 
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7.1.9. Comparison of reference populations and post transfusion samples 
Post-transfusion samples were classified into 3 groups: the samples collected at the Ruhr-
University Bochum from volunteers receiving transfusion of blood stored for 14 days 
(Group TF-1) and for 28 days (Group TF-2, Section 7.1.6.2), and the excretion urine 
samples collected in Neuss (Group TF-3, Section 7.1.6.1). 
92% of the samples from Group TF-1 showed higher levels of 5oxo-MEHP and 
5OH-MEHP than the 99.9% reference limit of 157.3 ng/mL and 193.0 ng/mL, 
respectively. Regarding TF-2, 92% of 5oxo-MEHP and all 5OH-MEHP concentrations 
were found to be higher than the reference limits. Levels of both metabolites exceeded 
the corresponding reference limits in all post-transfusion samples of Group TF-3 (Figure 
7.12). 
The findings of Monfort et al. suggest that transfusion of DEHP seems to promote an 
increase in the rate of oxidative metabolism of MEHP to secondary metabolites, or a 
rapid elimination of MEHP [237]. In contrast, in this study the ratios of the secondary 
metabolites to MEHP did not show significant difference in the post-transfusion samples 
compared to the control groups (Table 7.8). Earlier studies showed that the relative 
distribution of the metabolites excreted in urine after intravenous exposure was similar to 
the distribution after oral administration [98,103]. Due to the rapid metabolism of DEHP 
and the different elimination half-life times of the metabolites, the main factor 
influencing the ratios of the metabolites is the time between the exposure and the 
collection of the urine specimens. 
The ratios of both oxidative metabolites relative to MEHP were consistent which is in 
agreement with earlier studies showing that the kinetic profiles of these two metabolites 
are similar [103]. The data may suggest a lower ratio of 5OH-MEHP to 5oxo-MEHP in 
post-transfusion samples compared to their ratio in the control samples. This could be a 
result of different pharmacokinetic behaviour of the metabolites after parenteral 
exposure, however, due to the limited amount of data it needs to be investigated further. 
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Table 7.8: Average ratios of DEHP metabolite concentrations in different study groups. 
Sample Group Average ratio of the metabolites 
 5oxo-MEHP / MEHP 5OH-MEHP / MEHP 5OH-MEHP / 5oxoMEHP 
Athletes 5.74 15.84 3.76 
Control-1 0.90 1.84 2.04 
Control-2 4.92 10.62 2.68 
Control-3 3.01 6.16 2.28 
TF-1 2.64 4.21 1.57 
TF-2 1.58 2.47 1.56 
TF-3 9.49 18.06 1.71 
 




Figure 7.12: Concentrations of urinary DEHP metabolites 5OH-MEHP (a) and 5oxo-MEHP (b) in athletes’ 
samples, in different control groups and in transfused patients. 100 samples collected from healthy volunteers 
(Control-1), samples collected from healthy volunteers for the longitudinal study (Control-2), control samples 
collected from subjects receiving blood transfusions at the Ruhr-University Bochum (Control-3), samples from 
subjects receiving transfusions after 14 days blood storage (TF-1), after 28 days blood storage (TF-2) and 
samples from transfused patients of the excretion study (TF-3). Horizontal bars indicate the medians, boxes 
enclose the 25th and 75th percentiles, whiskers indicate the minimum and maximum data values excluding the 
outliers and circles illustrate the outside values. 
(a) 
(b) 
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7.1.10. Conclusion 
A direct injection HPLC-(ESI)-MS/MS method is presented for the quantification of 
three DEHP metabolites in human urine as a marker for illicit blood transfusion in sports 
drug testing. The straightforward assay provides good sensitivity and reliability for the 
determination of phthalate monoesters using 13C-labelled internal standards without 
purification, concentration or further sample preparation steps resulting in a high-
throughput method, that ensures compatibility to existing “dilute-and-shoot” screening 
methods in doping control. Currently, the presented assay covers only DEHP. However, 
an implementation of alternatively used plasticisers in blood bags or other medical 
devices seems to be promising assuming that the substances used have comparable 
physical properties [147]. As a future prospect the applicability of the method on 
different plasticisers has to be investigated. 
Within this study it was clearly demonstrated that urinary concentration levels of the 
secondary DEHP metabolites 5OH-MEHP and 5oxo-MEHP after blood transfusion 
significantly differs from concentrations found in a control group. The reference limits 
(99.9%) obtained from the investigation of control and athletes’ specimens enables the 
identification of abnormally high concentrations of DEHP metabolites indicating 
homologous or autologous blood transfusion. Nevertheless, to prosecute blood doping 
this assay provides valuable data that can be used as supporting evidence in 
interpretation of conspicuous Biological Passport data. Based on this study, the 
abnormally high concentrations of DEHP metabolites analysed at the Laboratory for 
Doping Analysis at the Institute of Biochemistry of the German Sports University 
Cologne are reported to federations which adopted the biological passport program. 
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7.2. INTEGRATION OF DI(2-ETHYLHEXYL) PHTHALATE METABOLITES 
INTO SCREENING PROCEDURE 
The phthalate metabolites are excreted into urine mainly as conjugates following 
phase-II glucuronidation [20]. Commonly, these conjugates are enzymatically 
hydrolysed and determined with LC-MS/MS [29]. To ensure compatibility with direct 
injection screening procedures and enable the comprehensive monitoring of 
concentration levels in routine doping control samples the implementation of 
glucuronidated DEHP metabolites as target analytes into a multi-target approach was 
required. 
7.2.1. Chromatographic and mass spectrometric parameters 
The assay is based on LC-(ESI)-MS/MS using direct injection of urine specimens to 
screen for various classes of prohibited substances. Using a highly sensitive new 
generation hybrid mass spectrometer enables a combined screening of diuretics, beta2-
agonists, narcotics, stimulants and their sulfo-conjugates, plasma volume expanders, 
selective androgen receptor modulators and 5-amino-4-imidazolecarboxyamide 
ribonucleoside (AICAR). The possibility of fast polarity switching (50 ms) ensures an 
optimized ionisation, regardless of differences in the acidic or basic character of the 
molecules. Therefore, the detection of a wide range of doping agents can be 
accomplished in one analytical run. Analysing native urine specimens using direct 
injection provides the ability to screen for many different compounds and their 
metabolites without time-consuming sample preparation steps. 
The chromatographic run was optimised taking into account the chemical versatility of 
the analytes, resulting in a wide range of polarities. A gradient starting at 100% aqueous 
buffer (5 mM ammonium acetate, 0.1% glacial acetic acid, pH = 3.5) was required to 
ensure sufficient retention for hydrophilic compounds. To avoid column blockage a pre-
column was used. Over 2000 analyses were conducted with the same analytical column 
without any loss in chromatographic performance. As presented (Table 7.10) the relative 
retention times of the analytes proved to be stable with CVs of less than 2%, fulfilling 
the recommended identification criteria [248]. 
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Due to the lack of reference material the glucuronidated DEHP metabolites were 
characterised and identified using liquid chromatography coupled to 
high resolution / high accuracy mass spectrometry (Exactive OrbiTrap®, Thermo Fisher) 
(for method see Table 11.1). A post-transfusion sample was analysed containing known 
amounts of 5OH-MEHP (665 ng/mL) and 5oxo-MEHP (421 ng/mL), in which the 
glucuronidated conjugates of 5OH-MEHP and 5oxo-MEHP were identified as 
deprotonated molecular ions [M-H]ˉ at m/z 469.1708 Da and 467.1559 Da with 
calculated errors of 1.48 ppm and 0.03 ppm, respectively (Table 7.9, Figure 11.1, Figure 
11.2). 
 
Table 7.9: Results of high accuracy mass measurement of urinary phthalate monoester glucuronides. 








5oxo-MEHP-gluc 7.91 467.1559 467.1559 0.0328 
5OH-MEHP-gluc 1 7.64 469.1715 469.1708 -1.4811 
5OH-MEHP-gluc 2 7.98 469.1715 469.1710 -1.1201 
5OH-MEHP-gluc 3 8.40 469.1715 469.1716 0.2181 
a RT: retention time 
 
Additionally, the glucuronides of 5OH-MEHP and 5oxo-MEHP (5OH-MEHP-gluc and 
5oxo-MEHP-gluc) were investigated with liquid chromatography-tandem mass 
spectrometry in enhanced (linear ion trap) product ion mode (Figure 7.13). The most 
abundant product ions at m/z 291 and 293 were generated by the loss of glucuronic acid 
(-176 Da) from the conjugated molecules and consequently the ion corresponding to 
glucuronic acid was observed at m/z 175. The fragment of 5oxo-MEHP-gluc at m/z 143 
and the corresponding fragment of 5OH-MEHP-gluc at m/z 145 were identified as the 
deprotonated analogues of 5-(hydroxymethyl)heptane-2-one and 2-ethylhexane-1,5-diol 
resulting from the loss of 2-formylbenzoic acid from the unconjugated molecules. The 
fragment at m/z 113 is assigned as the product of elimination of formaldehyde (CH2O, 
-30 Da) or methanol (CH3OH, -32 Da) from the fragments at m/z 143 or 145, 
respectively, or by elimination of water (H2O, -18 Da) and carbon-dioxide (CO2, -44 Da) 
from the product ion at m/z  175 (glucuronic acid) [249]. The product ion at m/z 85 was 
characterized as a specific fragment of the glucuronic acid [249]. For screening purposes 
the ion transitions at m/z 469/293 for 5OH-MEHP-gluc and at m/z 467/291 for 
5oxo-MEHP-gluc were monitored. As depicted in Figure 7.14 and Figure 11.2, the peak 
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7.2.3. Validation results 
In order to test for assay suitability, the following parameters were determined; 
specificity, ion suppression / enhancement, intra- and inter-day precision, LOD, accuracy 
and linearity. The method was validated for 5OH-MEHP-gluc and 5oxo-MEHP-gluc 
using post-transfusion samples. 
7.2.3.1. Specificity 
In terms of specificity, no interfering signals of the matrix were detected at the expected 
retention times of the analytes except for low basal levels of phthalate metabolites which 
was also found in earlier studies [29]. 
7.2.3.2. Robustness 
Stable retention times are of the utmost importance for reliable evaluation, especially if 
native urine is injected. Analysis of QC samples over 4 weeks yielded stable retention 
times (CV <2%) for all compounds (Table 7.10). 
7.2.3.3. Ion suppression / enhancement 
There was no evidence of ion suppression or enhancement as no significant decrease or 
increase of the electrospray response was observed at the expected retention times of the 
analytes when urinary matrix was injected. 
7.2.3.4. Precision 
Intra-and inter-day precisions were determined at three concentration levels with 
coefficients of variation of less than 20% for all analytes. 
7.2.3.5. LOD 
At the required signal-to-noise ratio of 3, the LODs were estimated to be 20 and 
30 ng/mL for 5oxo-MEHP-gluc and 5OH-MEHP-gluc respectively (Table 7.10). 
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7.2.3.6. Accuracy and linearity 
Correlation of 5OH-MEHP and 5oxo-MEHP concentrations and the relative intensities 
of the corresponding 5OH-MEHP-gluc and 5oxo-MEHP-gluc were determined to 
demonstrate the suitability of the method for semi-quantitative purposes. The 
unconjugated phthalate concentrations of the samples were measured according to the 
method described earlier (Section 6.1.2 and 6.1.3). The relative intensities of phthalate 
glucuronides were highly correlated to the corresponding phthalate concentrations 
(r = 0.993 for 5oxo-MEHP, r = 0.990 for 5OH-MEHP) suggesting that the method 
provides reliable data to screen for abnormally high concentrations of DEHP metabolites 
indicating homologous or autologous blood transfusion (Figure 7.15). 
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Figure 7.15: Correlation of 5OH-MEHP (a) and 5oxo-MEHP (b) concentrations and the relative 
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Table 7.10: Summary of screening validation results. 
Compound LOD Precision Concentration Intra-day precision Inter-day precision 
RRTa (n=6) (ng/mL) CV (%) (n=6/6/6) CV (%) (n=18/18/18) 
  (ng/mL) CV (%) QClow QCmiddle QChigh QClow QCmiddle QChigh QClow QCmiddle QChigh 
5OH-MEHP-gluc 30 1.36 100 550 1010 10.88 7.85 7.33 10.09 5.51 6.35 
5oxo-MEHP-gluc 20 1.10 100 550 1010 10.89 8.91 7.45 10.91 6.57 4.65 
a RRT: relative retention time 
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7.2.4. Routine samples 
Approximately 13,000 samples were tested for the glucuronide conjugates of DEHP 
metabolites over a year period. From these samples, 160 samples were tested in order to 
quantify the unconjugated metabolites. In 44 cases the concentrations exceeded the 
reference limits calculated from the athletes’ population and the results were reported to 
the federations. 
From the 44 cases 13 samples originated from athletes doing indoor sports and 31 from 
athletes exercising outdoor; 27 were taken in-competition and 17 out-of-competition. 15 
were cyclists’ samples, 12 were taken in-competition (IC) and 3 were taken 
out-of-competition (OOC). In addition, there were adverse analytical findings for 
hydroxyethyl starch in 3 of the cyclists’ samples. 
It is noteworthy, that samples from certain countries outside of the European Union 
showed slightly higher mean urinary DEHP concentrations. 
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7.2.5. Conclusion 
The ongoing increase of the number of prohibited compounds and samples in sports drug 
testing forces doping-control laboratories to develop multi-target assays that combine 
high-throughput, simplified sample preparation and a reliable detection for different 
classes of compounds. Glucuronidated DEHP metabolites were integrated into a 
comprehensive, simple and robust method based on LC-(ESI)-MS/MS enabling the 
monitoring of concentrations far below the required limits after direct injection of urine 
specimens. Using the presented method, screening for such markers in each doping 






Methods of blood doping such as autologous and homologous blood transfusions are 
some of the most challenging doping practices in competitive sports. Whereas 
homologous blood transfusion is detectable via minor blood antigens, the detection of 
autologous blood transfusion is still not feasible. 
A promising approach to indicate homologous or autologous blood transfusion is the 
quantification of increased urinary levels of di(2-ethylhexyl) phthalate (DEHP) 
metabolites found after blood transfusion. 
The commonly used plasticiser for flexible PVC products, such as blood bags, is DEHP 
which is known to diffuse into the stored blood. Therefore, a straightforward, rapid and 
reliable assay was developed for the quantification of the main metabolites 
mono(2-ethyl-5-oxohexyl) phthalate, mono(2-ethyl-5-hydroxyhexyl) phthalate and 
mono(2-ethylhexyl) phthalate that can easily be implemented into existing multi-target 
methods used for sports drug testing.  
Quantification of the DEHP metabolites was accomplished after enzymatic hydrolysis of 
urinary glucuronide conjugates and direct injection using isotope-dilution liquid-
chromatography / tandem mass spectrometry. 
The method was fully validated for quantitative purposes considering the following 
parameters; specificity, linearity (1-250 ng/mL), inter- (2.4-4.3%) and intra-day precision 
(0.7-6.1%), accuracy (85-105%), limit of detection (0.2-0.3 ng/mL), limit of 
quantification (1 ng/mL), stability and ion suppression effects. 
Urinary DEHP metabolites were measured in control groups without special exposure to 
DEHP (n = 100 from Cologne and n = 356 from Bochum), in athletes (n = 468) being 
subject to routine doping control and in hospitalised patients receiving blood transfusions 
(n = 10 from Neuss and n = 25 from Bochum). This investigation demonstrates that 
significantly increased levels of secondary DEHP metabolites were found in urine 
samples collected after blood transfusion. It is emphasised that this assay presents 
additional data in the interpretation of the Athlete Biological Passport and it is not 
intended to be used separately as a proof of blood doping. 
To investigate the possibility of increased urinary concentrations of the metabolites 
caused by e.g. residential, dietary or environmental exposure the intra-individual 
variability of urinary DEHP metabolites among seven volunteers without special 
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occupational exposure to DEHP during one week (n = 253) was accomplished. Although 
urinary concentrations of DEHP metabolites showed considerable intra-individual 
variation, no increased values have been observed comparable to the concentrations 
measured in urine specimens collected after blood transfusion. 
Additionally, the conjugates of secondary DEHP metabolites were integrated into an 
existing multi-target screening procedure based on liquid chromatography / electrospray 
ionisation tandem mass spectrometry (LC-(ESI)-MS/MS). 
The assay was fully validated for qualitative purposes considering the following 
parameters; specificity, intra- (3.2-16.6%) and inter-day precision (0.4-19.9%) at low, 
medium and high concentration, robustness, limit of detection (20 and 30 ng/mL for 
5oxo-MEHP-gluc and 5OH-MEHP-gluc respectively) and ion suppression/enhancement 
effects. 
Analysis of post-transfusion and routine doping control samples demonstrated the 
applicability of the method for sports drug testing. This straightforward and reliable 
approach accomplishes the combination of different screening procedures resulting in a 
high-throughput method that requires only a small volume of urine sample in the µl 





Az autológ és a homológ vértranszfúzió kimutatása a doppinganalitika legnagyobb 
kihívást jelentő feladatai közé tartozik. Míg a homológ vértranszfúzió kimutatása 2004 
óta lehetséges minor vér antigéneken keresztül, az autológ transzfúzió kimutatása 
jelenleg nem lehetséges. 
Egy ígéretesnek tűnő módszer a homológ és autológ vértranszfúzió kimutatására a 
di(2-ethil-hexil)ftalát (DEHP) metabolitok megemelkedett koncentrációjának vizeletből 
történő meghatározása. 
A módszer alapja, hogy a vér tárolására és szállítására használt PVC zsákok ftalát 
lágyítókat tartalmaznak, amelyek idővel a vérbe diffundálnak. Vértranszfúzió után ezen 
lágyító molekulák metabolitjai meghatározhatóak a vizeletben, lehetővé téve a 
vértranszfúzió kimutatását. A legáltalánosabban alkalmazott lágyító a DEHP, amelynek 
metabolitjai – mono(2-etil-hexil)ftalát (MEHP), mono(2-etil-5-hidroxi-hexil)ftalát 
(5OH-MEHP) és mono(2-etil-5-oxo-hexil)ftalát (5oxo-MEHP) – nagyrészt glükuronid-
konjugátumként ürülnek a vizelettel. 
Munkám során kifejlesztettem és validáltam egy megbízható és gyors analitikai módszert 
a fent említett DEHP metabolitok (MEHP, 5oxo-MEHP és 5OH-MEHP) vizeletből 
történő meghatározására. A komponensek meghatározását a glükuronid-konjugátumok 
enzimatikus hidrolízisét követő direkt injektálással és LC-MS/MS detektálással 
végeztem. 
A DEHP metabolitok koncentrációját vizsgáltam sportolóktól származó rutin 
doppinganalitikai mintákban (n = 468), különböző kontrollcsoportokban (n = 100, Köln 
és n = 356, Bochum), valamint vértranszfúzión átesett betegektől származó 
vizeletmintákban (n = 10, Neuss and n = 25, Bochum). A vértranszfúziót követő 24 
órában gyűjtött vizelet mintákban lényegesen magasabb oxidatív DEHP metabolit 
koncentrációkat mértem a kontrollcsoportokhoz képest. A módszer kiegészítő adatokat 
nyújt a sportolók biológiai útleveléhez (Athlete Biological Passport), így egyéb 
rendellenes vérparaméterekkel együtt (pl.: hematokrit, hemoglobin, retikulocita szám, 
vörösvértest szám stb.) a vérdopping megerősítő bizonyítékául szolgál. 
A DEHP metabolit koncentrációk lakóhelyi, étrendi vagy környezeti kitettség hatására 
esetlegesen bekövetkező egyéni időbeli variabilitását hét önkéntestől egy héten keresztül 
gyűjtött vizeletminták (n = 253) elemzésével határoztam meg. Bár az eredmények 
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jelentős egyéni változékonyságot mutatnak, a vértranszfúzió után gyűjtött mintákban 
mért koncentrációkat megközelítő értéket egy mintában sem mértem. Továbbá, a 
longitudinális vizsgálatok hasznos információval szolgálnak az emelkedett DEHP 
metabolit koncentrációk értelmezéséhez. 
Az oxidatív DEHP metabolitok glükuronid-konjugátumait beépítettem egy LC-MS/MS 
szűrőmódszerbe, amely jelenleg használatban van számos tiltott szer együttes 
vizsgálatára. A módszert kvalitatív és szemi-kvantitatív szempontok szerint validáltam az 
általam vizsgált komponensekre. Az eljárás doppinganalitikai alkalmasságát igazoltam 
vértranszfúzión átesett önkéntesektől, valamint hozzávetőleg 13000 sportolótól származó 
vizeletminta elemzésével. 
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HPLC system Thermo Accela UPLC system 
HPLC column Hypersil Gold, 50 mm x 2.1 m, 1.9 µm 
Mobile Phase A: 0.1% formic acid B: acetonitrile 
Gradient 0 min 100% A 0% B 
 2 min 100% A 0% B 
 8 min 0% A 100% B 
 9 min 0% A 100% B 
 2.5 min post-run equilibration time 
Flow rate 0.25 mL/min   
Injection Volume 10 µL   
Mass spectrometric parameters 
Mass spectrometer 
Thermo Fisher Exactive OrbiTrap® with heated electrospray 
ionisation (HESI-I-probe) 
Ionisation ESI in negative ion mode (50 msec) 
Scan Mode full scan 
Resolution 30000 FWHM 
Capillary Temperature 275°C 
Sheat Gas N2, 40 psi 
Auxiliary Gas N2, 4 psi 





RT: 0.00 - 12.12 SM: 7G





























m/z= 467.14-467.17 F: 
FTMS {1,3}  - p ESI Full 




Figure 11.1: Chromatogram of 5oxo-MEHP-gluc (see method in Table 11.1). 
 
RT: 3.56 - 12.12 SM: 7G




























m/z= 469.17-469.18 F: 
FTMS {1,3}  - p ESI Full 




Figure 11.2: Chromatogram of 5OH-MEHP-gluc indicating different locations of the glucuronic 




1. ATSDR (2002) Toxicological Profile for Di (2-ethylhexyl) phthalate. US Department of Health and 
Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry,Atlanta, GA 
2. SCENIHR (2008) Opinion on the safety of medical devices containing DEHP-plasticized PVC or other 
plasticizers on neonates and other groups possibly at risk. European Comission, Health and Consumer 
Protection Directorate, Scientific Committee on Emerging and Newly-Identified Health Risks,  
3. CERHR (2006) Monograph on the Potential Human Reproductive and Developmental Effects of Di(2-
Ethylhexyl) Phthalate (DEHP). National Toxicology Program, Center for the Evaluation of Risks to 
Human Reproduction 
4. IARC (2000) Di(2-ethylhexyl) phthalate. IARC Monographs.  
5. Inoue K, Okumura H, Higuchi T, Oka H, Yoshimura Y, Nakazawa H (2002) Characterization of 
estrogenic compounds in medical polyvinyl chloride tubing by gas chromatography-mass spectrometry and 
estrogen receptor binding assay. Clin Chim Acta 325:157-163 
6. Inoue K, Kawaguchi M, Yamanaka R, Higuchi T, Ito R, Saito K, Nakazawa H (2005) Evaluation and 
analysis of exposure levels of di(2-ethylhexyl) phthalate from blood bags. Clin Chim Acta 358:159-166 
7. SCMPMD (2002) Medical devices containing DEHP plasticised PVC, Neonates and other groups 
possibly at risk from DEHP toxicity. European Commission, Health & Consumer Protection Directorate 
http://ec.europa.eu/health/ph_risk/committees/scmp/documents/out43_en.pdf, Accessed March 2013 
8. Hill SS, Shaw BR, Wu aH (2001) The clinical effects of plasticizers, antioxidants, and other 
contaminants in medical polyvinylchloride tubing during respiratory and non-respiratory exposure. Clin 
Chim Acta 304:1-8 
9. Brock JW, Caudill SP, Silva MJ, Needham LL, Hilborn ED (2002) Phthalate Monoesters Levels in the 
Urine of Young Children. Bull Environ Contam Toxicol 68:309-314 
10. Becker K, Seiwert M, Angerer J, Heger W, Koch HM, Nagorka R, Rosskamp E, Schluter C, Seifert B, 
Ullrich D (2004) DEHP metabolites in urine of children and DEHP in house dust. Int J Hyg Environ 
Health 207 (5):409-417 
11. Blount BC, Silva MJ, Caudill SP, Needham LL, Pirkle JL, Sampson EJ, Lucier GW, Jackson RJ, Brock 




12. Fromme H, Bolte G, Koch HM, Angerer J, Boehmer S, Drexler H, Mayer R, Liebl B (2007) 
Occurrence and daily variation of phthalate metabolites in the urine of an adult population. Int J Hyg 
Environ Health 210 (1):21-33 
13. Kato K, Silva MJ, Reidy JA, Hurtz D, Malek NA, Needham LL, Nakazawa H, Barr DB, Calafat AM 
(2004) Mono(2-ethyl-5-hydroxyhexyl) phthalate and mono-(2-ethyl-5-oxohexyl) phthalate as biomarkers 
for human exposure assessment to di-(2-ethylhexyl) phthalate. Environ Health Perspect 112 (3):327-330 
14. Koch HM, Drexler H, Angerer J (2003) An estimation of the daily intake of di(2-ethylhexyl)phthalate 
(DEHP) and other phthalates in the general population. Int J Hyg Environ Health 206 (2):77-83 
15. Koch HM, Rossbach B, Drexler H, Angerer J (2003) Internal exposure of the general population to 
DEHP and other phthalates - determination of secondary and primary phthalate monoester metabolites in 
urine. Environ Res 93 (2):177-185 
16. Preuss R, Koch HM, Angerer J (2005) Biological monitoring of the five major metabolites of di-(2-
ethylhexyl)phthalate (DEHP) in human urine using column-switching liquid chromatography-tandem mass 
spectrometry. J Chromatogr B 816 (1-2):269-280 
17. Silva MJ, Barr DB, Reidy JA, Malek NA, Hodge CC, Caudill SP, Brock JW, Needham LL, Calafat 
AM (2004) Urinary levels of seven phthalate metabolites in the U.S. population from the National Health 
and Nutrition Examination Survey (NHANES) 1999-2000. Environ Health Perspect 112:331-338 
18. Wittassek M, Wiesmüller GA, Koch HM, Eckard R, Dobler L, Müller J, Angerer J, Schlüter C (2007) 
Internal phthalate exposure over the last two decades - A retrospective human biomonitoring study. Int J 
Hyg Environ Health 210 (3-4):319-333 
19. Albro PW, Thomas R, Fishbein L (1973) Metabolism of diethylhexyl phthalate by rats, isolation and 
characterisation of the urinary metabolite. Journal of Chromatography 76:321-330 
20. Silva MJ, Barr DB, Reidy JA, Kato K, Malek NA, Hodge CC, Hurtz D, Calafat AM, Needham LL, 
Brock JW (2003) Glucuronidation patterns of common urinary and serum monoester phthalate metabolites. 
Arch Toxicol 77 (10):561-567 
21. Barr DB, Silva MJ, Kato K, Reidy JA, Malek NA, Hurtz D, Sadowski M, Needham LL, Calafat AM 
(2003) Assessing human exposure to phthalates using monoesters and their oxidized metabolites as 
biomarkers. Environ Health Perspect:1148-1151 
22. Koch HM, Bolt HM, Angerer J (2004) Di(2-ethylhexyl)phthalate (DEHP) metabolites in human urine 
and serum after a single oral dose of deuterium-labelled DEHP. Arch Toxicol 78 (3):123-130 
23. Arndt Pa, Kumpel BM (2008) Blood doping in athletes - detection of allogeneic blood transfusions by 
flow cytofluorometry. Am J Hematol 83:657-667 
References 
 117 
24. Giraud S, Robinson N, Mangin P, Saugy M (2008) Scientific and forensic standards for homologous 
blood transfusion anti-doping analyses. Forensic Sci Int 179:23-33 
25. Voss SC, Thevis M, Schänzer W (2007) Detection of homologous blood transfusion. Int J Sports Med 
28:633 - 637 
26. Nelson M, Ashenden M, Langshaw M, Popp H (2002) Detection of homologous blood transfusion by 
flow cytometry: A deterrent against blood doping. Haematologica 84 (8):881 
27. Pottgiesser T, Umhau M, Ahlgrim C, Ruthardt S, Roecker KAI, Schumacher YO (2007) Hb mass 
measurement suitable to screen for illicit autologous blood transfusions. Medicine & Science in Sports & 
Exercise 39 (10):1748-1756 
28. Pialoux V, Mounier R, Brugniaux JV (2009) Hemoglobin and hematocrit are not such good candidates 
to detect autologous blood doping. Int J Hematol 89:714-715 
29. Monfort N, Ventura R, Latorre A, Belalcazar V, López M, Segura J (2010) Urinary di-(2-
ethylhexyl)phthalate metabolites in athletes as screening measure for illicit blood doping: a comparison 
study with patients receiving blood transfusion. Transfusion 50 (1):145-149 
30. Harper CA (1999 ) Modern plastics handbook. McGraw Hill Professional, New York 
31. Gooch JW (2011) Encyclopedic Dictionary of Polymers, DEHP. Springer, New York 
32. The Council of the European Economic Community (1967) Annex 1 of Directive 67/548/EEC on the 
classification, packaging and labelling of dangerous substances. Official Journal of the European 
Communities 
33. The Council of the European Economic Community (1967) Directive 67/548/EEC on the 
classification, packaging and labelling of dangerous substances. Official Journal of the European 
Communities 
34. CDRH (2001) Safety Assessment of Di(2-ethylhexyl) phthalate (DEHP) Released from PVC Medical 
Devices. Center for Devices and Radiological Health, US Food and Drug Administration 
35. ECB (2008) European Union Risk Assessment Report, Bis(2-ethylhexyl) phthalate (DEHP). Institute 
for Health and Consumer Protection, European Chemicals Bureau, Italy 
36. ECHA (2009) Data on manufacture, import, export, uses and releases of bis(2-ethylhexyl)phthalate 
(DEHP) as well as information on potential alternatives to its use. European Chemicals Agency  
37. ECPI (2008) European Council for Plasticisers and Intermediates (ECPI), http://www.ecpi.org.  
38. The Commission of the European Communities (2007) Directive 2007/19/EC amending Directive 
2002/72/EC relating to plastic materials and articles intended to come into contact with food, The list of 
References 
 118 
simulants to be used for testing migration of constituents of plastic materials and articles intended to come 
into contact with foodstuffs. Official Journal of the European Union 
39. The Commission of the European Communities (2002) Directive 2002/72/EC, Plastic materials and 
articles intended to come into contact with foodstuffs. Official Journal of the European Communities 
40. The European Parliament and the Council of the European Union (2005) Directive 2005/84/EC 
amending for the 22nd time Council Directive 76/769/EEC, Restrictions on the marketing and use of 
certain dangerous substances and preparations (phthalates in toys and childcare articles). Official Journal 
of the European Union 
41. The Commission of the European Communities (1976) Directive 76/769/EEC,  Restrictions on the 
marketing and use of certain dangerous substances and preparations.  
42. The Commission of the European Communities (2004) Directive 2004/93/EC amending Council 
Directive 76/768/EEC for the purpose of adapting its Annexes II and III to technical progress. Official 
Journal of the European Union 
43. The Commission of the European Communities (1976) Directive 76/768/EEC on the approximation of 
the laws of the Member States relating to cosmetic products.  
44. Wittassek M, Koch HM, Angerer J, Bruning T (2011) Assessing exposure to phthalates - the human 
biomonitoring approach. Mol Nutr Food Res 55 (1):7-31 
45. Clark K, Cousins I, MacKay D (2003) 3Q. Phthalate Esters. In: Staples CA (ed) The Handbook of 
Environmental Chemistry. Springer, New York pp 227–262 
46. Wahl HG, Hoffmann A, Häring H-U, Liebich HM (1999) Identification of plasticizers in medical 
products by a combined direct thermodesorption–cooled injection system and gas chromatography–mass 
spectrometry. J Chromatogr A 847:1-7 
47. European Comission (2004) Final Report - Life Cycle Assessment of PVC and of principal competing 
materials. http://ec.europa.eu/enterprise/sectors/chemicals/files/sustdev/pvc-final_report_lca_en.pdf, 
Accessed April 2013 
48. Ozge A, Baldini M, Goldstein R (1964) Effect of plastic and glass surfaces on clot retraction and 
serotonin uptake of platelet-rich plasma stored at 4°C. J Lab Clin Med 63:378-393 
49. Guess WL, Jacob J, Autian J (1967) A study of polyvinyl chloride blood bag assemblies I. Alteration 
or contamination of ACD solutions. Drug Intelligence 1:120-127 
50. Jaeger RJ, Rubin RJ (1970) Contamination of blood stored in plastic packs. Lancet 296 (7664):151 
References 
 119 
51. Jaeger RJ, Rubin RJ (1970) Plasticizers from plastic devices extraction, metabolism, and accumulation 
by biological systems. Science 170 (956):460-462 
52. Jaeger RJ, Rubin RJ (1972) Migration of a phthalate ester plasticizer from polyvinyl chloride blood 
bags into stored human blood and its localization in human tissues. N Engl J Med 287:1114-1116 
53. Valeri CR, Contreras TJ, Feingold H, Sheibley RH, Jaeger RJ (1973) Accumulation of di-2-ethylhexyl 
phthalate (DEHP) in whole blood, platelet concentrates, and platelet-poor plasma. 1. Effect of DEHP on 
platelet survival and function. Environ Health Perspect 3:103-118 
54. Jaeger RJ, Rubin RJ (1973) Di-2-ethylhexyl phthalate, a plasticizer contaminant of platelet 
concentrates. Transfusion 13 (2):107-108 
55. Contreras TJ, Sheibley RH, Valeri CR (1974) Accumulation of Di-2-ethylhexyl phthalate (DEHP) in 
whole blood, platelet concentrates, and platelet-poor plasma. Transfusion 14 (1):34-46 
56. Rock G, Secours VE, Franklin CA, Chu I, Villeneuve DC (1978) The accumulation of mono-2-
ethylhexylphthalate (MEHP) during storage of whole blood and plasma. Transfusion 18 (5):553-558 
57. Peck CC, Odom DG, Friedman HI, Albro PW, Hass JR, Brady JT, Jess DA (1979) Di-2-ethylhexyl 
phthalate (DEHP) and mono-2-ethylexyl phthalate (MEHP) accumulation in whole blood and red cell 
concentrates. Transfusion 19 (2):137-146 
58. Guess WL (1978) Safety evaluation of medical plastics. Clin Toxicol 12 (1):77-95 
59. Sasakawa S, Mitomi Y (1978) Di-2-ethylhexylphthalate (DEHP) content of blood or blood components 
stored in plastic bags. Vox Sang 34 (2):81-86 
60. Northrup SJ (1986) The leachability of DEHP in Fenwal blood packs. Technical Review (Fenwal) 
61. Albro PW, Corbett JT (1978) Distribution of di- and mono-(2-ethylhexyl) phthalate in human plasma. 
Transfusion 18 (6):750-755 
62. Vessman J, Rietz G (1978) Formation of mono(ethylhexyl)phthalate from di(ethylhexyl)phthalate in 
human plasma stored in PVC bags and its presence in fractionated plasma proteins. Vox Sang 35 (1-2):75-
80 
63. Marcel YL (1973) Determination of di-2-ethylhexyl phthalate levels in human blood plasma and 
cryoprecipitates. Environ Health Perspect 3:119–121 
64. Kevy SV, Button LN, Jacobson MS (1975) Toxicology of plastic devices having contact with blood 
(PB-247 168). National Heart and Lung Institute, Springfield, VA 
References 
 120 
65. Griffiths WC, Camara PD, Saritelli A, Gentile J (1988) The in vitro serum protein-binding 
characteristics of bis-(2-ethylhexyl)phthalate and its principal metabolite, mono-(2-ethylhexyl)phthalate. 
Environ Health Perspect 77:151-156 
66. Waldman AA (1988) Effects of palsticizers on red blood cells and platelets during storage. Plasma 
Ther Transfus Tech 9:317-330 
67. Miripol JE, Stern IJ (1977) Decreased accumulation of phthalate plasticizer during storage of blood as 
packed cells. Transfusion 17 (1):71-73 
68. Gulliksson H, Karlman G, Segerlind A, Gullbring B (1986) Preservation of red blood cells: Content of 
microaggregates and di-2-ethylhexylphthalate (DEHP) in red blood cells stored in saline-adenine-glucose-
mannitol (SAGM) medium. Vox Sang 50 (1):16–20 
69. Rock G, Tocchi M, Ganz PR, Tackaberry ES (1984) Incorporation of plasticizer into red cells during 
storage. Transfusion 24 (6):493-498 
70. Rock G, Labow RS, Tocchi M (1986) Distribution of di(2-ethylhexyl) phthalate and products in blood 
and blood components. Environ Health Perspect 65:309-316 
71. Labow RS, Tocchi M, Rock G (1986) Platelet storage. Effects of leachable materials on morphology 
and function. Transfusion 26 (4):351-357 
72. Horowitz B, Stryker MH, Waldman AA, Woods KR, Gass JD, Drago J (1985) Stabilization of red 
blood cells by the plasticizer, diethylhexylphthalate. Vox Sang 48 (3):150-155 
73. Estep TN, Pedersen RA, Miller TJ, Stupar KR (1984) Characterization of erythrocyte quality during 
the refrigerated storage of whole blood containing di-(2-ethylhexyl) phthalate. Blood 64 (6):1270-1276 
74. Labow RS, Card RT, Rock G (1987) The effect of the plasticizer di(2-ethylhexyl)phthalate on red cell 
deformability. Blood 70 (1):319-323 
75. Greenwalt TJ, McGuinness CG, Dumaswala UJ (1991) Studies in red blood cell preservation: 4. 
Plasma vesicle hemoglobin exceeds free hemoglobin. Vox Sang 61 (1):14-17 
76. Myhre BA, Johnson D, Marcus CS, Demaniew S, Carmen R, Nelson E (1987) Survival of red cells 
stored for 21 and 35 days in a non-di-(2-ethylhexyl)phthalate plastic container. Vox Sang 53 (4):199-202 
77. AuBuchon JP, Estep TN, Davey RJ (1988) The effect of the plasticizer di-2-ethylhexyl phthalate on the 
survival of stored RBCs. Blood 71 (2):448-452 
78. Hess JR, Rugg N, Knapp AD, Gormas JF, Silberstein EB, Greenwalt TJ (2000) Successful storage of 
RBCs for 9 weeks in a new additive solution. Transfusion 40 (8):1007-1011 
References 
 121 
79. Hess JR, Lippert LE, Derse-Anthony CP, Hill HR, Oliver CK, Rugg N, Knapp AD, Gormas JF, 
Greenwalt TJ (2000) The effects of phosphate, pH, and AS volume on RBCs stored in saline-adenine-
glucose-mannitol solutions. Transfusion 40 (8):1000-1006 
80. Hill HR, Oliver CK, Lippert LE, Greenwalt TJ, Hess JR (2001) The effects of polyvinyl chloride and 
polyolefin blood bags on red blood cells stored in a new additive solution. Vox Sang 81 (3):161–166 
81. Högman CF, Eriksson L, Ericson A, Reppucci AJ (1991) Storage of saline-adenine-glucose-mannitol-
suspended red cells in a new plastic container: polyvinylchloride plasticized with butyryl-n-trihexyl-citrate. 
Transfusion 31 (1):26-29 
82. Seidl S, Gosda W, Reppucci AJ (1991) The in vitro and in vivo evaluation of whole blood and red cell 
concentrates drawn on CPDA-1 and stored in a non-DEHP plasticized PVC container. Vox Sang 61 (1):8-
13 
83. Muylle L, Vanderplanken M, Goossens W, Stewart M, Payrat JM (1994) Storage of saline-adenine-
glucose-mannitol suspended red cells in diethylhexyl phtalate and butyryl-n-trihexyl-citrate plasticized 
polyvinyl chloride containers. An in vitro comparative study. Transfus Apher Sci 15 (2):163-169 
84. Simon TL, Sierra ER, Ferdinando B, Moore R (1991) Collection of platelets with a new cell separator 
and their storage in a citrate-plasticized container. Transfusion 31 (4):335-339 
85. Gulliksson H, Shanwell A, Wikman A, Reppucci AJ, Sallander S, Udén AM (1991) Storage of 
platelets in a new plastic container. Polyvinyl chloride plasticized with butyryl-n-trihexyl citrate. Vox Sang 
61 (3):165-170 
86. Seeman P, Kwant WO, Sauks T (1969) Membrane expansion of erythrocyte ghosts by tranquilizers and 
anesthetics. Biochim Biophys Acta 183 (3):499-511 
87. Chi LM, Wu WG, Sung KL, Chien S (1990) Biophysical correlates of lysophosphatidylcholine- and 
ethanol-mediated shape transformation and hemolysis of human erythrocytes. Membrane viscoelasticity 
and NMR measurement. Biochim Biophys Acta 1027 (2):163-171 
88. Bull MH, Brailsford JD, Bull BS (1982) Erythrocyte membrane expansion due to the volatile 
anesthetics, the 1-alkanols, and benzyl alcohol. Anesthesiology 57 (5):399-403 
89. Draper CJ, Greenwalt TJ, Dumaswala UJ (2002) Biochemical and structural changes in RBCs stored 
with different plasticizers: the role of hexanol. Transfusion 42 (7):830-835 
90. Niino T, Ishibashi T, Ishiwatab H, Takeda K, Onodera S (2003) Characterization of human salivary 
esterase in enzymatic hydrolysis of phthalate esters. Journal of Health Science 49 (1):76-81 
91. Albro PW, Corbett JT, Schroeder JL, Jordan S, Matthews HB (1982) Pharmacokinetics, interactions 
with macromolecules and species differences in metabolism of DEHP. Environ Health Perspect 45:19-25 
References 
 122 
92. Albro PW, Thomas RO (1973) Enzymatic hydrolysis of Di-(2-ethylhexyl) phthalate by lipases. 
Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism 306 (3):380-390 
93. Daniel JW, Bratt H (1974) The absorption, metabolism and tissue distribution of di(2-ethylhexyl) 
phthalate in rats. Toxicology 2 (1):51-65 
94. Albro PW (1986 ) Absorption, metabolism, and excretion of di(2-ethylhexyl) phthalate by rats and 
mice. Environ Health Perspect 65:293–298 
95. Albro PW, Tondeur I, Marbury D, Jordan S, Schroeder J, Corbett JT (1983) Polar metabolites of Di-(2-
ethylhexyl)phthalate in the rat. Biochim Biophys Acta 760 (2):283-292 
96. Peck CC, Albro PW (1982 ) Toxic potential of the plasticizer Di(2-ethylhexyl) phthalate in the context 
of its disposition and metabolism in primates and man. Environ Health Perspect 45:11–17 
97. Schmid P, Schlatter C (1985) Excretion and metabolism of di(2-ethylhexyl)-phthalate in man. 
Xenobiotica 15 (3):251-256 
98. Koch HM, Bolt HM, Preuss R, Angerer J (2005) New metabolites of di(2-ethylhexyl)phthalate (DEHP) 
in human urine and serum after single oral doses of deuterium-labelled DEHP. Arch Toxicol 79 (7):367-
376 
99. Koch HM, Drexler H, Angerer J (2004) Internal exposure of nursery-school children and their parents 
and teachers to di(2-ethylhexyl)phthalate (DEHP). Int J Hyg Environ Health 207 (1):15-22 
100. Buchta C, Bittner C, Höcker P, Macher M, Schmid R, Seger C, Dettke M (2003) Donor exposure to 
the plasticizer di(2-ethylhexyl)phthalate during plateletpheresis. Transfusion 43:1115-1120 
101. Buchta C, Bittner C, Heinzl H, Höcker P, Macher M, Mayerhofer M, Schmid R, Seger C, Dettke M 
(2005) Transfusion-related exposure to the plasticizer di(2-ethylhexyl)phthalate in patients receiving 
plateletpheresis concentrates. Transfusion 45 (5):798-802 
102. Koch HM, Angerer J, Drexler H, Eckstein R, Weisbach V (2005) Di(2-ethylhexyl)phthalate (DEHP) 
exposure of voluntary plasma and platelet donors. Int J Hyg Environ Health 208 (6):489-498 
103. Koch HM, Bolt HM, Preuss R, Eckstein R, Weisbach V, Angerer J (2005) Intravenous exposure to 
di(2-ethylhexyl)phthalate (DEHP): metabolites of DEHP in urine after a voluntary platelet donation. Arch 
Toxicol 79 (12):689-693 
104. Silva MJ, Reidy Ja, Preau Jr JL, Needham LL, Calafat AM (2006 ) Oxidative metabolites of 




105. Fromme H, Lahrz T, Piloty M, Gebhart H, Oddoy A, Rüden H (2004) Occurrence of phthalates and 
musk fragrances in indoor air and dust from apartments and kindergartens in Berlin (Germany). Indoor Air 
14 (3):188-195 
106. Bornehag C-G, Sundell J, Weschler CJ, Sigsgaard T, Lundgren B, Hasselgren M, Hägerhed-Engman 
L (2004) The association between asthma and allergic symptoms in children and phthalates in house dust: 
a nested case-control study. Environ Health Perspect 112 (14):1393-1397 
107. EFSA (2005) Opinion of the Scientific Panel on food additives, flavourings, processing aids and 
materials in contact with food (AFC) on a request from the Commission related to bis(2-
ethylhexyl)phthalate (DEHP) for use in food contact materials The EFSA Journal 243:1-20 
108. CSTEE, EU Scientific Committee on Toxicity Ecotoxicity and the Environment (1998) Opinion on 
phthalate migration from soft PVC toys and child-care articles. Brussels, Belgium 
109. EPA, US Environmental Protection Agency (1992) Bis(2-ethylhexyl) phthalate (DEHP) Hazard 
Summary (Revised in January 2000). http://www.epa.gov/ttnatw01/hlthef/eth-phth.html, Accessed April 
2013 
110. David RM (2004) Commentary regarding the article by Koch et al.: An estimation of the daily intake 
of di(2-ethylhexyl)phthalate (DEHP) and other phthalates in the general population. Int. J. Hyg. Environ. 
Health, 206, 77 – 83 (2003). Int J Hyg Environ Health 207 (1):75-76 
111. David RM (2000) Exposure to phthalate esters. Environ Health Perspect 108 (10):A440 
112. Kohn MC, Parham F, Masten SA, Portier CJ, Shelby MD, Brock JW, Needham LL (2000) Human 
exposure estimates for phthalates. Environ Health Perspect 108 (10):A440-A442 
113. Guo Y, Alomirah H, Cho HS, Minh TB, Mohd MA, Nakata H, Kannan K (2011) Occurrence of 
phthalate metabolites in human urine from several Asian countries. Environ Sci Technol 45 (7):3138-3144 
114. NHANES (2012) Fourth National Report on Human Exposure to Environmental Chemicals. Centers 
for Disease Control and Prevention,National Center for Environmental Health (Updated Feb 2013) 
115. Hoppin JA, Brock JW, Davis BJ, Baird DD (2002) Reproducibility of urinary phthalate metabolites in 
first morning urine samples. Environ Health Perspect 110:515-518 
116. Hauser R, Meeker JD, Park S, Silva MJ, Calafat AM (2004) Temporal variability of urinary phthalate 
metabolite levels in men of reproductive age. Environ Health Perspect 112 (17):1734-1740 
117. Duty SM, Calafat AM, Silva MJ, Ryan L, Hauser R (2005) Phthalate exposure and reproductive 
hormones in adult men. Hum Reprod 20 (3):604-610 
References 
 124 
118. Kato K, Silva MJ, Needham LL, Calafat AM (2005) Determination of 16 phthalate metabolites in 
urine using automated sample preparation and on-line preconcentration/high-performance liquid 
chromatography/tandem mass spectrometry. Anal Chem 77 (9):2985-2991 
119. Adibi JJ, Whyatt RM, Williams PL, Calafat AM, Camann D, Herrick R, Nelson H, Bhat HK, Perera 
FP, Silva MJ, Hauser R (2008) Characterization of phthalate exposure among pregnant women assessed by 
repeat air and urine samples. Environ Health Perspect 116:467-473 
120. Högberg J, Hanberg A, Berglund M, Skerfving S, Remberger M, Calafat AM, Filipsson AF, Jansson 
B, Johansson N, Appelgren M, Håkansson H (2008) Phthalate diesters and their metabolites in human 
breast milk, blood or serum, and urine as biomarkers of exposure in vulnerable populations. Environ 
Health Perspect 116 (3):334-339 
121. Herr C, zur Nieden A, Koch HM, Schuppe HC, Fieber C, Angerer J, Eikmann T, Stilianakis NI 
(2009) Urinary di(2-ethylhexyl)phthalate (DEHP)--metabolites and male human markers of reproductive 
function. Int J Hyg Environ Health 212 (6):648-653 
122. Frederiksen H, Jorgensen N, Andersson AM (2010) Correlations between phthalate metabolites in 
urine, serum and seminal plasma from young danish men determined by isotope dilution liquid 
chromatography tandem mass spectrometry. J Anal Toxicol 34:400-410 
123. Park MS, Yang YJ, Hong YP, Kim SY, Lee YP (2010) Assessment of Di (2-ethylhexyl) phthalate 
exposure by urinary metabolites as a function of sampling time. J Prev Med Public Health 43:301-308 
124. Peck JD, Sweeney AM, Symanski E, Gardiner J, J M, Calafat AM, Schantz SL (2010) Intra- and 
inter-individual variability of urinary phthalate metabolite concentrations in Hmong women of 
reproductive age. J Expo Anal Environ Epidemiol 20:90-100 
125. Guo Y, Wu Q, Kannan K (2011) Phthalate metabolites in urine from China, and implications for 
human exposures. Environ Int 37 (5):893-898 
126. Monfort N, Ventura R, Balcells G, Segura J (2012) Determination of five di-(2-ethylhexyl)phthalate 
metabolites in urine by UPLC-MS/MS, markers of blood transfusion misuse in sports. J Chromatogr B 
908:113-121 
127. Doull J, Cattley R, Elcombe C, Lake B, Swenberg J, Wilkinson C, Williams G, van Gemert M (1999) 
A cancer risk assessment of di(2-ethylhexyl)phthalate: application of the new U.S. EPA Risk Assessment 
Guidelines. Regul Toxicol Pharm 29 (3):327-357 
128. Liss GM, Albro PW, Hartle RW, Stringer WT (1985 ) Urine phthalate determinations as an index of 




129. Hines CJ, Hopf NBN, Deddens JA, Calafat AM, Silva MJ, Grote AA, Sammons DL (2009) Urinary 
phthalate metabolite concentrations among workers in selected industries: A pilot biomonitoring study. 
Ann Occup Hyg 53 (1):1-17 
130. Haishima Y, Seshimo F, Higuchi T, Yamazaki H, Hasegawa C, Izumi S, Makino T, Nakahashi K, Ito 
R, Inoue K, Yoshimura Y, Saito K, Yagami T, Tsuchiya T, Nakazawa H (2005) Development of a simple 
method for predicting the levels of di(2-ethylhexyl) phthalate migrated from PVC medical devices into 
pharmaceutical solutions. Int J Pharm 298 (1):126-142 
131. Hanawa T, Muramatsu E, Asakawa K, Suzuki M, Tanaka M, Kawano K, Seki T, Juni K, Nakajima Si 
(2000) Investigation of the release behavior of diethylhexyl phthalate from the polyvinyl-chloride tubing 
for intravenous administration. Int J Pharm 210 (1–2):109-115 
132. Hanawa T, Endoh N, Kazuno F, Suzuki M, Kobayashi D, Tanaka M, Kawano K, Morimoto Y, 
Nakajima Si, Oguchi T (2003) Investigation of the release behavior of diethylhexyl phthalate from 
polyvinyl chloride tubing for intravenous administration based on HCO60. Int J Pharm 267 (1–2):141-149 
133. Kambia K, Dine T, Gressier B, Bah S, Germe AF, Luyckx M, Brunet C, Michaud L, Gottrand F 
(2003) Evaluation of childhood exposure to di(2-ethylhexyl) phthalate from perfusion kits during long-
term parenteral nutrition. Int J Pharm 262 (1-2):83-91 
134. Loff S, Kabs F, Witt K, Sartoris J, Mandl B, Niessen KH, Waag KL (2000) Polyvinylchloride 
infusion lines expose infants to large amounts of toxic plasticizers. J Pediatr Surg 35 (12):1775-1781 
135. Loff S, Kabs F, Subotic U, Schaible T, Reinecke F, Langbein M (2002) Kinetics of diethylhexyl-
phthalate extraction from polyvinylchloride-infusion lines. Journal of Parenteral and Enteral Nutrition 26 
(5):305-309 
136. Loff S, Subotic U, Reinicke F, Wischmann H, Brade J (2004) Extraction of di-ethylhexyl-phthalate 
from perfusion lines of various material, length and brand by lipid emulsions. J Pediatr Gastroenterol Nutr 
39 (4):341-345 
137. Faouzi MA, Dine T, Gressier B, Kambia K, Luyckx M, Pagniez D, Brunet C, Cazin M, Belabed A, 
Cazin JC (1999) Exposure of hemodialysis patients to di-2-ethylhexyl phthalate. Int J Pharm 180:113-121 
138. Rael LT, Bar-Or R, Ambruso DR, Mains CW, Slone DS, Craun ML, Bar-Or D (2009) Phthalate esters 
used as plasticizers in packed red blood cell storage bags may lead to progressive toxin exposure and the 
release of pro-inflammatory cytokines. Oxidative Medicine and Cellular Longevity 2 (3):166-171 
139. Smith A, Thrussell IR, Johnson GW (1989) The prevention of plasticizer migration into nutritional 
emulsion mixtures by use of a novel container. Clin Nutr 8:173-177 
140. Allwood MC (1986) The release of phthallate ester plasticizer from intravenous administration sets 
into fat emulsion. Int J Pharm 29:233-236 
References 
 126 
141. Faouzi MA, Khalfi F, Dine T, Luyckx M, Brunet C, Gressier B, Goudaliez F, Cazin M, Kablan J, 
Belabed A, Cazin JC (1999) Stability, compatibility and plasticizer extraction of quinine injection added to 
infusion solutions and stored in polyvinyl chloride (PVC) containers. J Pharm Biomed Anal 21:923-930 
142. Faouzi MA, Dine T, Luyckx M, Brunet C, Mallevais M-L, Goudaliez F, Gressier B, Cazin M, Kablan 
J, Cazin JC (1995) Stability, compatibility and plasticizer extraction of miconazole injection added to 
infusion solutions and stored in PVC containers. J Pharm Biomed Anal 13:1363 1372 
143. Ito R, Seshimo F, Miura N, Kawaguchi M, Saito K, Nakazawa H (2005) High-throughput 
determination of mono- and di(2-ethylhexyl)phthalate migration from PVC tubing to drugs using liquid 
chromatography–tandem mass spectrometry. J Pharm Biomed Anal 39:1036–1041 
144. Sjöberg P, Bondesson U, Sedin G, Gustafsson J (1985) Dispositions of di- and mono-(2-ethylhexyl) 
phthalate in newborn infants subjected to exchange transfusions. Eur J Clin Invest 15 (6):430-436 
145. Sjöberg P, Bondesson U, Kjellen L, Lindquist NG, Montin G, Plöen L (1985) Kinetics of di-(2-
ethylhexyl) phthalate in immature and mature rats and effect on testis. Acta Pharmacol Toxicol (Copenh) 
56 (1):30-37 
146. Plastemart: Alternatives for PVC in medical applications though developed, are less cost effective. 
Available at: http://wwwplastemartcom/upload/Literature/Alternatives-PVC-medical-applications-
developed-but-less-cost-effectiveasp, Accessed March 2013 
147. Simmchen J, Ventura R, Segura J (2012) Progress in the removal of di-[2-ethylhexyl]-phthalate as 
plasticizer in blood bags. Transfus Med Rev 26 (1):27-37 
148. Van Vliet ED, Reitano EM, Chhabra JS, Bergen GP, Whyatt RM (2011) A review of alternatives to 
di(2-ethylhexyl) phthalate-containing medical devices in the neonatal intensive care unit. J Perinatol 31 
(8):551-560 
149. Turner VS, Mitchell SG, Kang SK, Hawker RJ (1995) A comparative study of platelets stored in 
polyvinyl chloride containers plasticised with butyryl trihexyl citrate or triethylhexyl trimellitate. Vox 
Sang 69 (3):195-200 
150. Lindström A, Hakkarainen M (2007) Migration resistant polymeric plasticizer for poly(vinyl 
chloride). J App Polym Sci 104 (4):2458-2467 
151. Ajili SH, Ebrahimi NG, Khorasani MT (2003) Study on thermoplastic polyurethane/polypropylene 
(TPU/PP) blend as a blood bag material. J App Polym Sci 89:2496–2501 
152. Lee JH, Kim KO, Ju YM (1998) Polyethylene oxide additive–entrapped polyvinyl chloride as a new 
blood bag material. J Biomed Mater Res 48:328-334 
References 
 127 
153. Ferruti P, Mancin I, Ranucci E, De Felice C, Latini G, Laus M (2003) Polycaprolactone-poly(ethylene 
glycol) multiblock copolymers as potential substitutes for di(ethylhexyl) phthalate in flexible poly(vinyl 
chloride) formulations. Biomacromolecules 4:181-188 
154. Messori M, Toselli M, Pilati F, Fabbri E, Fabbri P, Pasquali L, Nannarone S (2004) Prevention of 
plasticizer leaching from PVC medical devices by using organic–inorganic hybrid coatings. Polymer 45 
(3):805-813 
155. Holme S (2005) Current issues related to the quality of stored RBCs. Transfus Apher Sci 33 (1):55-61 
156. Meryman HT, Hornblower MLS, Syring RL (1986) Prolonged storage of red cells at 4° C. 
Transfusion 26 (6):500-505 
157. World Anti-Doping Agency http://www.wada-ama.org/en/Resources/Q-and-A/Blood-Doping/.  
Accessed March 2013 
158. Giraud S, Sottas P-E, Robinson N, Saugy M (2010) Blood Transfusion in Sports. In: Thieme D, 
Hemmersbach P (eds) Doping in Sports: Biochemical Principles, Effects and Analysis. Springer-Verlag, 
Berlin Heidleberg,  
159. Ekblom B, Goldbarg A, Gullbring B (1972) Response to exercise after blood loss and reinfusion. J 
Appl Phys 33 (2):175-180 
160. Eichner R (2007) Blood Doping - Infusion, erythropoietin and artifical blood. Sports Med 37 (4-
5):389-391 
161. Lasne F, de Ceaurriz J (2000) Recombinant erythropoietin in urine. Nature 405 (6787):635 
162. Lippi G, Banfi G (2006) Blood transfusions in athletes. Old dogmas, new tricks. Clin Chem Lab Med 
44 (12):1395-1402 
163. Ashenden M (2004) Contemporary issues in the fight against blood doping in sport. Haematologica 
89 (8):901-903 
164. Ashenden M (2002) A strategy to deter blood doping in sport. Haematologica 87:225-234 
165. Malcovati L (2003) Hematologic passport for athletes competing in endurance sports - A feasibility 
study. Haematologica 88 (5):570-581 
166. Cazzola M (2000) A global strategy for prevention and detection of blood doping with erythropoietin 
and related drugs. Haematologica 85 (6):561-563 
167. World Anti-Doping Agency http://www.wada-ama.org/en/Science-Medicine/Athlete-Biological-
Passport/.  Accessed March 2013 
References 
 128 
168. Nelson M, Popp H, Sharpe K, Ashenden M (2003) Proof of homologous blood transfusion through 
quantification of blood group antigens. Haematologica 88 (11):1284-1295 
169. Berglund B, Hemmingsson P, Birgegård G (1987) Detection of autologous blood transfusion in cross-
country skiers. Int J Sports Med 8 (2):66-70 
170. Damsgaard R, Munch T, Mørkeberg J, Mortensen SP, González-Alonso J (2006) Effects of blood 
withdrawal and reinfusion on biomarkers of erythropoiesis in humans: Implication for anti-doping 
strategies. Haematologica 91 (7):1006-1008 
171. Burge C, Skinner S (1995) Determination of hemoglobin mass and blood volume with CO: 
Evaluation and application of a method. J Appl Phys 79 (2):623-631 
172. Schmidt W, Prommer N (2005) The optimised CO-rebreathing method: a new tool to determine total 
haemoglobin mass routinely. Eur J Appl Physiol 95 (5-6):486-495 
173. Pottgiesser T, Specker W, Umhau M, Roecker K, Schumacher YO (2009) Post-transfusion stability of 
haemoglobin mass. Vox Sang 96 (2):119-127 
174. Eastwood A, Hopkins WG, Bourdon PC, Withers RT, Gore CJ (2008) Stability of hemoglobin mass 
over 100 days in active men. J Appl Phys 104:982-985 
175. Green H, Sutton J, Coates G, Ali M, Jones S (1991) Response of red cell and plasma volume to 
prolonged training in humans. J Appl Phys 70 (4):1810-1815 
176. Shoemaker J, Green H, Coates J, Ali M, Grant S (1996) Failure of prolonged exercise training to 
increase red cell mass in humans. Am J Physiol 270:121-126 
177. Brugniaux JV, Schmitt L, Robach P, Nicolet G, Fouillot J-P, Moutereau S, Lasne F, Pialoux V, Saas 
P, Chorvot M-C, Cornolo J, Olsen NV, Richalet J-P (2006) Eighteen days of “living high, training low” 
stimulate erythropoiesis and enhance aerobic performance in elite middle-distance runners. J Appl Phys 
100:203–211 
178. Saunders PU, Telford RD, Pyne DB, Hahn AG, Gore CJ (2009) Improved running economy and 
increased hemoglobin mass in elite runners after extended moderate altitude exposure. J Sci Med Sport 12 
(1):67-72 
179. Robertson EY, Saunders PU, Pyne DB, Gore CJ, Anson JM (2010) Effectiveness of intermittent 
training in hypoxia combined with live high/train low. Eur J Appl Physiol 110 (2):379-387 
180. Prommer N, Sottas PE, Schoch C, Schumacher YO, Schmidt W (2008) Total hemoglobin mass - a 
new parameter to detect blood doping? Med Sci Sports Exerc 40 (12):2112-2118 
References 
 129 
181. Mørkeberg J, Belhage B, Ashenden M, Bornø A, Sharpe K, Dziegiel MH, Damsgaard R (2009) 
Screening for autologous blood transfusions. Int J Sports Med 30 (4):285-292 
182. Mørkeberg J, Sharpe K, Belhage B, Damsgaard R, Schmidt W, Prommer N, Gore CJ, Ashenden MJ 
(2011) Detecting autologous blood transfusions: a comparison of three passport approaches and four blood 
markers. Scand J Med Sci Sports 21 (2):235-243 
183. Banfi G, Lombardi G, Colombini A, Lippi G (2010) A world apart: Inaccuracies of laboratory 
methodologies in antidoping testing. Clin Chim Acta 411 (15-16):1003-1008 
184. Jelkmann W, Lundby C (2011) Blood doping and its detection. Blood 118 (9):2395-2404 
185. Anderson WAC, Barnes KA, Castle L, Damant AP, Scotter MJ (2002) Determination of isotopically 
labelled monoesterphthalates in urine by high performance liquid chromatography-mass spectrometry. The 
Analyst 127:1193–1197 
186. Koch HM, Gonzalez-Reche LM, Angerer J (2003) On-line clean-up by multidimensional liquid 
chromatography-electrospray ionization tandem mass spectrometry for high throughput quantification of 
primary and secondary phthalate metabolites in human urine. J Chromatogr B 784 (1):169-182 
187. Jeong JY, Lee JH, Kim EY, Kim PG, Kho YL (2011) Determination of phthalate metabolites in 
human serum and urine as biomarkers for phthalate exposure using column-switching LC-MS/MS. Saf 
Health Work 2 (1):57-64 
188. Kato K, Shoda S, Takahashi M, Doi N, Yoshimura Y, Nakazawa H (2003) Determination of three 
phthalate metabolites in human urine using on-line solid-phase extraction–liquid chromatography–tandem 
mass spectrometry. J Chromatogr B 788:407-411 
189. Egestad B, Green G, Sjöberg P, Klasson-Wehler E, Gustafsson J (1996) Chromatographic 
fractionation and analysis by mass spectrometry of conjugated metabolites of bis(2-ethylhexyl)phthalate in 
urine. J Chromatogr B 677:99-109 
190. Blount BC, Milgram KE, Silva MJ, Malek Na, Reidy Ja, Needham LL, Brock JW (2000) Quantitative 
detection of eight phthalate metabolites in human urine using HPLC-APCI-MS/MS. Anal Chem 72:4127-
4134 
191. Calafat AM, Slakman aR, Silva MJ, Herbert AR, Needham LL (2004) Automated solid phase 
extraction and quantitative analysis of human milk for 13 phthalate metabolites. J Chromatogr B 805:49-56 
192. Silva MJ, Malek NA, Hodge CC, Reidy JA, Kato K, Barr DB, Needham LL, Brock JW (2003) 
Improved quantitative detection of 11 urinary phthalate metabolites in humans using liquid 




193. Pan G, Hanaoka T, Yoshimura M, Zhang S, Wang P, Tsukino H, Inoue K, Nakazawa H, Tsugane S, 
Takahashi K (2006) Decreased serum free testosterone in workers exposed to high levels of di-n-butyl 
phthalate (DBP) and di-2-ethylhexyl phthalate (DEHP), A cross-sectional study in China. Environ Health 
Perspect 114 (11):1643-1648 
194. Silva MJ, Slakman aR, Reidy Ja, Preau JL, Herbert AR, Samandar E, Needham LL, Calafat AM 
(2004) Analysis of human urine for fifteen phthalate metabolites using automated solid-phase extraction. J 
Chromatogr B 805:161-167 
195. Kato K, Silva MJ, Needham LL, Calafat AM (2006) Quantifying phthalate metabolites in human 
meconium and semen using automated off-line solid-phase extraction coupled with on-line SPE and 
isotope-dilution high-performance liquid chromatography-tandem mass spectrometry. Anal Chem 78 
(18):6651-6655 
196. Inoue K, Kawaguchi M, Okada F, Yoshimura Y, Nakazawa H (2003) Column-switching high-
performance liquid chromatography electrospray mass spectrometry coupled with on-line of extraction for 
the determination of mono- and di-(2-ethylhexyl) phthalate in blood samples. Anal Bioanal Chem 375 
(4):527-533 
197. Fromme H, Küchler T, Otto T, Pilz K, Müller JM, Wenzel A (2002) Occurrence of phthalates and 
bisphenol A and  F in the environment. Water Res 36:1429–1438 
198. Lin Z-P, Ikonomou MG, Jing H, Mackintosh C, Gobas FA (2003) Determination of phthalate ester 
congeners and mixtures by LC/ESI-MS in sediments and biota of an urbanized marine inlet. Environ Sci 
Technol 37:2100-2108 
199. Giust JA, Seipelt CT, Anderson BK, Deis DA, Hinders JD (1990) Determination of bis(2-ethylhexyl) 
phthalate in cow's milk and infant formula by high-performance liquid chromatography. J Agric Food 
Chem 38 (2):415-418 
200. Niino T, Ishibashi T, Itho T, Sakaia S, Ishiwatab H, Yamada T, Onodera S (2002) Simultaneous 
determination of phthalate di- and monoesters in poly(vinylchloride) products and human saliva by gas 
chromatography–mass spectrometry. J Chromatogr B 780:35– 44 
201. David F, Sandra P, Tienpont B, Vanwalleghem F (2003) Part Q. Phthalate Esters. In: Staples CA (ed) 
The Handbook of Environmental Chemistry, vol 3. Springer, Berlin, pp 9-56 
202. George C, Prest H (2001) A new approach to the analysis of phthalate esters by GC/MS. Agilent 
Technologies Application Note, http://wwwchemagilentcom/Library/applications/59882244ENpdf, 
Accessed March 2013 (5988-2244EN) 
References 
 131 
203. Butler J, O’Brien P, Crain S, Yargeau V (2012) Determination of DEHP in culture media by GC-
MS/MS using PCI ammonia. Thermo Fisher Scientific Application Note, , 
https://staticthermoscientificcom/images/D20806~pdf (AN52282) 
204. Wahl HG, Hong Q, Stübe D, Maier ME, Häring H-U, Liebich HM (2001) Simultaneous analysis of 
the di(2-ethylhexyl)phthalate metabolites 2-ethylhexanoic acid, 2-ethyl-3-hydroxyhexanoic acid and 2-
ethyl-3-oxohexanoic acid in urine by gas chromatography–mass spectrometry. J Chromatogr B 758:213–
219 
205. Albro PW, Jordan ST, Schroeder JL, Corbett JT (1982) Chromatographic separation and quantitative 
determination of the metabolites of di-(2-ethylhexyl) phthalate from urine of laboratory animals. Journal of 
Chromatography 244:65-79 
206. Needham LL, Patterson DG, Jr., Barr DB, Grainger J, Calafat AM (2005) Uses of speciation 
techniques in biomonitoring for assessing human exposure to organic environmental chemicals. Anal 
Bioanal Chem 381 (2):397-404 
207. Latini G (2005) Monitoring phthalate exposure in humans. Clin Chim Acta 361 (1-2):20-29 
208. Thieme D, Grosse J, Lang R, Mueller RK, Wahl A (2001) Screening, confirmation and quantitation of 
diuretics in urine for doping control analysis by high-performance liquid chromatography–atmospheric 
pressure ionisation tandem mass. J Chromatogr B 757:49–57 
209. Deventer K, Delbeke FT, Roels K, Van Eenoo P (2002) Screening for 18 diuretics and probenecid in 
doping analysis by liquid chromatography-tandem mass spectrometry. Biomed Chromatogr 16:529-535 
210. Sanz-Nebot V, Toro I, Bergés R, Ventura R, Segura J, Barbosa J (2001) Determination and 
characterization of diuretics in human urine by liquid chromatography coupled to pneumatically assisted 
electrospray ionization mass spectrometry. J Mass Spectrom 36 (6):652-657 
211. Murray GJ, Danaceau JP (2009) Simultaneous extraction and screening of diuretics, beta-blockers, 
selected stimulants and steroids in human urine by HPLC-MS/MS and UPLC-MS/MS. J Chromatogr B 
877 (30):3857-3864 
212. Ventura R, Roig M, Montfort N, Sáez P, Bergés R, Segura J (2008) High-throughput and sensitive 
screening by ultra-performance liquid chromatography tandem mass spectrometry of diuretics and other 
doping agents. Eur J Mass Spectrom 14 (3):191-200 
213. Kolmonen M, Leinonen A, Kuuranne T, Pelander A, Ojanperä I (2009) Generic sample preparation 
and dual polarity liquid chromatography – time-of-flightmass spectrometry for high-throughput screening 
in doping analysis. Drug Test Anal 1:250–266 
214. Vonaparti A, Lyris E, Angelis YS, Panderi I, Koupparis M, Tsantili-Kakoulidou A, Peters RJB, 
Nielen MWF, Georgakopoulos C (2010) Preventive doping control screening analysis of prohibited 
References 
 132 
substances in human urine using rapid-resolution liquid chromatography/high-resolution time-of-flight 
mass spectrometry. Rapid Commun Mass Spectrom 24:1595–1609 
215. Thomas A, Guddat S, Kohler M, Krug O, Schänzer W, Petrou M, Thevis M (2010) Comprehensive 
plasma-screening for known and unknown substances in doping controls. Rapid Commun Mass Spectrom 
24:1124-1132 
216. Thevis M, Opfermann G, Schänzer W (2003) Liquid chromatography/electrospray ionization tandem 
mass spectrometric screening  and confirmation methods for 2-agonists in human or equine urine. J Mass 
Spectrom 38:1197-1206 
217. Thomas A, Sigmund G, Guddat S, Schänzer W, Thevis M (2008) Determination of selected 
stimulants in urine for sports drug analysis by solid phase extraction via cation exchange and means of 
liquid chromatography-tandem mass spectrometry. Eur J Mass Spectrom 14 (3):135-143 
218. Deventer K, Pozo OJ, Van Eenoo P, Delbeke FT (2007) Development of a qualitative liquid 
chromatography/tandem mass spectrometric method for the detection of narcotics in urine relevant to 
doping analysis. Rapid Commun Mass Spectrom 21 (18):2015-3023 
219. Edinboro LE, Backer RC, Poklis A (2005) Technical note: Direct analysis of opiates in urine by liquid 
chromatography-tandem mass spectrometry. J Anal Toxicol 29 (7):704-710 
220. Gustavsson E, Andersson M, Stephanson N, Beck O (2007) Validation of direct injection electrospray 
LC-MS/MS for confirmation of opiates in urine drug testing. J Mass Spectrom 42:881–889 
221. Guddat S, Thevis M, Thomas A, Schänzer W (2008) Rapid screening of polysaccharide-based plasma 
volume expanders dextran and hydroxyethy starch in human urine by liquid chromatography-tandem mass 
spectrometry. Biomed Chromatogr 22 (7):695-701 
222. Gutiérrez-Gallego R, Segura J (2004) Rapid screening of plasma volume expanders in urine using 
matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry. Rapid Commun Mass 
Spectrom 18 (12):1324-1330 
223. Deventer K, Van Eenoo P, Delbeke FT (2006) Detection of hydroxyethylstarch (HES) in human urine 
by liquid chromatography-mass spectrometry. J Chromatogr B 834 (1-2):217-220 
224. Thörngren J-O, Östervall F, Garle M (2008) A high-throughput multicomponent screening method for 
diuretics, masking agents, central nervous system (CNS) stimulants and opiates in human urine by UPLC–
MS/MS. J Mass Spectrom 43:980–992 
225. Badoud F, Grata E, Perrenoud L, Avois L, Saugy M, Rudaz S, Veuthey JL (2009) Fast analysis of 
doping agents in urine by ultra-high-pressure liquid chromatography-quadrupole time-of-flight mass 
spectrometry: I. Screening analysis. J Chromatogr A 1216 (20):4423-4433 
References 
 133 
226. Analytical Methods Committee (2001) Robust statistics: a method of coping with outliers. AMC 
technical brief no 6 Royal Society of Chemistry, Analytical Methods Committee 
http://www.rsc.org/images/brief6_tcm18-25948.pdf, Accessed March 2013 
227. Analytical Methods Committee (2001) Robust statistics: a method of coping with outliers. AMC 
Technical Brief No 6 Royal Society of Chemistry, Analytical Methods Committee 
http://www.rsc.org/images/brief6_tcm18-25948.pdf Accessed March 2013 
228. Miller JN (1993) Tutorial review - Outliers in experimental data and their treatment. The Analyst 118 
(5):455 
229. Fisher RA (1954) Statistical Methods for Research Workers. Twelfth edn. Hafner Publishing 
Company Inc., New York 
230. World Anti-Doping Agency (2009) Harmonization of analysis and reporting of 19-norsteroids related 
to nandrolone - WADA Technical Document - TD2009NA. http://www.wada-
ama.org/Documents/World_Anti-Doping_Program/WADP-IS-
Laboratories/Archives/WADA_TD2009NA_Harmonization_Analysis_Reporting_19-Norsteroids_EN.pdf, 
Accessed March 2013 
231. World Anti-Doping Agency (2012) World Anti-Doping Code, International Standard for Laboratories 
version 7.0. http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-IS-
Laboratories/ISL/WADA_Int_Standard_Laboratories_2012_EN.pdf, Accessed March 2013 
232. Validation of Analytical Procedures: Text and Methodology Q2 (R1) (2005). 
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__
Guideline.pdf, Accessed March 2013. ICH Harmonised Tripartite Guideline 
233. Annesley TM (2003) Ion Suppression in Mass Spectrometry. Clinical Chemistry 49 (7):1041–1044 
234. Samandar E, Silva MJ, Reidy Ja, Needham LL, Calafat AM (2009) Temporal stability of eight 
phthalate metabolites and their glucuronide conjugates in human urine. Environ Res 109:641-646 
235. World Anti-Doping Agency (2012) Decision limits for the confirmatory quantification of threshold 
substances - WADA Technical Document - TD2012DL. http://www.wada-
ama.org/Documents/World_Anti-Doping_Program/WADP-IS-
Laboratories/Technical_Documents/WADA-TD2012DL-Decision-Limits-for-the-Confirmatory-
Quantification-Threshold-Substances-EN.pdf, Accessed March 2013 
236. Slot C (1965) Plasma creatinine determination. A new and specific Jaffe reaction method. Scand J 
Clin Lab Invest 17:381-387 
References 
 134 
237. Monfort N, Ventura R, Platen P, Hinrichs T, Brixius K, Schänzer W, Thevis M, Geyer H, Segura J 
(2012) Plasticizers excreted in urine: indication of autologous blood transfusion in sports. Transfusion 52 
(3):647-657 
238. R Development Core Team (2010) R: A language and environment for statistical computing. R 
Foundation for Statistical Computing, Vienna, Austria. http://www.Rproject.org, Accessed August 2010 
239. Venables WN, Ripley BD (2002) Modern Applied Statistics with S. Fourth Edition. Springer, New 
York 
240. World Anti-Doping Agency (2010) Minimum required performance levels for detection of prohibited 
substances - WADA Technical Document – TD2010MRPL. http://www.wada-
ama.org/documents/world_anti-doping_program/wadp-is-
laboratories/wada_td2010mrplv1.0_minimum%20required%20performance%20levels_sept%2001%20201
0_en.pdf, Accessed March 2013 
241. Validation of Analytical Procedures: Text and Methodology Q2 (R1) (2005). 
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__
Guideline.pdf. ICH Harmonised Tripartite Guideline 
242. Phenomenex (2006) Using Aromatic Selectivity with Gemini C6-Phenyl for Difficult Separations. 
TN-1029. https://phenomenex.blob.core.windows.net/documents/9d55731e-ec80-4d43-ac97-
c2e8c41b6d2a.pdf?returnURL=/Search, Accessed March 2013 
243. Lorber M, Koch HM, Angerer J (2011) A critical evaluation of the creatinine correction approach: 
Can it underestimate intakes of phthalates? A case study with di-2-ethylhexyl phthalate. Journal of 
Exposure Science and Environmental Epidemiology 21 (6):576-586 
244. CDC (2009) Fourth National Report on Human Exposure to Environmental Chemicals. 
http://www.cdc.gov/exposurereport/pdf/FourthReport.pdf. Centers for Disease Control and Prevention, 
Atlanta, GA, USA 
245. CDC (2012) Fourth National Report on Human Exposure to Environmental Chemicals - Updated 
Tables. http://www.cdc.gov/exposurereport/pdf/FourthReport_UpdatedTables_Sep2012.pdf. Centers for 
Disease Control and Prevention, Atlanta, GA, USA 
246. Preau Jr JL, Wong L-Y, Silva MJ, Needham LL, Calafat AM (2010) Variability over one week in the 
urinary concentrations of metabolites of diethyl phthalate and di(2-ethylhexyl) phthalate among 8 adults: 
an observational study. Environ Health Perspect 118 (12):1748-1754 
247. Frederiksen H, Aksglaede L, Sorensen K, Skakkebaek NE, Juul A, Andersson AM (2011) Urinary 
excretion of phthalate metabolites in 129 healthy Danish children and adolescents: estimation of daily 
phthalate intake. Environ Res 111 (5):656-663 
References 
 135 
248. World Anti-Doping Agency (2010) Identification criteria for qualitative assays incorporating column 
chromatography and mass spectrometry - WADA Technical Document – TD2010IDCR. http://www.wada-
ama.org/Documents/World_Anti-Doping_Program/WADP-IS-
Laboratories/Technical_Documents/WADA_TD2010IDCRv1.0_Identification%20Criteria%20for%20Qua
litative%20Assays_May%2008%202010_EN.doc.pdf, Accessed March 2013 
249. Draper WM, Brown FR, Bethem R, Miille MJ (1989) Thermospray mass spectrometry and tandem 
mass spectrometry of polar, urinary metabolites and metabolic conjugates. Biomed Environ Mass 
Spectrom 18:767-774 
 
 
